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Abstract 
 
Introduction: In post-haemorrhagic communicating hydrocephalus, cerebrospinal 
fluid flow and drainage is obstructed by subarachnoid fibrosis in which the potent 
fibrogenic cytokine transforming growth factor-β1 has been aetiologically implicated. 
Here, the hypothesis that the transforming growth factor-β antagonist Decorin has 
therapeutic potential for (1) reducing fibrosis and the development of hydrocephalus 
and (2) degrading fibrosis and resolving established hydrocephalus, was tested using 
a rat model of juvenile communicating hydrocephalus. 
 
Methods: In the acute study, hydrocephalus was induced by a single basal cistern 
injection of kaolin in 3-week-old rats, immediately followed by 3 or 14 days of 
continuous intraventricular infusion of either human recombinant Decorin or 
phosphate-buffered saline (vehicle). In the chronic study, hydrocephalus was allowed 
to develop for 7 days before continuous intraventricular infusion of either human 
recombinant Decorin or phosphate-buffered saline for a further 14 days. Ventricular 
expansion was measured by magnetic resonance imaging. Inflammation, fibrosis, 
Decorin, transforming growth factor-β/Smad2/3 activation and hydrocephalic brain 
pathology were evaluated by immunohistochemistry and basic histology. 
 
Results: In the acute study continuous Decorin infusion prevented the development 
of hydrocephalus by blocking transforming growth factor-β-induced subarachnoid 
fibrosis and protected against hydrocephalic brain damage. In the chronic study 
 
 
Decorin had no impact on hydrocephalus, TGF-β1 levels or subarachnoid fibrosis, 
however the efficiency of Decorin infusion was in disrepute.  
 
Conclusion: The results suggest that Decorin is a potential clinical therapeutic for 
the prevention of juvenile post-haemorrhagic communicating hydrocephalus.   
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1.1. Introduction to hydrocephalus 
Hydrocephalus is a complicated and poorly understood condition that can 
affect any age, from foetal development through to adulthood. It is described as a 
pathophysiological condition caused by a disturbance in cerebrospinal fluid (CSF) 
dynamics and characterised by ventricular enlargement (Oi, 2010; Fig. 1.1). In the 
United States paediatric hydrocephalus accounts for 3% of all paediatric hospital 
charges which in 2003, amounted to $2 billion dollars (Simon et al., 2008). 
Congenital hydrocephalus can be a consequence of myelomeningocele, aquaduct 
stenosis and cranioencephalic malformations (such as Dandy-Walker malformation). 
Acquired hydrocephalus can be idiopathic (normal pressure hydrocephalus) or 
caused by infection, trauma, haemorrhage and tumours (Massimi et al., 2009). 
Currently hydrocephalus is managed by implanting an intraventricular shunt to drain 
CSF however this treats the symptoms and not the cause of the condition. 
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Figure 1.1. Diagram representing the development of hydrocephalus. Hydrocephalus is the enlargement of the brain 
ventricles and is treated by implantation of a ventricular shunt to drain cerebrospinal fluid. 
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1.2. Cerebrospinal fluid dynamics 
CSF is produced by the choroid plexus and circulates from the lateral 
ventricles, through the third and fourth ventricles and into the subarachnoid space 
where it is drained into the venous sinuses and lymphatics (Fig. 1.2). CSF has both 
mechanical and biochemical functions that help to protect the brain and allow normal 
brain function. CSF gives the brain buoyancy which reduces tension on the lower 
portion of the brain, and acts as a fluid ‘cushion’ to protect the brain from physical 
impact on the skull (Redzic and Segal, 2004). CSF also regulates intracranial 
pressure (ICP) in conjunction with changes in cerebral blood flow, removes toxic 
metabolic waste and moves nutrients, neurotransmitters and hormones around the 
brain (Di Terlizzi and Platt, 2006) 
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Figure 1.2. Diagram representing CSF dynamics in the human and rat brain. 
CSF is produced by the choroid plexus and flows from the lateral ventricles, through 
the third and fourth ventricle and into the subarachnoid space, where it is absorbed 
through the arachnoid villi/granulations into the blood stream or through the lymphatic 
circulation. 
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1.2.1. The choroid plexus and cerebrospinal fluid formation 
The choroid plexus is a structure found in the lateral, third and fourth ventricles 
and is an extension of the ependymal epithelium. The choroid plexus consists of a 
single layer of epithelial cells joined by tight junctions over a network of fenestrated 
capillaries (Redzic and Segal, 2004). The choroid plexus epithelium is polarised, has 
numerous mitochondria, microvilli and long cilia on the apical surface and infoldings 
on the basal surface (Fig. 1.3). These morphological features allow the choroid 
plexus to function as secreting epithelium (Strazielle and Ghersi-Egea, 2000). 
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Figure 1.3. Diagram of the choroid plexus. The choroid plexus is composed of a 
layer of epithelial cells, fenestrated capillaries, dendritic cells and macrophages. The 
epithelial cells are specialised and have microvilli and cilia on the apical membrane, 
infoldings on the basal membrane and are joined by cellular junctions. 
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CSF formation occurs in 2 stages: First, the hydrostatic pressure causes 
passive filtration of fluid from the blood through the fenestrated endothelium into the 
choroidal interstitial fluid; then ions are transported actively from the choroidal 
interstitial fluid across the choroid plexus epithelium and into the CSF. This generates 
an osmotic gradient causing the transcellular movement of water from the interstitial 
fluid into the CSF through aquaporin 1 channels on the epithelial cells (Sakka et al., 
2011).  
The first stage of active secretion is the conversion of H2O and CO2 to HCO3
- 
and H+ catalysed by the enzyme carbonic anhydrase. The ion exchangers on the 
basal membrane then exchange H+ for Na+ and HCO3
- for Cl-. On the apical surface 
the Na+/K+ATPase actively pumps 2K+ in and 3Na+ out and the Cl-Na+K+ 
cotransporter, driven by the accumulation of Cl-, moves 2Cl-, Na+ and K+ ions out. 
HCO3
- and K+ also passively move out of the cells on the apical membrane through 
HCO3
- and K+ channels respectively on the apical surface. The net movement of Na+, 
Cl- and HCO3
- from the epithelial basal membrane into the CSF generates an osmotic 
gradient causing the movement of water in the same direction (Fig. 1.4; Speake et 
al., 2001; Redzic and Segal, 2004). 
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Figure 1.4. Diagram representing the formation of CSF. (A) Fluid diffuses out of 
the blood vessels into the interstitial fluid. (B) The carbonic anhydrase enzyme 
catalyses the conversion of H2O and CO2 to HCO3
- and H+. (C) At the basolateral 
membrane ion exchangers substitute H+ and HCO3
- for Na+ and Cl- respectively. (D) 
On the apical surface the Na+/K+ATPase actively pumps 2K+ in and 3Na+ out and the 
Cl-Na+K+ cotransporter, driven by the accumulation of Cl-, moves 2Cl-, Na+ and K+ 
ions out. HCO3
- and K+ also passively move out of the cells. (E) The net movement of 
Na+, Cl- and HCO3
- generates an osmotic gradient causing the movement of water in 
the same direction. 
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The production of CSF is regulated by neurogenic and endocrine 
mechanisms. The choroid plexus is innervated by sympathetic and cholinergic nerve 
fibres and although there are variations among species, it is believed that 
sympathetic innervation reduces CSF secretion while cholinergic innervation 
increases CSF secretion (Nilsson et al., 1992). CSF formation requires high cerebral 
blood flow and therefore vasoactive molecules may also influence the rate of CSF 
formation (Szmydynger-Chodobska et al., 1994). The vasoactive intestinal 
polypeptide, peptide histidine isoleucine and Neuropeptide Y are all found in nerve 
fibres in the choroid plexus. Results from various studies suggest that they may be 
involved in modulating the sympathetic adrenergic response. Moreover, receptors 
and binding sites for serotonin, atrial natriuretic peptide, endothelin 1 and angiotensin 
II have also been discovered on the choroid plexus epithelial cell membrane 
suggesting that these neuropeptides may also play a role in CSF production (Nilsson 
et al., 1992). Vasopressin is the most widely investigated peptide and it has been 
shown that at high levels (levels only observed after severe haemorrhage) it reduces 
cerebral blood flow and in turn decreases CSF production (Chodobski and 
Szmydynger-Chodobska, 2001). This suggests that even though these 
neuropeptides can significantly reduce cerebral blood flow this does not always result 
in reduced CSF production.  
 
1.3. Ependyma 
The ventricles are lined by a layer of cells known as the ependyma. 
Ependymal cells are low columnar to cuboidal epithelial cells with the apical surface 
covered with cilia and microvilli and a basement membrane at the basal surface. 
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Ependymal cells are joined to one another mainly by gap junctions and sometimes 
tight junctions (Del Bigio, 2010). The cilia beat in a coordinated fashion in the same 
direction causing the constant flow of CSF through the ventricular system (Meunier et 
al., 2013) while the microvilli play a role in the exchange of molecules with the CSF. 
The ependyma is the interface between the CSF and the brain parenchyma, and 
allows diffusion of fluid and molecules between the interstitial fluid and the CSF 
(Abbott, 2004), therefore contributing to the extrachoroidal production of CSF (Curl 
and Pollay, 1968). The ependyma is also the source of multiple growth factors 
including basic fibroblast growth factor (FGF-2), hence the ependyma may provide 
trophic support to the neural progenitor cells in the underlying subventricular zone, or 
by releasing growth factors into the CSF to get to other regions of the brain 
(Hayamizu et al., 2001; Johanson et al., 2011). In addition, the ependyma is the first 
line of defence against infection by acting as a physical barrier and responding to 
inflammatory cytokines through toll like receptors and complement molecules, 
although the ependyma does act to reduce intraventricular inflammation (Neal and 
Gasque, 2013).  
 
1.4. The meninges and subarachnoid space 
The meninges are composed of three layers; the pia mater, the arachnoid 
mater and the dura mater (Fig. 1.5). The meninges function is to protect the brain, 
maintain the blood brain barrier and the blood CSF barrier and are involved in the 
absorption and drainage of CSF. The pia mater is composed of a single continuous 
layer of flattened cells connected by desmosomes and gap junctions (Adeeb et al., 
2013b). The pia mater covers the brain and lines the subarachnoid space through 
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which CSF flows. The pia mater is attached to the brain via the extracellular 
basement membrane, the glial limitans, and also covers the small blood vessels that 
enter the subarachnoid space from the brain (Siegenthaler et al,, 2013). The inner 
reticular cell layer of the arachnoid mater transverses the subarachnoid space and 
forms arachnoid trabeculae composed of a web of collagenous fibres covered by 
arachnoid trabecular cells (fibroblasts). The trabeculae form a network of extracellular 
channels allowing the flow of CSF through the subarachnoid space (Vandenabeele et 
al., 1996). The outer arachnoid layer lines the subarachnoid space and is composed 
of multiple layers of tightly packed arachnoid barrier cells. The cells lie on a basal 
lamina and are characterised by their flat shape, lack of extracellular space and 
collagen fibres between them and the presence of desmosomes and tight junctions. 
These arachnoid barrier cells are responsible for CSF absorption and form the barrier 
between CSF and blood. (Adeeb et al., 2013b; Siegenthaler et al., 2013). The outer 
layer of the meninges is the dura mater which attaches to the skull bone and is 
composed of fibroblasts, collagen and elastic fibrils. The inner dural border cell layer 
contains flattened fibroblastic cells forming cellular junctions between the arachnoid 
barrier cells, and is characterised by little extracellular spaces and the lack of 
extracellular collagen fibres. The middle dura layer is the meningeal layer and is 
flexible as it contains many fibroblasts that lie in a collagen matrix. The outer layer 
has fewer fibroblasts compared to the meningeal layer but more collagen and elastic 
fibres, making it a strong and durable layer that forms the periosteal lining that 
adheres to the skull bone (Adeeb, 2012; Mack et al., 2009).  
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Figure 1.5. Diagram of the meninges. The meninges is composed of three layers; 
the pia mater, the arachnoid mater and the dura mater. The pia mater covers the 
brain and lines the subarachnoid space through which CSF flows. The arachnoid 
mater transverses and lines the subarachnoid space forming a CSF-blood barrier. 
The outer layer is the dura mater which attaches to the skull bone and is composed 
of fibroblasts, collagen and elastic fibrils. 
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1.4.1. Arachnoid granulations, lymphatics and the absorption of cerebrospinal 
fluid 
Arachnoid granulations and villi are located in the lateral lacunae of the 
superior sagittal sinus and over the cerebral cortices. Only arachnoid villi are present 
in infants and therefore it is speculated that arachnoid granulations develop from villi 
and with age increase in complexity (Jayatilaka, 1969; Pollay, 2010). Human 
arachnoid granulations have four components; a central core, an arachnoid cell layer, 
a cap cell cluster and a thin fibrous capsule (Kida et al., 1988; Fig. 1.6). The central 
core is an extension of the subarachnoid space protruding into the lumen and 
contains collagen trabeculae and arachnoid trabecular cells. Lining the core is the 
arachnoid barrier cell layer which continues from the arachnoid mater. This single 
layer of cells forms multiple layers of arachnoid barrier cells at the apical portion 
called the cap cell cluster. Covering the arachnoid cells is the thin fibrous capsule 
that is composed of vascular endothelial cells, and fibroblasts and connective tissue 
from the dura mater. This fibrous capsule does not cover the apical portion of the 
granulation and therefore the cap cell cluster is in direct contact with the blood vessel 
lumen (Upton and Weller, 1985; Kida et al., 1988; Kapoor et al., 2008). Jayatilaka 
(1969) has suggested that humans have two types of arachnoid granulations: type 1, 
with the structure outlined above and type 2, with a layer of endothelial cells covering 
the cap cell cluster. Type 1 granulations appear to be specific for humans as other 
mammals only have type 2 granulations. In contrast Ohta et al (2002) has suggested 
that humans only have type 2 granulations. In the rat, Jayatilaka (1969) has not 
observed arachnoid villi or granulations whereas Kida et al (1993) detected 
arachnoid villi in the superior  and inferior sagittal sinus. Due to the differing opinions 
15 | P a g e  
 
on the structure of arachnoid granulations there are two proposed mechanisms of 
CSF drainage; first, through extracellular cisterns and second, by active transport 
through endothelial cells via pinocytic vesicles and vacuoles (Pollay, 2010). 
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Figure 1.6. Diagram of the arachnoid granulations. Arachnoid granulations are 
composed of 4 main parts; the core, the arachnoid cell layer, the cap cell cluster and 
the fibrous capsule. CSF drains through the arachnoid granulations into the blood 
vessels. 
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More recently, studies have revealed the importance of the lymphatic system 
in CSF drainage. Boulton et al (1999) have demonstrated the equal contribution of 
lymphatic vessels and arachnoid villi to CSF drainage after injecting human serum 
albumin into the lateral ventricles of rats (although the authors recognise that this 
experimental approach may lead to an underestimation of lymphatic drainage). 
Injections of Indian ink (Walter et al., 2006) and Microfil® (Johnston et al., 2004) into 
the subarachnoid space have demonstrated that the respective compounds are 
present discontinuously around the olfactory nerves in the cribriform plate and nasal 
mucosa. These compounds were also observed in the lymphatic network of the nasal 
mucosa and in the cervical lymph nodes. Walter et al (2006) have hypothesised that 
there is no direct communication between the subarachnoid space and the lymphatic 
system and suggested that the meninges fuse together at the cribriform plate. This 
implies that CSF is drained through channels between the epineurial and perineurial 
layers around the olfactory nerves and then diffuses into lymphatic vessels of the 
nasal mucosa. Therefore in some mammals where arachnoid granulations are 
absent or the arachnoid villi are not prominent, lymphatic drainage may be the major 
route of CSF drainage, and the arachnoid villi may only contribute under high 
intracranial pressure (Nagra et al., 2008). 
 
1.5. Glial cells 
1.5.1. Astrocytes 
Astrocytes are ten times more abundant than neurones in the brain. There are 
two main subtypes; protoplasmic astrocytes have finely branched processes that 
envelop synapses and are located in grey matter, and fibrous astrocytes have long 
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fibre-like processes that make contacts with nodes of ranvier and so are mainly found 
in white matter (Sofroniew and Vinters, 2010).  
During neural development astrocytes have an integral role in the guidance of 
developing axons by forming boundaries and in mediating synapse formation and 
elimination (Sofroniew and Vinters, 2010; Allen, 2013). Although the involvement of 
astrocytes in the functional part of the blood brain barrier is unresolved, astrocytes 
are involved in the development and maintenance of the blood brain barrier (Ballabh 
et al., 2004). In addition, in the adult brain astrocytes are involved in maintaining 
brain homeostasis. Astrocytes maintain extracellular K+ levels by removing K+ from 
the extracellular space after neuronal depolarisation through the actions of Ca+2 
channels, Ca+2  activated K+ channels, Na+/K+-ATPase transporter and K+ spatial 
buffering (Allen, 2013). One of the most important roles of astrocytes is the recycling 
of glutamate. Astrocytes take up glutamate which is subsequently converted to the 
inactive glutamine by the enzyme glutamine synthetase. Glutamine is then released 
and taken up by neurones and converted back to glutamate by the enzyme 
glutaminase (Kimelberg and Nedergaard, 2010). Astrocytic processes make contacts 
with both synapses and blood vessels hence they are involved in neurovascular 
coupling; the relationship between neuronal activity and cerebral blood flow (Longden 
et al., 2011). Neural activity leads to an increase in intracellular Ca+2 in astrocytes, 
inducing in turn the release of vasoactive molecules, resulting in the increase in 
blood vessel diameter and subsequent increase in blood flow (Zonta and 
Carmignoto, 2002). 
 Reactive astrogliosis is the most prominent cellular response to all forms of 
CNS injury and is regulated by specific signalling pathways which can lead to gain 
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and loss of functions through altered gene and protein expression. Mild to moderate 
astrogliosis causes hypertrophy of the cell body and processes which, if the trigger is 
removed, resolves and the astrocytes return to their original state. The initial 
hypertrophy is associated with an increase in GFAP, vimentin, and nestin expression 
which is in turn associated with increased stiffness of astrocytes (Lu et al., 2010). 
Hypertrophy of astrocytes does not only transpire adjacent to the injury but occurs 
throughout the brain. In severe astrogliosis the astrocytes also proliferate rapidly 
causing overlapping of cell processes and the formation of a glial scar which can 
persist even after the trigger has disappeared (Sofroniew, 2009). There are many 
molecules released by all cell types in the CNS (neurones, oligodendrocytes, 
microglia, endothelial cells, pericytes and other astrocytes) that can mediate different 
aspects of reactive gliosis. These include growth factors, cytokines, neurotransmitters 
and reactive oxygen species to name a few (Sofroniew and Vinters, 2010). Often 
reactive astrogliosis is beneficial as it is neuroprotective and promotes neuronal 
survival, it prevents the infiltration of inflammatory cells into uninjured tissue via the 
glial scar, it facilitates tissue and blood brain barrier repair by promoting ECM 
production and helps to clear debris by inducing microglia (Bush et al., 1999; 
Faulkner et al., 2004; Myer et al., 2006). However the same roles reactive astrocytes 
conduct that are beneficial can result in detrimental effects if astrogliosis is 
prolonged. Reactive astrogliosis can produce high levels of pro-inflammatory 
cytokines which exacerbate inflammation after injury. It can also damage neurones 
by producing high levels of reactive oxygen species and glutamate and be inhibitory 
to axonal growth by promoting the production of ECM and growth inhibitory 
proteoglycans (Sofroniew and Vinters, 2010).  
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1.5.2. Microglia 
Microglial cells have finely branched processes with a small elongated nucleus 
(Aguzzi et al., 2013). In the normal brain microglial cells are referred to as ‘resting’ 
microglia, a controversial term as it implies that they are in a quiescent state which is 
far from the truth. Although their soma remains fairly stationary, their processes are 
constantly moving, new processes are continually formed and old processes are 
withdrawn. This suggests that these cells are constantly monitoring and surveying 
their surrounding area, removing debris in the close vicinity, thus making them 
primed to respond to injury immediately. Therefore, microglial cells are the primary 
immune response in the central nervous system. Similar to astrocytes, microglia 
appear to occupy a specific area that does not overlap with other microglia and their 
processes are in contact with neurones, astrocytes and blood vessels (Nimmerjahn 
et al., 2005; Kettenmann et al., 2011). 
When microglia become activated their processes are shortened, thickened 
and they take on a more amoeboid morphology (Aguzzi et al., 2013). As microglia 
are primed to react immediately, microglia activation often occurs before other cells 
react to injury in the brain (kreutzberg, 1996) and only microglia in the immediate 
vicinity will become activated (Nimmerjahn et al., 2005). During activation, microglial 
cells migrate to the injury site, secrete pro-inflammatory cytokines and increase 
adhesion to invading inflammatory cells. If there is no further damage then the 
microglia will return to their resting state. However if there is neuronal cell death the 
microglia will proliferate and phagocytose pathogens and cellular debris and also 
form a protective barrier around the injury site to protect healthy neurones 
(Nimmerjahn et al., 2005; Raivich et al., 1999). 
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1.6. Post-haemorrhagic hydrocephalus 
There are two types of hydrocephalus that develop after a haemorrhage; 
acute non-communicating hydrocephalus and chronic communicating hydrocephalus. 
Communication is dependent upon the CSF being able to flow freely between the 
lateral ventricles and the subarachnoid space (Rekate, 2008; Oi, 2010). Non-
communicating hydrocephalus usually develops within the first 24 hours after a bleed 
due to blood clots obstructing the ventricular system. On the other hand 
communicating hydrocephalus develops later (around 2 weeks) as a result of 
obstruction at the site of CSF absorption, most likely due to the development of 
subarachnoid fibrosis (Bederson and AANS Publications Committee., 1997; Strahle 
et al., 2012). 
 
1.6.1. Subarachnoid haemorrhage 
Subarachnoid haemorrhage (SAH) is a bleed in the subarachnoid space 
between the pia and the arachnoid mater. It is most commonly caused by a ruptured 
cerebral aneurysm but can also occur as a consequence of a traumatic injury 
(Bederson and AANS Publications Committee., 1997). Latest statistics illustrate that 
worldwide, SAH affects around 9 in 100,000 people every year and is associated with 
a high morbidity and mortality rate (de Rooij et al., 2007). The symptoms of SAH are 
sudden onset severe headache which can be accompanied by loss of consciousness 
and/or signs of meningism such as vomiting and neck stiffness (Ferro et al., 2008; 
Kumar and Friedman, 2011). The existence of an aneurysm is confirmed by intra-
arterial angiography (Ferro et al., 2008) and the presence of subarachnoid haematic 
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densities on early CT scans indicates SAH. If the CT scan is performed later on a 
lumbar puncture is necessary to confirm the diagnosis.  
SAH is generally treated by either neurosurgical clipping or endovascular 
coiling to stabilise the patient before additional medical management to prevent 
further complications such as rebleeding, delayed ischaemia, vasospasm, and 
hydrocephalus (Al-Shahi et al., 2006). The risk of developing hydrocephalus is 
associated with a higher grade of SAH (based on the Fisher SAH Scale) and the 
presence of intraventricular blood (Wang et al., 2012). 
 
1.6.2. Intraventricular haemorrhage 
Intraventricular haemorrhage (IVH) commonly develops as a result of a bleed 
in the germinal matrix entering the ventricles and can affect 20% of premature or very 
low birth weight infants (Merhar, 2012). These infants are more at risk because the 
capillaries in the germinal matrix are not fully developed and are very delicate. When 
combined with the respiratory problems commonly seen in preterm infants which 
cause fluctuations in cerebral blood flow, it leads to haemorrhage and bleeding into 
the ventricles (Ballabh, 2010). The clinical presentation of IVH varies from no signs to 
changes in haematocrit levels, unconsciousness, abnormal eye movements and 
altered mobility and seizures. IVH can be diagnosed using cranial ultrasound and the 
severity of IVH ranges from mild haemorrhage in the germinal matrix to an 
intraventricular haemorrhage that fills more than 50% of the ventricles with dilation of 
the ventricles (Martin, 2011). IVH is the second leading cause of hydrocephalus in 
infants and the incidence has remained fairly constant in the last 20 years, 
accounting for around 20% of cases (Massimi et al., 2009). 
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1.6.3. Treatment of Hydrocephalus 
Non-communicating hydrocephalus developing after SAH is treated by 
placement of an external ventricular drain within the ventricle before surgery is 
carried out on the aneurysm (Kumar and Friedman, 2011). Communicating 
hydrocephalus affects around 20% of surviving SAH patients (Vale et al., 1997), with 
the main symptoms being urinary incontinence, gait disturbances and cognitive 
impairment and requires implantation of a permanent ventricular shunt (Edwards et 
al., 2004).  
Treatment for post IVH-hydrocephalus in premature infants is more complex 
as ventriculo-peritoneal shunt cannot be implanted until the infant weighs 2kg (very 
low birth weight infants weigh less than 1.5kg). Initially, the development of 
hydrocephalus is controlled by performing repeated lumbar punctures or ventricular 
taps, however both procedures are associated with an increased risk of infection. 
Alternatively, a ventricular access device can be implanted to facilitate repeat 
ventricular taps. Later on, an external ventricular drain can then be implanted 
although there is still a risk of up to 50% infection with this technique (Brouwer, 
2011).  
Drug treatments have also been trialled to reduce the need for shunt 
implantation. Acetazolamide and furosemide have been shown to reduce CSF 
production by inhibiting the carbonic anhydrase enzyme and the Na+-K+-Cl- 
symporter respectively. Unfortunately a large randomised trial into the use of these 
drugs in post haemorrhagic ventricular dilatation in infants demonstrated that they did 
not have a beneficial effect, and even caused an increase in the number of initial 
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shunt placements. Moreover, an increased neurological morbidity was observed 
(anonymous, 1998).  
Streptokinase, urokinase or tissue plasminogen activator are fibrinolytics and 
have been given intraventricularly to breakdown blood clots to restore normal CSF 
flow. Similarly, these drugs did not show beneficial effects and carried an increased 
risk of haemorrhage (Whitelaw and Odd, 2007). Antifibrolytic therapy has been 
further investigated in DRIFT (drainage, irrigation and fibrinolytic therapy) aiming to 
remove blood, iron, inflammatory and profibrotic molecules before hydrocephalus is 
established but the increased risk of secondary IVH outweighed the benefits 
(Whitelaw et al., 2007). 
Consequently the only current standard of care for post-haemorrhagic 
hydrocephalus is the implantation of a ventriculo-peritoneal shunt. Unfortunately 
shunt failure is still a large problem in the management of hydrocephalus 
(Bergsneider et al., 2006) because of risk of further intracerebral haemorrhage, 
infection and general lack of shunt longevity (O'Kelly et al., 2009). Infants with IVH 
tend to be very young and so the risk of shunt malfunction is much higher. Their 
incompetent immune system favours infection and the shunts are more easily 
blocked by blood clots from the haemorrhage (Shooman et al., 2009). In the United 
States there were around 39,000 admissions in 2003 surrounding paediatric 
hydrocephalus. Half of these admissions were due to shunt related issues but 
surprising the admission for shunt complications was much higher than the 
admission for the initial shunt placement (Simon et al., 2008). A recent study in 
Australia indicates that 75% of expenditure for hydrocephalus is due to complications 
or failure to treat hydrocephalus (Pham et al., 2013). 
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Other complications of shunt malfunction include impaired cognitive 
development, reduced IQ, prolonged hospital visits, more surgeries and an increased 
risk of mortality (Kandasamy et al., 2011). However, even without the complications 
mentioned above, after shunt treatment there is still residual morbidity and 
hydrocephalic children suffer with motor deficits, visual or auditory deficits, epilepsy 
and severe behavioural disorders affecting social integration (Hoppe-Hirsch et al., 
1998). Consequently there is a need for research into developing novel preventative 
therapies, especially as this type of hydrocephalus develops after a specific insult 
and therefore there is the potential for preventing it. 
 
1.7. Murine models of haemorrhage and hydrocephalus 
1.7.1. Subarachnoid haemorrhage models 
There are two main experimental murine models of SAH used by researchers 
in the field. The first model is the blood injection model, where blood is removed from 
the tail and injected into either the prechiasmatic cistern (Prunell et al., 2002; Tait et 
al., 2010) or the cisterna magna (Solomon et al., 1985; Sajanti et al., 1999; Gul et al., 
2010). The second model is the endovascular perforation model where a sharpened 
suture is advanced along the internal carotid artery to perforate the bifurcation of the 
anterior and middle cerebral arteries (Park et al., 2008; Suzuki et al., 2010). The 
endovascular perforation model, although more severe, more closely resembles 
human SAH. This model demonstrates a greater reduction in cerebral blood flow, a 
greater increase in ICP and more neuronal death but consequently has a higher 
mortality rate (Jeon et al., 2009; Lee et al., 2009). All the models show other features 
observed in human SAH, including vasospasm and cerebral ischaemia (Jeon et al., 
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2009). They also show an increase in collagen synthesis and deposition in the 
meninges which can lead to chronic fibrosis (Sajanti et al., 1999). This high collagen 
deposition is also observed in post mortem tissue from SAH patients (Motohashi et 
al., 1995) and patients with SAH appear to have greater levels of collagen 
propeptides in their CSF (Sajanti and Majamaa, 1999).  
There are only a limited number of studies assessing the underlying aetiology 
of post-haemorrhagic hydrocephalus in adult SAH murine models. One of the pitfalls 
of the blood injection technique is that large amounts of blood cannot be injected as it 
results in an increased risk of mortality. However the quantity of blood injected is a 
critical variable, as a thick collection of subarachnoid blood is associated with the 
development of post-haemorrhagic hydrocephalus (Graff-Radford et al., 1989; Dorai 
et al., 2003). To overcome this problem some investigators have conducted double 
injections, where the first injection of blood is followed 2 days later by a second 
injection to increase the maximum amount of blood administered (Carpenter et al., 
2001; Gules et al., 2002). However a possible concern may be that the double 
injection technique models rebleeding, a separate complication of SAH that is not 
associated with an increased risk of developing post-SAH communicating 
hydrocephalus. SAH models develop extensive fibrosis in the subarachnoid space 
over 4 weeks but enlargement of the ventricles is harder to come by (Sajanti et al., 
1999). Recently Chu et al. (2011) reported the induction of hydrocephalus in 21 out 
of 50 rats after a double injection of blood (800μl in total) into the cisterna magna. 
These results are interesting as previous studies conducting a double injection with a 
total of 800μl of blood have not reported enlarged ventricles (Takata et al., 2008).  
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1.7.2. Intraventricular haemorrhage models 
Unfortunately only a small number of studies have been conducted into IVH 
taking into account that the presence of IVH in SAH patients is one of the factors 
associated with the development of shunt dependent hydrocephalus (Graff-Radford 
et al., 1989, Dorai et al., 2003). Lodhia et al (2006) has demonstrated that an 
injection of blood into the lateral ventricles in adult rats results in a peak ventricular 
dilatation at two days which is still observed at 8 weeks although to a lesser degree. 
The initial peak corresponds to the acute non-communicating hydrocephalus that 
develops due to blood clots causing an obstruction. Cherian et al (2004) has 
generated a model of neonatal IVH by administering 2 injections (1 in each lateral 
ventricle on consecutive days) of 80µl citrated blood. The mortality rate with this 
procedure was over 20% and hydrocephalus was induced in 65% of rats. 
Interestingly 50% of the control rats which received two injections of artificial CSF 
also developed hydrocephalus. 
 
1.7.3. Biological Molecules that Induce Hydrocephalus 
1.7.3.1. Growth Factors 
The general consensus is that the formation of chronic subarachnoid fibrosis 
contributes to the development of post-haemorrhagic hydrocephalus by blocking CSF 
drainage and therefore the pro-fibrotic molecules released during a haemorrhage 
could be used to induce experimental hydrocephalus.  
Transforming Growth Factor (TGF)-βs are a family of multifunctional cytokines 
that are released from activated platelets (TGF-βs will be discussed in depth in 
section 1.9). Transgenic mice that specifically overexpress TGF-β1 in astrocytes 
28 | P a g e  
 
(Galbreath et al., 1995; Wyss-Coray et al.,1995) develop communicating 
hydrocephalus within 7-20 days after birth with an increase in the deposition of ECM 
in the meninges (Wyss-Coray et al., 1995). Moreover several studies have shown 
that a single intrathecal injection of human recombinant TGF-β1 into neonatal mice 
induces hydrocephalus within 6 weeks (Kanaji et al., 1997; Tada et al., 1994). These 
animals also show the appearance of subarachnoid fibrosis, proliferation of 
meningeal cells and subsequent disturbed CSF flow (Moinuddin and Tada, 2000). In 
these mice, hydrocephalus could be prevented by injecting a TGF-β1 antibody 
(Kanaji et al., 1997). Interestingly this last experiment was replicated in adult rats 
and, even though they developed meningeal fibrosis, they did not develop enlarged 
ventricles (Nakazato et al., 2002). All together these studies clearly suggest a role for 
TGF-β1 in the development of hydrocephalus. 
Fibroblast growth factor 2 (FGF-2; also known as basic fibroblast growth 
factor) is produced by glia and neurones throughout the brain and is also present in 
ependymal and blood vessel basement membranes (Logan et al., 1992; Matsuyama 
et al., 1992). It is a potent mitogenic, fibrogenic and angiogenic agent which also 
regulates motility, adhesion, differentiation, cell survival and apoptosis (Greenwood 
et al., 2008). Continual infusion of FGF-2 into the lateral ventricle of rats for 12 days 
induced communicating hydrocephalus with increased deposits of collagen in close 
proximity to arachnoid villi in the superior sagittal sinus. FGF-2 infusion also caused a 
reduction in CSF production and an increase in resistance to CSF absorption 
(Johanson et al., 1999). Although FGF-2 has also induced hydrocephalus in mice 
(Ohmiya et al., 2001) and marmosets (Pearce et al., 1996), a link between FGF-2 
and the development of hydrocephalus in humans has not been established.  
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The development of hydrocephalus is most likely to be multifactorial, involving 
multiple molecular pathways, and thus combinations of growth factors may be 
involved in inducing hydrocephalus. Other growth factors that are released by 
activated platelets that may play a role in the development of post-haemorrhagic 
hydrocephalus are platelet derived growth factor (PDGF) and epidermal growth factor 
(EGF; Rendu and Brohard-Bohn, 2001). Both PDGF and EGF promote the 
proliferation of meningeal cells in vitro (Motohashi et al., 1995b) and therefore could 
contribute to the development of chronic fibrosis and obstruct CSF drainage. 
 
1.7.3.2. β1-Integrins  
It has been suggested that meningeal fibrosis may not completely explain the 
pathology of hydrocephalus since it has been demonstrated that hydrodynamic 
factors also play an important role in the regulation of interstitial fluid and CSF 
volume (Oreskovic and Klarica, 2011). β1-integrins mediate cell-extracellular matrix 
adhesion and act as mechanoreceptors by actively conveying force transmission 
which allows cells to alter interstitial pressure (Wiig et al., 2003). For example, β-
integrin receptors may allow connective tissue cells to exert tension on collagen and 
fibril networks preventing the connective tissue from expanding (Wiig et al., 2003). 
Nagra et al (2009) have shown that 2 weeks after injection of β1-integrin antibodies 
into the lateral ventricle of rats, the majority of animals developed hydrocephalus and 
they could detect changes in pressure between the parenchyma and the ventricles. 
Although it is not well understood how β1-integrin antibodies induce hydrocephalus 
this approach opens many avenues for investigation. It highlights the fact that 
modulating specific proteins can affect pressure gradients and that molecular 
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pathways could be targeted to develop a treatment for hydrocephalus. β1-integrins 
may also have relevance to post-SAH hydrocephalus as integrins are involved in 
blood clotting, in the aggregation of blood platelets and extravasation of white blood 
cells (Wiig et al., 2003).  
 
1.7.4. Inflammatory Molecules 
Inflammation is an important aspect in the development of hydrocephalus. 
Lysophosphatidylcholine (LPC) is a lipid associated with inflammatory disorders, as it 
has multiple effects on cells involved in inflammation. For example, it acts as a 
chemo-attractant, regulates proliferation and induces the expression of growth 
factors in a variety of immune and endothelial cells (Kim et al., 2007; Okajima et al., 
1998). LPC injection into the internal capsule causes an inflammatory response 
which spreads from the parenchyma into the ventricles, leading to the development 
of communicating hydrocephalus (Tourdias et al., 2009).  
Neuraminidase catalyses the removal of terminal sialic acid residues from 
many different glycoconjugates and is usually found in bacteria and viruses where it 
plays a role in pathogenesis (Gaskell et al., 1995). Grondona et al (1996) 
administered neuraminidase into the lateral ventricle of rats as sialoglycoproteins are 
involved in the adhesion of ependymal cells. In these studies, neuraminidase caused 
the ependymal cells to die and detach, except in regions sealed by tight junctions 
such as the choroid plexus and the subcommissural organ. Hydrocephalus 
developed after 4 days as a result of obliteration of the cerebral aqueduct (Grondona 
et al., 1996), and therefore was classed as non-communicating hydrocephalus.  
Defects in adhesion and in cilia function appeared to be related to the development 
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of hydrocephalus (Del Bigio, 2010). These models emphasise the importance of 
inflammation and the integrity of the ependyma in the development of hydrocephalus. 
 
1.7.5. Non-Biological Molecules that Induce Hydrocephalus 
1.7.5.1. Dextran 
Since the exchange of fluid and solutes between the parenchyma and the 
ventricles plays an important role in CSF dynamics (Oreskovic and Klarica, 2011), 
changes in CSF osmolarity could potentially unbalance this exchange and lead to 
ventricular enlargement and hydrocephalus. Krishnamurphy et al (2009) have 
demonstrated that continuous infusion of a hyperosmotic solution of Dextran (10kD) 
into the lateral ventricle of rats causes ventricular enlargement that appears to be 
more pronounced than with FGF-2 treatment. Dextran causes no blockage or fibrosis 
therefore it would be interesting to see whether the ventricular enlargement resolved 
once infusion was stopped, or if the dextran was exchanged for a hypo-osmotic 
solution. 
 
1.7.5.2. Kaolin 
The kaolin model of hydrocephalus is the best characterised and most widely 
used. Kaolin, an aluminum silicate, induces an inflammatory response with the 
concomitant deposition of collagen and dense fibrosis in areas of the subarachnoid 
space close to the injection site (Hatta et al., 2006; Nakagawa et al., 1985). 
Kaolin is usually injected into the cisterna magna where it induces 
inflammation generally at the site of the foramina of Luschka, and ultimately 
produces an obstructive type of hydrocephalus, in most instances, between the 
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ventricular system and the subarachnoid space (Irigoin et al., 1990; Kondziella et al., 
2002; Nagra et al., 2008; Nakagawa et al., 1985). However, a study by Lopes et al 
(2009) in mice showed development of extraventricular hydrocephalus after injection 
into the cisterna magna and surmised that the hydrocephalus was of the 
communicating form with the obstruction at the site of CSF absorption. More recently 
the injection of kaolin has been attempted in the basal cisterns (Li et al., 2008; Nagra 
et al., 2010; Wagshul et al., 2009) and the cerebral convexities (Li et al., 2008). In 
both cases communicating hydrocephalus was generated with kaolin deposits in the 
basal cisterns and no obstruction at the foramina of Luschka (Li et al., 2008). The 
pathophysiology of hydrocephalus develops due to of a variety of different insults; 
gradual stretching and compression of brain tissue, chronic cerebral ischaemia, 
accumulation of toxic metabolic waste products and alterations in neurotransmitter 
systems (Braun et al., 1998; Del Bigio, 2000). The kaolin injection model successfully 
replicates the development and the pathophysiological consequence of acquired 
hydrocephalus. 
 
1.8. Pathological consequences of experimental hydrocephalus 
The pathology of hydrocephalus has been thoroughly investigated and the 
majority of data has been gathered using the kaolin model of hydrocephalus 
(discussed in section 1.7.5.2). 
 
1.8.1. Ventricular enlargement 
The pathology of hydrocephalus is closely associated with the age of onset of 
hydrocephalus, its duration and the rate at which the ventricles expand (Del Bigio, 
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2004). The rate of ventricular expansion varies between studies, possibly due to the 
diversity of concentrations and volumes of kaolin injected. Kondziella et al (2002) 
have demonstrated that the ventricles continue to enlarge for up to 8 weeks post 
kaolin injection, with the most significant change taking place between the 4th and 6th 
weeks. Conversely, Tashiro et al (1997a) have described the enlargement of 
ventricles as an initial rapid increase followed by a slow but steady progression. 
Braun et al (1998) suggestion of 3 types of hydrocephalus; progressive, declining 
and stable, better reflects the variety of hydrocephalus observed in the kaolin model 
and in human hydrocephalus.  
 
1.8.2. Intracranial pressure 
In the acute stages of hydrocephalus the enlargement of ventricles is closely 
associated with an increase in ICP. However, between 4 and 6 weeks the raised ICP 
returns to normal levels without a reduction in ventricular enlargement (Egawa et al., 
2002; Kondziella et al., 2002). In addition, at this point CSF outflow resistance 
decreases which could all be a consequence of alternative CSF pathways opening 
(Kondziella et al., 2009) such as compensatory spinal mechanisms (Voelz et al., 
2007).  
 
1.8.3. Cerebral blood flow, blood vessels and oxidative metabolism 
In the initial stages of hydrocephalus, cerebral blood flow (CBF) is reduced 
throughout the brain, with levels reaching the ischaemic threshold in the 
periventricular white matter. However 8 weeks after the induction of hydrocephalus, 
CBF is restored to normal levels. The reduction in CBF is most likely due to 
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compression of blood vessels associated with the increase in ICP rather than the 
enlargement of the ventricles (Klinge et al., 2003). Hydrocephalus also causes 
functional damage to the sympathetic nervous system which could result in a 
reduction in CBF through incomplete adrenergic denervation of the cerebral blood 
vessels (Caner et al., 1991). In addition to affecting CBF, hydrocephalus also causes 
a reduction in the number and diameter of capillaries in white and grey matter (Oka 
et al., 1985), and the vessels become spastic with corrugation of their endothelium 
and lamina elastica (Caner et al., 1993).  
Alterations in CBF resulting in ischaemia will affect oxidative metabolism. A 
number of investigators (Braun et al., 1999, Kondziella et al., 2009) have shown that 
hydrocephalic rats have increased levels of lactate in their CSF, which is also 
abundant in the brain parenchyma when hydrocephalus is fatal. Greater lactate 
concentrations are an indication of cerebral ischaemia as it indicates impairment in 
energy metabolism (Braun et al., 1997, Braun et al., 1998). In the acute stages, the 
increase in lactate concentration and lactate dehydrogenase activity shows the 
conversion to anaerobic glycolysis (Hidaka et al., 1997) whereas in the chronic 
stages of hydrocephalus energy metabolism shifts back to being aerobic (Sogabe et 
al., 1989, Matsumae et al., 1990), possibly due to the normalisation of CBF. 
 
1.8.4. Cerebrospinal fluid dynamics 
Multiple studies have shown that kaolin-induced hydrocephalus leads to an 
increase in CSF outflow resistance (Brinker et al., 1998; Luedemann et al., 2002; 
Nagra et al., 2010) which is consistent with human hydrocephalus. In this model 
there is also a reduction in lymphatic CSF absorption mainly through the cribriform 
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plate (Nagra et al., 2008; Nagra et al., 2010) and other CSF outflow pathways, such 
as the spinal perineural CSF outflow pathways, may also be recruited (Luedemann et 
al., 2002). The arachnoid villi may be involved although they are not considered 
important in CSF absorption under normal conditions in rats (Nagra et al., 2008). 
There are also changes in the pulsatile CSF flow through the cerebral aqueduct 
depending on the extent of ventriculomegaly. Severe ventricular enlargement 
appears to be associated with persistent elevated pulsations, whereas mild 
ventricular enlargement is associated with mildly elevated pulsations (Wagshul et al., 
2009). The kaolin model has also been shown to have a reduction in the CSF 
formation rate (Hochwald et al., 1981; Nakamura and Hochwald, 1983, Caner et al., 
1991), most likely a compensatory mechanism which has been suggested to be 
related to an increase in ICP leading to a decrease in choroid plexus epithelial 
function (Knuckey et al., 1993). 
 
1.8.5. Behavioural and biochemical changes 
There are a number of behavioural changes observed with the development of 
hydrocephalus and these tend to be related to disturbances in various 
neurotransmitter systems in different areas of the brain. A number of studies have 
assessed the behavioural changes observed after kaolin injection and development 
of hydrocephalus. A reduction in weight and a loss of appetite appear to be very 
common, with some animals losing as much as 30% of their body weight (Nakamura 
and Hochwald, 1983; Lopes et al., 2009). Other areas affected by hydrocephalus 
include motor activity; the hydrocephalic animals had decreased activity and 
locomotion (Kuchiwaki et al., 1994; Del Bigio, 2000; Klinge et al., 2003), reduced 
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coordination and a body tremor (Tashiro et al., 1997b; Hwang et al., 2009). 
Hydrocephalic rats also have varying degrees of impairment in spatial memory 
depending on the severity of ventriculomegaly (Egawa et al., 2002; Okii et al., 2007) 
and learning ability (Shim et al., 2003). 
In the basal ganglia, a structure associated with the control of voluntary 
movements, the dopaminergic, GABAergic and cholinergic systems are all 
functionally damaged in hydrocephalic animals (Tashiro et al., 1997b). The 
noradrenergic system in the striatum (Miyake et al., 1992) and in the locus ceruleus, 
which is involved in cognition, has been shown to undergo functional injury (Tashiro 
and Drake, 1998). The noradrenergic system is also affected by incomplete 
denervation of the cerebral vessels caused by functional damage to the perivascular 
sympathetic nerve plexus (Caner et al., 1991). In the medial septum and 
hippocampus there is a reduction in the number of cholinergic neurones which may 
contribute to impairments in learning and memory processes (Shim et al., 2003). 
These changes to neurotransmitter systems are not permanent and can be reversed 
by shunting. Tashiro and Drake (1998) have demonstrated the importance of early 
shunt implantation, as shunting at 2 weeks appears to reverse the functional injury 
seen in the cholinergic, dopaminergic and noradrenergic systems.  However, 
shunting after 2 weeks does not seem to improve function.  
 
1.8.6. Ependyma and oedema 
The loss of ependymal cells lining the ventricle appears to be a prominent 
pathological feature of hydrocephalus and is associated with ventricular enlargement 
(Go and Molenaar, 1983). In the acute stages of hydrocephalus the ependyma 
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becomes flattened with a reduction in cilia, followed by focal ependymal loss and 
eventually widespread denudation (Bruni et al., 1985). Stretching of the ependyma 
can also lead to the opening of intercellular channels allowing CSF to access the 
underlying parenchyma (Gopinath et al., 1979). Investigations in congenital animal 
models have demonstrated that in the HTx rat (Kiefer et al., 1998) and in the Hy3 
mouse (Lawson and Raimondi, 1973) ventricular enlargement causes ependymal 
loss whereas in the hyh mouse, ependymal denudation occurs before enlargement of 
the ventricles (Jimenez et al., 2001). Transgenic mice with ciliopathies also develop 
hydrocephalus due to mutations in cilia causing impaired CSF flow and abnormal 
CSF production (Banizs et al., 2005). 
Impairment of ventricular fluid flow, CSF outflow resistance and increased ICP 
cause a reduction in CSF production by the choroid plexus (Knuckey et al., 1993) 
and an increase in CSF uptake through the transependymal route (Braun et al., 
1998). Enlargement of the ventricles causes compression of the brain parenchyma, 
particularity the grey matter which in turn reduces the total water content and impairs 
fluid diffusion (Massicotte et al., 2000). As white matter has a wider interstitial space 
and fluid moves through the intercellular spaces between ependymal, interstitial 
oedema develops in the brain parenchyma (Gopinath et al., 1979). The lack of fluid 
movement leads to the accumulation of toxic waste products that can affect 
neurotransmitter homeostasis (Del Bigio, 2004), impairment of oxidative metabolism 
and activation of anaerobic glycolysis (Kawamata et al., 2003). However, it has been 
show that oedema is only temporary as it subsides once ICP and CSF outflow 
resistance have normalised (Braun et al., 1997; Braun et al., 1998; Kondziella et al., 
2009). 
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1.8.7. Periventricular white matter 
Thinning of the corpus callosum is a hallmark of hydrocephalus and has been 
observed in both humans and hydrocephalus models. Enlargement of the ventricles 
causes stretching of the periventricular white matter which damages axons and 
myelin (Del Bigio, 2004). Increased free calcium and activity of calcium dependent 
proteolytic enzyme Calpain I suggests a role for calcium activated proteolysis in 
axonal damage (Del Bigio, 2000). It has also been shown a decrease in 
phospholipids and cholesterol (Higashi et al., 1986) which could be related to myelin 
damage and gliosis (Kondziella et al., 2008). Axonal degeneration was shown by 
silver staining in the sensorimotor cortex, corpus callosum, neostratium and 
hippocampus (Ding et al., 2001a). Even though there appears to be functional 
damage to neurones there is little evidence for neuronal cell death during 
hydrocephalus (Ding et al., 2001b, a).  
 
1.8.8. The glial response to hydrocephalus 
In hydrocephalus there is an ongoing reactive glial response which depends 
upon the severity of ventricular enlargement. Increases in both GFAP (a marker of 
astrocytes) and Iba-1 (a marker of microglia) are observed in the parietal cortex 
(Deren et al., 2010; Xu et al., 2012). Astroglial cells also proliferate around the 
ventricles and form a layer of reactive gliosis where there is a loss of ependymal cells 
(Del Bigio, 2004). 
Astrocyte metabolism also appears to be disturbed in hydrocephalic rats in the 
acute phase of hydrocephalus. These changes in metabolism have been determined 
by less glutamine reaching glutamatergic neurones (Kondziella et al., 2003), an 
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increase in glial glutamate dehydrogenase activity (Klinge et al., 2002) and 
decreased glutamate levels in the cortex, hippocampus and thalamus (Kondziella et 
al., 2009). Due to the interplay between glia and neurones, this has a large impact on 
energy metabolism and signalling (Kondziella et al., 2008).  
 
1.8.9. Kaolin and other neurodegenerative diseases 
Hydrocephalus has been associated with a number of other neurological 
conditions. Kaolin injected into aged rats (12 months old) to model normal pressure 
hydrocephalus (NPH) results in accumulation of β-amyloid due to disruption of its 
clearance (Klinge et al., 2006) and an increase in hyperphosphorylated tau 
(Silverberg et al., 2010). These are pathological changes also seen in patients with 
Alzheimer’s disease, further clarifying the link between the symptoms of NPH and 
Alzheimer’s disease. Hydrocephalus patients have also been seen to have 
Parkinsonism-like symptoms. When the kaolin injection is combined with 6-
hydroxydopamine treatment, an animal model of Parkinson’s disease, the 
Parkinsonism-like symptoms develop earlier and are more severe (Oi et al., 2004).  
 
1.8.10. Adults vs. neonates 
There are a few studies that have compared the development of 
hydrocephalus in neonates and adult rats/mice. The general consensus is that 
neonatal animals tend to develop a more severe form of hydrocephalus which is 
accompanied by brain distortion and greater ventriculomegaly. Nevertheless, 
neonates appear to survive longer in comparison to adult animals (Del Bigio, 2000; 
Del Bigio and Enno, 2008; Lopes et al., 2009). The severe form seen in neonates is 
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more likely to lead to oligodendrocyte cell death, axonal damage but also proliferation 
of cells (Del Bigio and Zhang, 1998) whereas the less severe adult form appears to 
cause global white matter ischaemia (Del Bigio, 2000). Neonates have expandable 
skulls thus allowing for greater ventricular enlargement which could explain the 
differences in the severity of hydrocephalus (Nagra et al., 2008). There are also 
differences in cerebral metabolism which suggests that adult rats are more tolerant to 
hydrocephalus compared with neonatal rats (Kondziella et al., 2002). 
Balasubramaniam and Del Bigio (2002) have further highlighted the differences 
between the two age groups by comparing the gene profiles of neonatal and adult 
rats after kaolin-induced hydrocephalus. Neonatal rats appear to have altered 
expression in neural genes relating to neuronal morphology and synapses, in 
oligodendrocyte and myelin genes relating to axonal damage and in neurotrophic 
factors. These all indicate alterations in genes contributing to neuronal survival, 
development and protection. This was not seen in adult rats and could be a feature of 
the plasticity of neonatal hydrocephalic brains (Kondziella et al., 2002, Del Bigio and 
Enno, 2008).  
 
1.9. Fibrosis 
1.9.1. Wound healing and fibrosis 
The wound healing response is similar in all tissues irrespective of the stimuli. 
This could be an infection, autoimmune reaction, toxin or mechanical injury. The 
stimulus causes epithelial and endothelial cell damage and apoptosis resulting in the 
initiation of the coagulation cascade and activation of platelets. Damaged 
epithelial/endothelial cells and activated platelets release chemo-attractant 
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molecules, and blood vessels become more permeable resulting in the recruitment 
and infiltration of monocytes and neutrophils (Wynn and Ramalingam, 2012). 
Neutrophils are attracted within hours of the injury followed by monocytes that mature 
into macrophages to phagocytose cellular debris (Stramer et al., 2007). Phagocytosis 
of dead cells cause the release of pro-inflammatory cytokines that promote 
inflammatory cell recruitment, however phagocytosis can also be anti-fibrotic as it 
clears apoptotic myofibroblasts and reduces pro-fibrotic stimuli (Wynn and Barron, 
2010). Inflammatory cells also produce toxic molecules that damage the surrounding 
tissue and exacerbate the response (Wynn, 2008). In wound healing there is a close 
link between inflammation and fibrosis. Embryonic wounds do not scar as the 
inflammatory response is not yet established whereas adult wounds produce a lot of 
scar tissue and produce a robust inflammatory response as inflammation is critical for 
preventing infection (Stramer et al., 2007).  
The pro-fibrotic cytokines produced by inflammatory cells activate fibroblasts, 
also termed myofibroblasts. Myofibroblasts not only originate from local 
mesenchymal cells but also from epithelial to mesenchymal transition (EMT), 
endothelial to mesenchymal transition (EndMT) and from fibrocytes derived from 
bone marrow stem cells. EMT often occurs after epithelial cell stress caused by 
injury. EMT is induced by cytokines often associated with fibrosis and requires 
proteolytic digestion of the basement membrane. It results in the loss of epithelial 
characteristics including polarity, cell junctions and intermediate filaments and the 
conversion to a more motile phenotype with the rearrangement of actin cytoskeleton 
and development of migratory podia (Kalluri and Neilson, 2003). Myofibroblasts are 
an integral part of wound healing. They contain actin microfilaments that form a local 
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adhesion with fibronectin in the extracellular matrix, so when myofibroblasts contract 
there is also contraction of the ECM. Contraction is stabilised by the deposition of 
ECM and the formation of granulation tissue. In normal healing wounds, the wound 
contracts so that the edges meet, epithelial cells repopulate the tissue and the 
myofibroblasts become apoptotic and are removed by phagocytosis (Gabbiani et al., 
2003; Porter, 2007).   
If the inflammatory response is persistent or recurrent it leads to the 
simultaneous occurrence of inflammation, tissue modelling and repair leading to 
fibrosis (Wynn. 2008). Fibrosis is the excessive accumulation of ECM molecules such 
as collagen, fibronectin and laminin. 
 
1.9.2. Fibrosis and hydrocephalus 
It is well recognised that post-haemorrhagic communicating hydrocephalus is 
caused by blockage of CSF absorption pathways by proliferation of leptomeningeal 
cells and fibrosis at the site of arachnoid granulations (Motohashi et al., 1995a; 
Massicotte and Del Bigio, 1999), and narrowing of the subarachnoid space by 
fibrosis leading to a disturbance in CSF flow. Collagen deposition is observed in the 
subarachnoid space of experimental hydrocephalus models (Suzuki et al., 1977; 
Sajanti et al., 1999; Moinuddin and Tada, 2000; Slobodian et al., 2007) and has been 
associated with an increase in collagen turnover measured by prolyl 4-hydroxylase 
activity (Sajanti et al., 1999), carboxyterminal propeptide of type I procollagen (Heep 
et al., 2002) and aminoterminal propeptide of type III procollagen levels in the CSF 
(Sajanti and Majamaa, 1999; Sajanti et al., 2000, 2001) 
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1.10. TGF-β1 
TGF-βs are multifunctional cytokines involved in proliferation, adhesion, 
motility, apoptosis and differentiation. TGF-β signalling is cell type and context 
dependent and therefore produces a wide range of contradictory effects. 
 
1.10.1. TGF-β1 signalling pathway 
TGF-β initiates intracellular signalling by binding to TGF-β receptor II (RII) 
causing it to complex with TGF-β receptor I (RI). TGF-βRII activates TGF-βRI by 
phosphorylation allowing it to bind to the receptor activated smads; Smad2 and 
Smad3. TGF-βRI then phosphorylates Smad2/3 at the carboxyl terminus causing 
them to be released, thus allowing them to form a complex with Smad4 that 
translocates to the nucleus (Wells, 2000; Lan, 2011; Fig. 1.7). Smads have a low 
affinity for DNA and thus require the cooperation transcription factors including both 
co-repressors and coactivators to regulate gene transcription (Schilling et al, 2008).  
In addition to TGF-β signalling through the Smad pathway it has also been 
demonstrated that TGF-β signals through various other pathways mediated by 
mitogen activated protein kinases (MAPKs) and Rho GTPases (Zhang, 2010). TGF-β 
activation of the MAPKs; extracellular signal related kinase (Erk), c-jun amino 
terminal kinase (JNK) and p38, can affect cell growth, apoptosis, ECM production 
and EMT transition (Hartsough and Mulder, 1997; Hocevar et al., 1999; Yu et al., 
2002). TGF-β signalling through the RhoA, a Rho-like GTPase, is involved in EMT 
and regulates stress fibre acquisition and the conversion to a more fibroblastic 
morphology (Bhowmick et al., 2001).  
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Figure 1.7. The TGF-β/Smad signalling pathway. TGF-β binds to its receptors, 
TGF-β receptor I (TGF-βR1) and receptor II (TGF-βRII). This leads to activation of 
the receptors and subsequent phosphorylation of the receptor activated the Smads; 
Smad2 and Smad3. Phosphorylated Smad2/3 then forms a complex with Smad4 and 
translocates to the nucleus where it facilitates the transcription of TGF-β related 
genes. 
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1.10.2. Regulation of TGF-β signalling 
The tightly regulated TGF-β signalling pathway allows for the various different 
responses to TGF-β. The first site of regulation is at the point of synthesis. TGF-β is 
produced as an inactive form bound to the latency associated protein (LAP). In order 
to become active TGF-β has to be dissociated from LAP before it can bind to TGF-
βRII, and is cleaved by proteases such as plasmin, thrombospondin 1, integrin αVβ6 
and free radicals. This process allows for its temporal and spatial control. For 
example, during inflammation an increase in integrin β6 causes an increase in the 
activation of TGF-β (Munger et al., 1999).  
Signalling can also be altered by recruiting different types of TGF-β RI. In 
endothelial cells, the recruitment of the activin receptor-like kinase (ALK)-5 leads to 
the activation of the Smad2/3 pathway and causes inhibition of proliferation and 
migration, and so TGF-β is anti-angiogenic. On the other hand the recruitment of 
ALK-1 which requires higher concentrations of TGF-β, activates the Smad1/5/8 
pathway leading to proliferation and migration, resulting in TGF-β being angiogenic. 
This paradoxical activity demonstrates how slight changes in the TGF-β signalling 
can have opposing effects (Goumans et al., 2002). 
Other signalling pathways can influence the smad pathway, for example 
MAPK can phosphorylate smad2/3 in a different area to the carboxyl terminus 
leading to impaired nuclear accumulation (Kretzschmar et al., 1999). The Smad-
signalling pathway is essential for inducing endogenous cytokine production and also 
activation of ECM gene expression by TGF-β and therefore is important in the 
induction of fibrosis (Verrecchia and Mauviel, 2002). However the induction of ECM 
genes also requires the cooperation of other pathways. This is demonstrated with the 
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induction of connective tissue growth factor (CTGF) by TGF-β which requires both 
smad and ras/mek/erk signalling (Chen et al., 2002). The MAPK pathways can 
produce transcription factors that cooperate with the smads to affect gene 
transcription (Zhang, 2009). Having different pathways cooperating together, 
producing transcription factors that can be synergistic with other pathways allows for 
a greater specificity of gene regulation (Schilling et al., 2008). 
 
1.10.3. TGF-β and wound healing 
TGF-β1 is involved in all processes of wound healing including inflammation, 
EMT and fibrosis and has demonstrated both anti- and pro- inflammatory and fibrotic 
effects. Consequently due to its key roles in various aspects of fibrosis, excessive 
TGF-β signalling has been implicated in fibrotic disorders in the kidney, liver, lung, 
skin and systemic conditions (reviewed in Bottinger, 2008). 
TGF-β is chemo-attractive for a multitude of inflammatory cells including 
monocytes, macrophages, neutrophils and mast cells. The monocytes that are 
recruited to the site of injury are also activated by TGF-β causing them to produce 
key inflammatory cytokines in addition to inducing its own expression (Wahl et al., 
1989). Once monocytes mature into macrophages they lessen the response to TGF-
β1 due to the downregulation of receptors (Wahl et al., 1987). However these cells 
do continue to produce TGF-β1 which in turn influences other cell types such as 
fibroblasts. The anti-inflammatory actions of TGF-β1 also relates to its influence on T 
cells. TGF-β1 is able to inhibit natural killer and cytotoxic T cells while promoting 
regulatory T cell and effector 17 T cell differentiation (Yang et al., 2010).  In addition 
regulatory T cells produce TGF-β1 to mediate immune suppression (Taylor, 2009).  
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TGF-β1 is chemotactic for fibroblasts, induces EMT and also plays a key role 
in the differentiation of fibroblasts into myofibroblasts (Kalluri et al., 2003; Bottinger, 
2010). TGF-β1 is also involved in inducing the production of extracellular matrix 
proteins such as collagen and fibronectin, and affects matrix degradation by reducing 
the expression of proteases such as matrix metalloproteinases (MMPs), and 
increasing the expression of protease inhibitors including tissue inhibitors of 
metalloproteinases (TIMPs; Verrecchia and Mauviel, 2002).  
 
1.10.4. TGF-β and the brain 
There are low levels of TGF-β1 in the CSF and brain parenchyma of healthy 
humans (Mogi et al., 1995; Krupinski et al., 1996; Flood et al., 2001) and rats 
(Unsicker et al., 1991). After central nervous system injury, TGF-β1 levels are 
increased around the lesion site, particularity in astrocytes (Logan et al., 1992). TGF-
β1 prevents astrocytes from proliferating and alternatively induces hypertrophy and 
migration of astrocytes, encouraging them to produce ECM (Unsicker et al., 1991; 
Morganti-Kossmann et al., 1992). In response to pro-inflammatory molecules 
microglial cells produce TGF-β1. In turn TGF-β1 affects microglial cells by reducing 
their activation, suppressing the release of pro-inflammatory cytokines, reducing their 
proliferation and also inducing apoptosis (Bottner et al., 2000; Lui et al., 2011). 
 
1.10.5. TGF-β and hydrocephalus 
Several lines of evidence implicate TGF-β1 in the development of post-
haemorrhagic hydrocephalus. Patients with SAH who go on to develop post-
haemorrhagic hydrocephalus have higher levels of TGF-β1 and β2 in their CSF 
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compared to those patients with SAH who don’t develop hydrocephalus (Kitazawa 
and Tada, 1994; Flood et al., 2001; Douglas et al., 2009). The hypothesis is that in 
SAH, blood enters the subarachnoid space and TGF-β1 is released by activated 
platelets (Assoian et al., 1983) into the CSF. TGF-β1 then induces its own expression 
in cells of the meninges and choroid plexus, resulting in a second increase in TGF-β1 
in CSF (Flood et al., 2001). It promotes the growth and proliferation of cells such as 
leptomeningeal cells and increases their production and deposition of extracellular 
matrix which ultimately obstructs CSF absorption sites leading to the development of 
hydrocephalus (Motohashi et al., 1995; Massicotte and Del Bigio, 1999). 
Experimental studies in models of hydrocephalus have also implicated TGF-
β1 in the development of hydrocephalus. Overexpression of TGF-β1 specifically in 
the CNS of transgenic mice (Galbreath et al., 1995; Wyss-Coray, et al.,1995) and an 
intrathecal injection of human recombinant TGF-β1 into neonatal mice (Tada et al., 
1994; Kanaji et al., 1997), lead to the development of hydrocephalus. The latter 
model also showed increased fibrosis and proliferation of meningeal cells resulting in 
disturbed CSF flow (Moinuddin and Tada, 2000) and the hydrocephalus could be 
prevented by injecting a TGF-β1 antibody (Kanaji et al., 1997). In a kaolin induced 
mouse model of hydrocephalus most macrophages in the subarachnoid space and 
the choroid plexus were TGF-β1 positive (Hatta et al., 2006). These studies together 
suggest a role for TGF-β1 in the development of hydrocephalus, possibly due to its 
effects on promoting fibrosis. 
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1.11. Decorin 
Decorin is a small leucine rich chondroitin-dermatan sulphate proteoglycan 
(CSPG). As the name suggests Decorin is composed of a protein core that contains 
leucine rich repeats and has a glycosaminoglycan side chain of either chondroitin 
sulphate or dermatan sulphate. Decorin’s curved shaped is attributed to the leucine 
rich repeats. Proteins that contain leucine rich repeats appear to be involved in 
protein-protein interactions (Kobe and Deisenhofer, 1995). Initially, Decorin’s role 
was first associated with the organisation of collagen fibril formation and 
maintenance during development and repair due to its binding properties to fibrillar 
collagens such as type I, II, V, VI and XIV. Decorin is found in tissues rich in these 
collagens such as the heart and lungs (Brown and Vogel, 1989; Hocking et al., 
1998). From knockout studies it has been demonstrated that a lack of Decorin 
causes abnormal formation of the collagen fibril network in the skin with collagen 
fibrils of different shapes and sizes leading to reduced strength (Danielson et al., 
1997). Since then Decorin has been shown to bind to a variety of different bioactive 
molecules all of which allows it to influence diverse cellular functions including protein 
synthesis, cell proliferation and inflammation. When considering the actions of 
Decorin it is important to realise that due to its diverse interactions it may lead to 
different responses in different situations (e.g. normal tissue vs. cancerous tissue).  
 
1.11.1. Decorin and TGF-β 
Yamaguchi et al. (1990) first demonstrated that Decorin binds to TGF-β and 
sequesters it into the ECM thus preventing it from interacting with its receptors (Fig. 
1.8). Although in some particular circumstances Decorin binding to TGF-β enhances 
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growth factor activity (Takeuchi et al., 1994), inhibition of TGF-β activity after Decorin 
binding is more widely reported. TGF-β has also been demonstrated to induce 
Decorin expression (Border et al., 1990) therefore it is hypothesised that it acts as a 
negative-feedback regulator of TGF-β activity. However, in fibroblasts from the skin 
(Breuer et al, 1990; Kahari et al, 1991), lung (Romaris et al, 1991), cornea (Brown et 
al, 1999), arterial smooth muscle cells (Schonherr et al., 1993) and human 
endothelial cells (Nelmarkka et al., 1997), TGF-β1 either had no impact or reduced 
Decorin expression. Therefore, in wound healing, the lack of Decorin expression 
could lead to aberrant TGF-β signalling and the formation of fibrosis. Increased levels 
of TGF-β1 and reduction in Decorin expression have been demonstrated in 
fibroblasts from hypertrophic scar tissue (Scott et al., 1998), myofibroblasts from liver 
fibrogenesis (Meyer et al., 1992) and bleomycin induced pulmonary fibrosis 
(Westergren-Thorsson et al.,1993).  
The antagonistic activity of Decorin has implicated it as an anti-fibrotic agent. 
In skin wounds, inhibition of TGF-β1 by Decorin leads to inhibition of fibroblast 
proliferation and reduction in collagen synthesis (Zhang et al., 2007). Also Decorin is 
able to delay wound contraction which is thought to be beneficial in reducing scar 
and promoting regeneration (Shafritz et al., 1994). Decorin reduces fibrosis in cardiac 
allografts causing reduced allograft rejection, and reduces hypertension induced 
cardiac fibrosis leading to improved cardiac function (Faust et al., 2009; Yan et al., 
2009). There is also evidence that Decorin may be involved in reversing cardiac 
remodelling through its inhibition of TGF-β1 (Jahanyar et al., 2007). In models of 
pulmonary fibrosis increasing Decorin levels suppresses TGF-β1 inhibition of lung 
morphogenesis (Zhao et al., 1999), reduces neutrophil infiltration (Giri et al, 1997) 
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and reduces the fibrogenic response (Kolb et al., 2001). In models of renal fibrosis 
including glomerulonephritis (Noble et al., 1992; Border et al., 1992), and in diabetic 
nephropathy (Wu et al., 2007), Decorin suppresses TGF-β1 induced ECM deposition. 
Decorin reduces scarring in eye pathologies including glaucoma and proliferative 
vitreoretinopathy (Grisanti et al., 2005; Nassar et al., 2011). Decorin also has 
beneficial effects after muscle injury by promoting the differentiation of myoblasts into 
myotubes instead of myofibroblasts thus reducing fibrous scar formation in addition 
to promoting muscle regeneration by inhibiting TGF-β and myostatin (Li et al., 2004, 
2007). 
TGF-β is also involved in inflammation and EMT and inhibition of TGF-β by 
Decorin has been shown to reduce the number of OX42/ED1 positive microglia 
(Engel et al., 1999), to increase activation of macrophages (Comalada et al., 2003) 
and to prevent the transformation of fibroblasts into myofibroblasts (Mohan et al., 
2010). Accordingly, in CNS lesions, Decorin reduces the deposition of chondroitin 
sulphate proteoglycans, fibronectin and laminin, and suppresses astrocytic, microglial 
and macrophage reactions in and around the wound (Logan et al., 1999a; Davies et 
al., 2004). Similarly, immuno-neutralisation of TGF-β2 suppresses inflammation and 
scarring in brain lesions (Logan et al., 1999b). All together, these findings suggest 
that Decorin could be a potential therapeutic for inhibiting TGF-β-induced post-
haemorrhagic fibrosis. 
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Figure 1.8. Inhibition of TGF-β1 by Decorin. Decorin Binds to TGF-β1, sequestering it into the extracellular matrix so that it 
is unable to bind to its receptors; TGF-β receptor I (TGF-βR1) and receptor II (TGF-βRII). 
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1.11.2. Decorin and the tyrosine kinase receptors 
Decorin’s involvement in signalling through the receptor tyrosine kinases (RTKs) 
was first identified when it was observed that Decorin arrested cell growth in squamous 
carcinoma cells through its affects on epidermal growth factor receptor (EGFR; De Luca 
et al., 1996).  
The EGF pathway is involved in cell proliferation, survival, angiogenesis, 
adhesion, migration/invasion and differentiation and therefore Decorin has been 
implicated as an anti-tumour agent. It has been shown that Decorin binds directly to the 
EGFR causing dimerisation of the receptor and activation of its signalling pathway 
(Moscatello et al., 1998, Iozzo et al., 1999). However this is only transient and is rapidly 
followed by internalisation of EGFR by caveolar mediated endocytosis and subsequent 
degradation by lysosomes (Csordás et al., 2000; Zhu et al., 2005). Inhibiting the EGF 
pathway leads to production of the cyclin dependent kinase inhibitor p21 that leads to 
growth arrest at the G1 phase of the cell cycle (Moscatello et al., 1998).  
Decorin also affects other members of the Erb family including ErbB2 and ErbB2. 
In breast carcinoma cells that lack EGFR but overexpress ErbB2, Decorin first causes 
transient activation of ErbB2 followed by its prolonged downregulation resulting in 
growth suppression and reduced metastasis (Reed et al., 2005; Goldoni et al., 2008). 
The initial activation also signals through the RhoA pathway to induce thrombospondin-1 
which results in Decorin inhibiting tumour angiogenesis in breast carcinoma cells (Neill 
et al., 2013). PCR array data also demonstrates that in carcinoma cells Decorin 
upregulates anti-angiogenic genes and downregulates pro-angiogenic genes (Neill et 
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al., 2012). However, in osteosarcoma cells that overexpress continually phosphorylated 
EGFR Decorin had no effect on growth suppression (Zafiropoulos et al., 2008). 
The hepatocyte growth factor receptor known as the met receptor is involved in 
tumour transformation, invasion and metastasis (Goldoni et al., 2009). In squamous and 
breast carcinoma cells Decorin binds to the Met receptor causing an initial activation 
followed by internal degradation of Met through E3 ubiquitin Ligase C. This causes 
attenuation of β-catenin levels leading to degradation of Myc, which was shown to 
reduce cell growth and suppress migration (Goldoni et al., 2009; Buraschi et al., 2010). 
Also by inhibiting the Met receptor, Decorin causes a reduction in VEGF and HIF1α, 
increased TIMP-1 and suppression of MMP2 and 9 leading to suppression of tumour 
angiogenesis (Neill et al., 2012). 
There is not extensive research into Decorin’s effects on TKRs in normal tissue. A 
study by Santra et al. (2008) investigating the effects of Decorin on mouse cerebral 
endothelial cells demonstrated the activation of EGFR signalling through ERK1/2 and 
PI3K pathways lead to an increase in VEGF. This in turn increased the protein levels of 
plasminogen and plasmin and reduced the activity of MMP2 and 9 thus leading to the 
promotion of angiogenesis. The results from this study appear to be contradictory to its 
effects in tumour environments.  
 
1.11.3. Other effects of Decorin 
Decorin acts as a cell adhesion modulator and is able to inhibit cell attachment in 
vitro by binding to fibronectin (Bidanset et al., 1992) and thrombospondin (Winnemoller 
et al., 1992). Decorin is able to increase the inhibition of thrombin by heparin sulphate II 
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and therefore could affect the coagulation of blood (Whinna et al., 1993). It also binds to 
C1q, inhibiting the C1 complex which is part of the classical complement pathway, and 
could consequently affect the innate immune response (Krumdieck et al., 1992).  
 
1.12. Hypothesis and aims 
1.12.1. Hypothesis 
Post-haemorrhagic hydrocephalus develops due to inflammation-induced fibrosis 
in the subarachnoid space that obstructs CSF drainage. The inflammatory cytokine 
TGF-β1 plays a significant role in the development of fibrosis through promoting ECM 
deposition, as well as preventing the degradation of fibrosis through inhibition of 
proteases. Several lines of evidence implicate TGF-β1 in the development of post-
haemorrhagic hydrocephalus, including: (i) CSF levels of TGF-β1 are higher in post-
haemorrhagic hydrocephalus patients compared with the levels recorded in patients with 
both non-haemorrhagic hydrocephalus and haemorrhage without hydrocephalus 
(Kitazawa and Tada, 1994; Whitelaw et al., 1999; Flood et al., 2001; Douglas et al., 
2009); (ii) ventriculomegaly is positively correlated with the intensity of TGF-β1 
immunostaining in experimental neonatal post-haemorrhagic hydrocephalus (Cherian et 
al., 2004); and (iii) hydrocephalus develops both in transgenic mice overexpressing 
TGF-β1 in astrocytes (Galbreath et al., 1995) and after intrathecal injection of human 
recombinant TGF-β1 (Tada et al., 1994; Kanaji et al., 1997). 
Therefore, it was hypothesised that if post-haemorrhagic communicating 
hydrocephalus is caused by TGF-β-induced subarachnoid fibrosis, then Decorin, a TGF-
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β antagonist, would be beneficial as a therapeutic agent by preventing the development 
of subarachnoid fibrosis and subsequently the development of hydrocephalus, and, by 
degrading subarachnoid fibrosis leading to the resolution of established hydrocephalus. 
 
1.12.2. Aims 
a) To generate an in vitro model of rat meningeal fibroblasts to assess the effects of 
human recombinant Decorin on TGF-β1-induced meningeal fibrogenesis. 
b) To develop a reliable in vivo rat model of communicating hydrocephalus and 
determine the changes in endogenous TGF-β1 in the model. 
c) To assess the ability of human recombinant Decorin to prevent subarachnoid 
fibrosis and the development of hydrocephalus in the model of communicating 
hydrocephalus developed in b). 
d) To assess the ability of human recombinant Decorin to degrade subarachnoid 
fibrosis and resolve established hydrocephalus. 
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Chapter 2 
 
Materials and Methods 
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Unless otherwise stated reagents were obtained from Sigma-Aldrich, Poole, UK. 
 
2.1. In Vitro methods (Chapter 3) 
2.1.1. Isolation and culture of rat meningeal fibroblasts 
Adult Sprague Dawley rats (weight ~ 200g) were killed in a rising CO2 chamber 
and the heads removed and put on ice. The top of the skull was carefully removed and 
the meninges peeled off the top of the brain and the base of the skull once the brain was 
removed. Meningeal tissue was placed in Dulbecco’s modified eagle medium (DMEM; 
Life Technologies, Paisley, UK) on ice and unwanted brain tissue or bone fragments 
were removed. The meningeal tissue was cut into 1mm2 pieces, transferred to a mini 
petri dish with DMEM supplemented with 100U/ml (1%) penicillin-streptomycin (pen-
strep; Life Technologies), containing dispase I (2.5U/ml; Life Technologies) and 
collagenase (200U/ml), and incubated for 2 hours at 37°C in a humidified 5% CO2 
chamber. The reaction was stopped by adding Complete Medium (DMEM, 1% pen-strep 
and 10% foetal bovine serum; FBS) and the tissue was gently triturated. The meningeal 
tissue was transferred to a 15ml falcon tube (Sarstedt, Leicester, UK) and centrifuged for 
5 minutes at 1,500 rpm. After removing the supernatant the cells were resuspended in 
Complete Medium and seeded in 2 wells of a 6 well tissue culture plate (BD 
Biosciences, Oxford, UK).   
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2.1.2. Passaging of cells 
When the meningeal cell culture had reached confluency the cells were washed in 
sterile 10mM phosphate buffered saline pH 7.4 (PBS) and incubated in 2% Trypsin-
EDTA (Life Technologies) at 37°C in a humidified 5% CO2 chamber for 5 minutes or until 
the cells had detached. Complete Medium was then added and the cell suspension was 
transferred to a 15ml falcon tube and centrifuged for 5 minutes at 1,200 rpm. After 
removing the supernatant the cells were resuspended in Complete Medium and seeded 
in 25, 75 or 175 cm2 vented flasks (Sarstedt). 
 
2.1.3. TGF-β1 and Decorin bioassay 
Rat meningeal fibroblasts were seeded onto 6 well tissue culture plates in Complete 
Medium at a density of 80,000-100,000 cells per well, and incubated at 37⁰C in a 
humidified 5% CO2 chamber for 48 hours. The medium was then removed and replaced 
with serum free medium (DMEM, 1% pen-strep) and incubated for a further 24 hours. 
The cells were treated with 10, 25 or 50ng/ml human recombinant TGF-β1 (PeproTech 
Inc, NJ, USA) and/or 20μg/ml non-cGMP (current good manufacturing practice) purified 
Decorin (Galacorin™, Catalent, Pharma Solutions, NJ, USA), and incubated for 48 
hours. The cells were then washed in PBS, scraped from the dish and centrifuged for 5 
minutes at 1,500 rpm. The supernatant was removed, the cell pellet incubated on ice for 
30 minutes with ice-cold lysis buffer (20mM Tris-HCl pH 7.4, 150mM NaCl, 1mM EDTA, 
0.5mM EGTA, 0.1% NP-40) containing 5μg/ml protease inhibitor cocktail, and then 
centrifuged for 30 minutes at 13,000 rpm at 4°C. The supernatant was removed and 
stored at -80°C. 
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2.2. Western blot (Chapter 3) 
2.2.1. Principles  
Western blotting is used to identify specific proteins based on their molecular 
weight characteristics and using the specificity of antigen-antibody interactions.  It is a 
semi-quantitative technique that allows differences in protein levels and isoforms to be 
identified between treatment groups. An electric current is used to separate proteins 
captured in a gel, with separation based on their size/charge, the separated proteins in 
the gel are then transferred to a nitrocellulose or polyvinylidene fluoride (PVDF) 
membrane ready for detection. The membrane is incubated with a primary antibody 
which binds to the specific protein of interest. A secondary antibody linked to 
horseradish peroxidase (HRP) binds to the primary antibody. The HRP catalyses the 
oxidation of luminol emitting light, as it decays. This reaction can then be caught on 
photographic film (Fig. 2.1). The intensity of the light emitted is proportional to the 
amount of protein present in the band of interest. 
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Figure 2.1. Principles of western blotting. (A) An electric current separates proteins 
along the gel according to their molecular weight. (B) Primary antibodies are used to 
bind to the protein of interest that has been transferred to a membrane, which is 
subsequently detected by a horseradish peroxidase (HRP) linked secondary antibody. 
HRP catalyses the oxidation of the chemiluminescent substrate, which subsequently 
decays and emits light. The intensity of light is proportional to the amount of the protein.  
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2.2.2. Polyacrylamide gel electrophoresis 
8% Tris-glycine sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis 
(PAGE) gels were prepared comprising stacking and resolving gels (Table 2.1). The cell 
lysate samples were defrosted on ice and equal amounts of protein (determined by 
BioRad protein Assay) the cell lysate was added to the 2X loading buffer (4% SDS, 20% 
glycerol, 2% 2-mercaptoethanol, 0.004% bromophenol blue and 0.125M Tris-HCl pH 
6.8) and placed on a heat block at 90°C for 4 minutes to denature the protein. Proteins 
were separated by electrophoresis using a XCell SureLock™ system (Life Technologies) 
at 125V for 2 hours. 
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 Stacking 
Gel 
8% 
Resolving 
Gel 
Protogel™ (40% Acrylamide 0.8% Bisacrylamide Stabilised 
Solution; National diagnostics) 
0.4ml 1.83ml 
0.5M Tris/Cl pH 6.8 1.85ml - 
1.5M Tris/Cl pH 8.8 - 1.65ml 
Distilled water 0.75ml 3.12ml 
10% SDS 30µl 66µl 
10% APS (ammonium persulfate) 15µl 23.1µl 
TEMED (Tetramethylethylenediamine) 7.5µl 9.9µl 
 
Table 2.1. SDS PAGE Gel composition. Amounts of each component used to make up 
the stacking and the 8% resolving gels. 
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2.2.3. Protein transfer and detection 
 An Immobilon-P PVDF membrane (Millipore, Watford, UK) was activated with 
100% methanol (Fisher Scientific, Leicestershire, UK) and the proteins were 
electrophoretically transferred to the activated PVDF membrane over 2 hours at 25V 
using an XCell IITM blot module (Life Technologies). After washing in TBST (0.12% Tris-
base, 0.88% NaCl, pH 7.4, 0.05% Tween20), the membrane was incubated in blocking 
buffer (TBST, 5% dried skimmed milk; Marvel, Lincolnshire, UK) for 1 hour at room 
temperature. It was then incubated with primary antibody solution (TBST, 5% dried 
skimmed milk) on a tilting platform overnight at 4°C. The membrane was washed in 
TBST before being incubated with secondary HRP conjugated antibody solution (TBST, 
5% dried skimmed milk) for 1hr at room temperature.  
Immunoreactive protein bands were detected using an enhanced 
chemiluminescence (ECL) solution according to the manufacturer’s protocol (GE 
Healthcare, Buckinghamshire, UK). Briefly, the membrane was covered with equal 
quantities of ECL detection reagent 1 and 2 and incubated for 1 minute before being 
placed in a cassette and exposured to Biomax Light film (Kodak, NY, USA). In order to 
detect other proteins of interest, the membrane was stripped and re-probed. Membranes 
were placed in stripping buffer (100mM glycine pH 2.9) for 30 minutes at room 
temperature before repeating the procedure outlined previously for the detection of 
proteins. 
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2.3. In Vivo Methods 
2.3.1. Experimental animals 
Adult male Sprague-Dawley rats (~250g; Charles River, Margate, UK) were 
housed in groups of 4 for experiments conducted in Chapter 3. Three week old 
Sprague-Dawley rats (~50g; Charles River, Massachusetts, USA and Margate, UK) 
were housed in litters in individual cages for experiments conducted in Chapters 4, 5 
and 6. The rats were kept under a 12 hour light/dark cycle with free access to food and 
water. Animals were monitored daily for adverse effects of treatments, such as distress, 
lethargy, weight loss and seizures, and any animals showing severe adverse effects 
were euthanised. All efforts were made to minimise post-surgery discomfort and the 
number of animals used. The experiments conducted at the University of Birmingham 
were in accordance with the Animals and Scientific Procedures Act 1986, licensed by 
the UK Home Office (Home Office Project Licence PPL 30.2720) and approved by the 
University of Birmingham Ethics Committee, Those conducted at the University of Utah 
were carried out in accordance with the guidelines of the National Institutes of Health 
Care and Use of Laboratory Animals and procedures were approved by the University of 
Utah Ethics Committee.  
 
2.3.2.  Injection of kaolin into the prechiasmatic cistern (Chapter 3) 
Rats were anaesthetised with 5% isoflurane (National Veterinary Supplies, Stoke, 
UK), maintained at 2-3% isoflurane and given a subcutaneous injection of 
Buprenorphine (National Veterinary Supplies). The head was shaved before the rat was 
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placed in the stereotactic apparatus (David Kopf Instruments, California, USA). A scalpel 
was used to make an incision along the midline on the top of the skull so that Bregma 
was revealed and marked. A Hamilton syringe was placed in the stereotactic frame and 
tilted 30° in the sagittal plane. The needle tip was placed 8mm anterior from Bregma and 
slightly lateral (to avoid hitting any major blood vessels) and the position on the cranium 
was marked. A dental drill was used to drill a burr hole through the cranium at this 
position. The needle was repositioned over the burr hole and slowly advanced until 
resistance was felt from the base of the skull (10mm from the surface of the brain; Fig. 
2.2.A). At this point 50µl of 25% Kaolin solution (250mg/ml; Fisher Scientific) in 0.9% 
sterile saline was slowly injected, and the needle withdrawn after being left in place for 1 
minute after the injection. Control animals received 50μl sterile 0.9% saline solution. The 
skin was then sutured and the rat allowed to recover.  
 
2.3.3. Injection of kaolin into the basal cisterns (Chapters 3, 4, 5 and 6) 
The method of basal cistern injection of kaolin was described by Li et al. (2008) 
and used in several subsequent studies (Wagshul et al., 2009, Nagra et al., 2010, 
Rashid et al., 2012). Rats were anaesthetised with 5% isoflurane, maintained at 2-3% 
and either given a subcutaneous injection of Buprenorphine (Chapters 3, 5 and 6) or 
Carprofen tablets (Chapter 4). Using aseptic techniques, the skin was incised along the 
ventral midline of the neck and the muscles mobilised to expose the atlanto-occipital 
membrane, the membrane between the occipital bone and the C1 vertebrae. A 30 
gauge needle, angled at 30-45° was used to first puncture the membrane allowing CSF 
to leak out before being inserted into the subarachnoid space (Fig. 2.2.B-F). The needle 
67 | P a g e  
 
was then advanced 1-2mm under the occipital bone and 30μl of 20% kaolin solution 
(200mg/ml; Fisher Scientific) in 0.9% sterile saline was injected over a period of 15 
seconds. The skin was sutured and the rats were either allowed to recover or transferred 
to a stereotactic frame (David Kopf Instruments) for osmotic pump and intraventricular 
cannula implantations. 
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Figure 2.2. Diagrams explaining the in vivo models of hydrocephalus. (A) In the prechiasmatic cistern model, 
kaolin was injected using a needle angled at 30⁰ through the brain to access the cistern. (B) In the basal cisterns 
model, kaolin was injected using an angled needle through the atlanto-occipital membrane. For the basal cistern 
approach, first an incision was made along the ventral midline of the neck (C) and forceps were used to blunt dissect 
the muscles apart to expose the atlanto-occipital membrane (D). An angled needle was then used to inject kaolin 
through the membrane and into the basal cisterns (black arrow; E).  (F) Photo demonstrating the surgical approach. 
OB – occipital bone, SH – sternohyoid muscle, SM – sternomastoid muscle. 
A B 
C D E F 
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2.3.4. Implantation of the osmotic mini pump and brain cannula (Chapters 4, 5 and 
6) 
Osmotic pumps (model 2002, Alzet, Durect Corporation, California, USA) were 
prepared under sterile conditions. Pumps were adapted for MRI by replacing the metal 
flow moderator with PEEK tubing and using a customised 5mm long PEEK brain 
cannula (Plastics 1, Virginia, USA) attached to the pedestal. The catheter tubing was 
attached to the brain cannula and then in addition to the pumps, was filled with either 
5mg/ml human recombinant Decorin (Galacorin™, Catalent, Pharma Solutions, New 
Jersey, USA) or PBS vehicle. The osmotic pumps were then connected to the brain 
cannula by the catheter tubing and primed in sterile saline overnight at 37°C to allow 
prompt delivery after implantation. 
After fixing the heads of anaesthetised rats in a stereotactic frame, the dorsal skull 
was exposed and a burr hole sited in the parietal bone using co-ordinates 1mm posterior 
and 1.5mm lateral to Bregma. The cannula was inserted into the right lateral ventricle 
and fixed in place with glue and bone cement (Biomet UK Ltd, Bridgend, UK) to a 
stabilising screw (Plastics1) and the osmotic pump was implanted subcutaneously in the 
neck region (Fig. 2.3). The surgical incision was sutured and the animal was allowed to 
recover. 
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Figure 2.3. Diagram representing the osmotic mini pump implantation. The brain 
infusion cannula was implanted into the lateral ventricle. The pump was attached by 
tubing to the brain infusion cannula and implanted subcutaneously in the neck region.  
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2.3.5. CSF collection 
For CSF removal, the rat was killed with an intraperitoneal injection of euthatol 
(National Veterinary Supplies) and then immediately placed in a head holder with the 
head fixed in a nose down position. Scissors were used to cut through the skin along the 
midline between the ears, and the superficial muscles were blunt dissected to expose 
the atlanto-occipital membrane at the back of the skull. A pulled glass micropipette made 
using a Flaming/Brown Micropipette puller (Sutter Instrument, California, USA), was 
inserted through this membrane and CSF allowed to flow out or removed gently with an 
attached syringe. On completion, the micropipette was slowly withdrawn, The CSF 
collected in eppendorf tubes and the rat perfused. The CSF was then frozen and stored 
at -20⁰C. 
 
2.3.6. Tissue preparation for histology 
The rats were perfused transcardially with PBS followed by 4% paraformaldehyde 
(PFA; Alfa Aesar, Massachusetts, USA) in PBS at pH7.4. Brains were immersed in 4% 
PFA overnight at 4°C, cryoprotected by sequential immersion in 10%, 20% and 30% 
sucrose solutions in PBS at 4°C and embedded in optimum cutting temperature (OCT) 
embedding matrix (Fisher Scientific, Loughborough, UK).Coronal sections, 15µm thick, 
were cut on a Bright cryostat (Bright Instrument, Cambridgeshire, UK), placed onto 
Superfrost Plus slides (Thermo Scientific, Massachusetts, USA), and stored at -20°C 
before staining. 
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2.4. Immunohistochemistry and immunocytochemistry 
2.4.1. Principles 
Immunohistochemistry and immunocytochemistry are techniques used to identify 
and localise specific proteins within tissue or cell samples respectively, by exploiting the 
specificity of antigen-antibody interactions. Primary antibodies detect and bind to the 
specific protein (antigen) of interest. Secondary antibodies bind to the primary antibody 
as they have been raised against the animal species from which the primary antibody 
was generated. Secondary antibodies are usually used to amplify the signal to improve 
sensitivity. Two detection methods were used in this study, the indirect 
immunofluorescent method and the avidin-biotin complex (ABC) method. The indirect 
immunofluorescent method utilised secondary antibodies labelled with a fluorescent dye 
(Fig. 2.4.A). The dye absorbs energy at a specific wavelength and emits it at a different 
wavelength, which can be detected using a fluorescence microscope. In the ABC 
method, the secondary antibody is conjugated to biotin, which binds to a preformed 
avidin-biotin complex containing biotin bound to HRP (Fig. 2.4.B). The HRP catalyses 
the oxidation of added 3, 3’-diaminobenzidine (DAB) and produces a brown precipitate 
over the binding site that can be visualised under a light microscope. 
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Figure 2.4. Immunohistochemistry methods. (A) Indirect immunofluorescent method. A secondary antibody 
conjugated to a fluorescent dye binds to the primary antibody. The dye emits a fluorescent light that can be detected 
using a fluorescence microscope. (B) Avidin-biotin complex (ABC) method. A biotinylated antibody binds to the 
primary antibody. This subsequently binds a preformed ABC that contains HRP. The HRP catalyses a substrate 
reaction which results in the precipitation of a coloured product over the binding site.  
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2.4.2. Immunocytochemistry 
Rat meningeal fibroblasts were plated onto a chamber slide which had been pre-
coated with 100μg/ml poly-D-lysine and incubated at 37°C in a humidified 5% CO2 
chamber for 48 hours until confluent. All subsequent incubations were performed at 
room temperature. The cells were washed in PBS then fixed in 4% PFA in PBS for 15 
minutes. The cells were then washed again in PBS before non specific binding sites 
were blocked in PBS containing 0.3% Tween20 (PBST), 2% bovine serum albumin 
(BSA) and 15% normal serum (Vector Laboratories) for 10 minutes. This was followed 
by incubation of the cells in primary antibody solution (primary antibody in PBST with 2% 
BSA) for 1 hour. The cells were again washed in PBS before being incubated in 
secondary antibody solution (secondary antibody in PBST with 2% BSA and 1.5% 
normal serum) for 1 hour in the dark. Finally the cells were washed in PBS before being 
mounted in VectaShield mounting medium containing DAPI (Vector Laboratories, 
Peterborough, UK). 
 
2.4.3. Immunofluorescence staining 
Slides were removed from the freezer and allowed to thaw. A circle was drawn with 
a hydrophobic ImmEdge pen (Vector Laboratories) around the section and allowed to 
dry for 5 minutes. Sections were washed in PBST (PBS with 0.3% Tween20) before 
non-specific binding sites were blocked in PBST containing 2% BSA and 15% normal 
goat serum for 20 minutes at room temperature. Sections were then incubated in the 
primary antibody solution (primary antibody in PBST with 2% BSA) either at 4°C 
overnight or at room temperature for 1 hour. After washing in PBST, sections were 
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incubated with appropriate Alexa Fluor® 488 or 594 labelled secondary antibodies (Life 
Technologies, Paisley, UK) in secondary antibody solution (PBST with 2% BSA and 
1.5% normal goat serum) for 1 hour at room temperature in the dark. Finally, sections 
were washed in PBST before mounting in Vectashield containing the nuclear stain DAPI 
(Vector Laboratories). 
 
2.4.4. Immunoperoxidase staining 
Slides were removed from the freezer and allowed to thaw. A circle was drawn with 
a hydrophobic ImmEdge pen (Vector Laboratories) around the section and allowed to 
dry for 5 minutes. The sections were washed in distilled water before being incubated 
with 0.3% H2O2 (70% methanol in PBS) for 30 minutes to inhibit endogenous 
peroxidase. Sections were washed in PBST before non-specific binding sites were 
blocked in PBST containing 2% BSA and 15% normal serum for 1 hour at room 
temperature, and then incubated in primary antibody solution at 4°C overnight. Sections 
were again washed in PBST before incubation in biotinylated secondary antibody 
solution (Vector Laboratories) for 30 minutes at room temperature. Sections were 
washed in PBST and then incubated for 30 minutes at room temperature in Avidin/Biotin 
Complex (ABC; Vectastain Elite ABC kit, Vector Laboratories) following the 
manufacturer’s instructions. After rinsing in PBST, sections were treated with 3’3 
diaminobenzidine (DAB) substrate (Vector Laboratories), washed in distilled water, 
counterstained with Mayer’s haematoxylin, washed in running water before dehydration 
through an ascending series of alcohol concentrations, cleared in Histoclear (Fisher 
Scientific) and mounted in Vectamount medium (Vector Laboratories). 
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2.5. Enzyme-linked immunosorbent assay  
2.5.1. Principles 
Enzyme-linked immunosorbent assay (ELISA) is a technique used to quantify the 
amount of a specific protein in solution by exploiting the specificity of antigen-antibody 
interactions. A 96 well plate is coated with capture antibody that binds to the specific 
protein (antigen) of interest. A detection antibody conjugated to biotin, which is raised 
against a different epitope of the protein to the capture antibody, also binds to the 
protein of interest. Steptavidin bound to HRP is then added and binds to the detection 
antibody. Finally a substrate for HRP is added which results in the generation of a 
coloured product (Fig. 2.5). The reaction is stopped and then the optical density of each 
well is measured using a microplate reader. This ELISA technique involves using 
antibodies either side of the substrate and so it is known as a sandwich ELISA. 
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Figure 2.5. ELISA method. (A) First the wells of a 96 well plate are coated with capture 
antibody which subsequently binds to the protein of interest (B). This protein is then 
detected with a biotinylated detection antibody (C). (D) Streptavidin conjugated to 
horseradish peroxidise (HRP) binds the detection antibody. (E) Finally a substrate is 
added and the conjugated HRP catalyses a reaction which results in the precipitation of 
a coloured product. 
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2.5.2. Decorin ELISA 
The ELISA kit used to detect and quantify Decorin was the human Decorin DuoSet 
(DY143, R&D Systems, UK) and both the protocol and reagents were supplied. All 
procedures were conducted at room temperature and between each step the wells were 
aspirated and washed with wash buffer (0.05% Tween20 in PBS). A 96 well plate was 
coated with capture antibody (2µg/ml monoclonal mouse anti-human Decorin diluted in 
PBS), covered and left overnight. Non specific binding sites in the wells were blocked 
with the reagent diluent (DY995, 1% BSA in PBS) for 1 hour followed by incubation with 
the CSF sample (1/10 dilution) or Decorin standards (recombinant human Decorin, serial 
dilutions up to 2000pg/ml) for 2 hours. The wells were then incubated with detection 
antibody (250ng/ml biotinylated mouse anti-human Decorin in reagent diluent) for 2 
hours, after which the wells were incubated with streptavidin conjugated to HRP (1/200 
in reagent diluent) in the dark for 20 minutes. Finally the wells were incubated in the 
substrate solution (DY999, equal amounts of H2O2 and tetramethylbenzidine) in the dark 
for 20 minutes and the reaction stopped with the stop solution (2N H2SO4). The optical 
density was determined immediately using a microplate reader set to 450nm (with the 
readings at 540/570nm subtracted for imperfections in the plate). All samples were run 
in duplicate and the average optical density of the two samples taken. 
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2.6. Antibodies 
Antibody  Detects Host Dilution Source Catalogue 
number 
α-smooth muscle 
actin 
 Mouse 1/100 Sigma-Aldrich, Poole, UK  
β-actin β-actin Mouse 1/1000 (WB) Sigma-Aldrich, Poole, UK A5441 
βIII-Tubulin Neurons Mouse 1/400 (ICC) Sigma-Aldrich, Poole, UK T8660 
CD11b (OX-42) Microglia and 
macrophages 
Mouse 1/50 (ICC), 1/500 (IF) Serotec, Oxford, UK MCA275R 
CD68 (ED-1) Macrophages and 
activated microglia 
Mouse 1/100 (ICC), 1/400 (IF) Serotec, Oxford, UK MCA341R 
Cleaved 
caspase 3 
Apoptotic cells Rabbit 1/200 (IF) Cell Signalling, MA, USA 9661S 
Collagen 1 Collagen 1 Rabbit 1/50 (ICC) Abcam, Cambridge. UK Ab292 
Decorin Human Decorin Mouse 1/400 (IF) Abcam, Cambridge, UK Ab54728 
Fibronectin Fibronectin Rabbit 1/200 (ICC/IF) Sigma-Aldrich, Poole, UK F3648 
GFAP Astrocytes Mouse 1/500 (ICC/IF) Sigma-Aldrich, Poole, UK G3893 
Ki67 Cell proliferation Rabbit 1/400 (IF) Abcam, Cambridge, UK Ab16667 
Laminin Laminin Rabbit 1/200 (IF) Sigma-Aldrich, Poole, UK L9393 
Nestin Neuroprogenitor 
cells 
Mouse 1/50 (IF) BD Biosciences, Oxford, UK 556309 
NG2 NG2 Rabbit 1/200 (ICC), 1/500 (WB) Millipore, MA, USA AB5320 
RECA-1 Rat endothelial cells Mouse 1/50 (ICC) Serotec, Oxford, UK MCA970R 
TGF-β1 TGF-β1 Mouse 1/200 (IP) Abcam, Cambridge, UK Ab27969 
TGF-β1  TGF-β1  Rabbit 1/200 (IP) Santa Cruz Biotechnology, Texas, USA Sc-146 
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Phosphorylated 
Smad2/3 
Phosphorylated 
Smad2/3 
Rabbit 1/200 (IP) Santa Cruz Biotechnology, Texas, USA Sc-11769-R 
Vimentin Vimentin Rabbit 1/200 (ICC) Abcam, Cambridge, UK Ab92547 
Alexa Fluor 488  Mouse IgG Goat 1/500 (ICC), 1/1000 (IF) Life Technologies, Paisley, UK A11029 
Alexa Fluor 488  Rabbit IgG Goat 1/500 (ICC), 1/1000 (IF) Life Technologies, Paisley, UK A11034 
Alexa Fluor 594  Mouse IgG Goat 1/500 (ICC), 1/1000 (IF) Life Technologies, Paisley, UK A11032 
Alexa Fluor 594  Rabbit IgG Goat 1/500 (ICC), 1/1000 (IF) Life Technologies, Paisley, UK A11037 
Biotinylated  Human IgG Donkey 1/500 (IP) Jackson ImmunoResearch Laboratories, 
PA,USA 
709-005-149 
Biotinylated Mouse IgG Horse 1/500 (IP) Vector Laboratories, Peterborough, UK BA2001 
Biotinylated  Rabbit IgG Goat 1/1000 (IP) Vector Laboratories. Peterborough, UK BA1000 
ECL HRP linked Mouse IgG Sheep 1/1000 (WB) GE Healthcare, Buckinghamshire, UK NA931-1ML 
ECL HRP linked Rabbit IgG Donkey 1/1000 (WB) GE Healthcare, Buckinghamshire, UK NA934-1ML 
Table 2.2. Table of Antibodies. Antibodies used for Western blotting (WB), immunocytochemistry (ICC), 
immunofluorescent staining (IF) and immunoperoxidase staining (IP). 
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2.7. Haematoxylin and Eosin (H&E) 
Slides were removed from the freezer and allowed to thaw. Sections were incubated 
in Harris haematoxylin for 2 minutes, washed in distilled water and briefly differentiated 
in 1% acid alcohol (1% HCl in 70% ethanol). The sections were then washed in water, 
followed by the blueing agent 0.1% sodium bicarbonate and then 90% ethanol. This was 
followed by incubation in alcoholic eosin (VWR International, Dublin, Ireland) for 1 
minute followed by 90% then 100% ethanol, cleared in Histoclear (Fisher Scientific) and 
mounted in Vectamount medium (Vector Laboratories). 
 
2.8. Semi-quantitative analysis 
Stained sections were viewed on an Axioplan 2 imaging epifluorescent microscope 
(Carl Zeiss, Germany) and micrographs were captured using an AxioCam HRc (Carl 
Zeiss). Images were analysed semi-quantitatively using ImageJ analysis software 
(Abramoff, 2004).  
 
2.8.1. Evaluation of GFAP immunofluorescent staining in Chapters 4, 5 and 6 
Nine regions of interest (3 regions x 3 coronal sections) per rat were selected from 
images of the corpus callosum, periventricular white matter (Fig. 2.6.A) or olfactory 
tubercle, and the percentage of immunofluorescent pixels above a set threshold 
calculated using ImageJ. First the region of interest (ROI) manager was opened using 
the tabs Analyze ToolsROI Manager (Fig. 2.7.A). This was to allow the ROI to be 
saved so that the same size area was used on all the images. Then the ROI was drawn 
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using the Rectangle Tool and was added to the ROI manager (Fig. 2.7.B). The 
threshold window was opened using the tabs ImageAdjust Threshold and the 
threshold was set by adjusting the brightness to include as much of the staining as 
possible. The threshold colour was changed to B&W so that the background was white 
and the staining was black (Fig. 2.8.A). The initial threshold was set on an image with a 
medium amount of staining and the same threshold value would then be used in all 
subsequent images. The ROI was then selected and the histogram was opened using 
the tabs AnalyzeHistogram. The graph had two peaks showing 0 and 255, the Count 
value was the total number of pixels, the mode was usually the number of white pixels 
from which the black pixel value was calculated and the percentage of black pixels 
measured (Fig. 2.8.B). 
 
2.8.2. Evaluation of ED-1 immunofluorescent staining in Chapter 5 
A composite image of the basal subarachnoid space was created using a series of 
images captured at x100 from a posterior coronal section of the brain (5.8mm post-
Bregma). A region of interest was drawn around the subarachnoid space and the 
percentage of pixels that were immunofluorescent above a set threshold was calculated 
as described in section 2.8.1.  
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Figure legend on following page... 
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Figure 2.6. Analysis of data. Images representing the areas of the brain where high 
magnification images were taken to analyse: (A), GFAP immunofluorescent staining in 
the corpus callosum (a) and the periventricular white matter (b); and (B), TGF-β1 and 
pSmad2/3 immunoperoxidase staining intensity in the ependyma of 4 ventricular regions 
(a-d).  (C) The Evan’s ratio was calculated as the ratio of the greatest width of both 
lateral ventricles (a) to the greatest width of the brain (b), at the level of the foramen of 
Monro.  (D) Example of a complete series of 30 coronal MRI scans, 0.75mm apart, from 
a Kaolin treated rat. The total ventricular volume was calculated as the sum of the 
lateral, third and fourth ventricular areas (yellow) in 15 sequential MRI scans multiplied 
by the distance between the scans (0.75mm). 
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Figure 2.7. Instructions for selecting a region of interest in ImageJ. (A) The region of interest (ROI) manager 
was opened using the tabs Analyze ToolsROI Manager. (B) The ROI was drawn using the Rectangle Tool and 
was added to the ROI manager. 
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Figure 2.8. Instructions on setting the threshold and determining the number of black pixels in ImageJ. (A) 
The threshold window was opened using the tabs ImageAdjust Threshold and the threshold was set by adjusting 
the brightness and selecting the threshold colour as B&W. (B). The histogram was opened using the tabs 
AnalyzeHistogram. The graph has two peaks showing 0 (white) and 255 (black) and the number of black pixels 
was calculated as the count value minus the mode value (white pixels). 
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2.8.3. Quantification of inflammatory cells in the subarachnoid space in Chapter 5 
To evaluate the acute inflammatory response in the subarachnoid space the 
number of eosinophils, neutrophils and macrophages were estimated on two posterior 
coronal sections per rat stained with haematoxylin and eosin. Up to 50 x1000 images 
(field of view 93.16x69.82µm) were taken at random within the subarachnoid space (the 
number depending upon the total area of the subarachnoid space in the section) and the 
number of cells within each field of view was counted manually. Eosinophils contained 
bright pink granules in the cytoplasm, Neutrophils had multi-lobed nuclei and pale pink 
cytoplasm and macrophages had an acentric large round or kidney shaped nucleus 
surrounded by light bluish cytoplasm (Fig. 5.4.A. in Chapter 5). Macrophages could 
only be definitively identified at the edge of the kaolin deposits and were therefore 
probably under-represented in the counts. Also cells that could not be positively 
identified by these criteria were classed as unidentified. The relative frequency of each 
cell type were represented as a percentage of the total number of cells. 
 
2.8.4. Evaluation of TGF-β1 and pSmad2/3 immunoperoxidase staining in 
chapters 4 & 6 
In the ependyma, 12 regions of interest (4 regions x 3 coronal sections) per rat were 
selected from images of the lateral ventricular ependyma (Fig. 2.6.B), and the mean pixel 
intensity (arbitrary units of pixel intensity) above background threshold (established using the no 
primary antibody control sections) was calculated. First an ROI was drawn using the polygon 
tool around the ependyma (Fig. 2.9.A) then the colour of the ROI was inverted by using the tabs 
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EditInvert. The histogram was then opened using the tabs AnalyzeHistogram and the Mean 
value represented the mean pixel intensity of the ependyma (Fig. 2.9.B). 
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Figure 2.9. Instructions on determining pixel intensity in ImageJ. (A) An ROI was drawn using the polygon tool around the 
ependyma and the colour inverted. (B) The histogram was then opened and the Mean value represented the mean pixel 
intensity of the ependyma. 
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2.9. Evaluation of ventricular size 
2.9.1. Principles of magnetic resonance imaging (MRI) 
MRI is a technique that exploits the fact that hydrogen nuclei (protons) in the body 
rotate on an axis and therefore generate a magnetic field.  The nuclei precess (move in 
a conical motion) around the direction of the magnetic field (Fig. 2.10.A). If a magnetic 
field is applied to a specific tissue, the nuclei align parallel to the field and together they 
form a net magnetisation (in the longitudinal direction; Fig. 2.10.B+C). During excitation, 
a perpendicular oscillating magnetic field (for example a coil with alternating currents) is 
applied at the same frequency as precession of the nuclei causing the net magnetisation 
to be rotated away from equilibrium in a perpendicular direction (Fig. 2.10.D). However 
after magnetisation, the nuclei do not remain in the same direction, as neighbouring 
nuclei precess at different frequencies causing dephasing to occur, leading to the nuclei 
pointing in all directions perpendicular to the magnetic field (Fig. 2.10.E). In firm tissue 
dephasing occurs relatively quickly as the neighbouring nuclei are constant, whereas in 
fluids the nuclei are more mobile and are interacting with new neighbouring nuclei all the 
time causing dephasing to happen relatively slowly. These interactions cause the 
magnetisation to constantly approach equilibrium and this is known as relaxation. The 
time it takes for the magnetisation to decrease in the perpendicular plane is known as 
T2 and the time it takes to decrease in the longitudinal plane is known as T1 (Fig. 
2.10.F). Dephasing causes a loss of signal however this can be regained through a 
refocusing pulse which realigns the nuclei in the perpendicular plane leading to an echo 
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which emits a signal and can be measured. Therefore magnetic resonance is measured 
using sequences that include the elements excitation, dephasing and refocusing.  
To create an image it is necessary to excite tissue in slices using gradient coils. 
These induce a gradient in the strength of the magnetic field from left to right which will 
only excite nuclei at a particular frequency causing them to emit a signal, thus creating a 
tissue ‘slice’. In each slice, gradients are then applied to cause different patterns of 
magnetisation and similarities between the pattern and the object being scanned will 
cause a signal to be emitted at a particular strength. Different patterns in each tissue 
slice can then be used to build up a total image resulting in the final magnetic resonance 
image. 
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Figure 2.10. Basic principles of MRI. (A) Nuclei have a magnetic field (blue arrow) and precess around it. (B) 
Nuclei in tissue point in all directions, however when a magnetic field is applied they will try and align, resulting in net 
magnetisation (blue arrow, C). (D) A coil with alternating currents (green) can cause the net magnetisation to rotate 
in a perpendicular direction (green arrow). (E) After, the nuclei will begin in phase but will slowly dephase due to 
differing precession frequencies. (F) The time it takes for the magnetisation to decrease in the perpendicular plane is 
T2, the time it takes to decrease in the longitudinal plane is T1. 
93 | P a g e  
 
2.9.2. MRI 
Imaging experiments were conducted using a Bruker Biospec 7T scanner (Bruker 
Biospin, Ettlington, Germany) equipped with a high performance gradient system 
(with 600mT/m maximum gradient amplitude, and 0.25ms rise time). Animals were 
anesthetised using 1–3% Isoflurane and their vital signs (respiration, rectal temperature, 
heart rate and oxygen saturation percentage) were continuously monitored using a MR 
compatible physio-logical monitoring system (SA Instruments, Stony Brook, NY, USA). 
Animals were placed in a 72-mm volume coil for signal transmission, and a quadrature 
surface coil that was placed on the animal's head was used for signal reception. T2-
weighted scans were acquired using rapid acquisition with a relaxation enhancement 
sequence of 4000ms repetition time, 40ms effective echo time, 8 echoes per image, 4 
averages, 30 coronal slices of 0.75mm slice thickness in a 2.5cm × 2.5cm field-of-view 
with a 98µm × 98µm in-plane resolution. 
 
2.9.3. Ventricular area on tissue sections 
Sections were stained with H&E using the protocol outlined in section 2.7. The 
degree of ventricular dilation was determined by measuring the size of the lateral 
ventricles in a defined anatomical plane. The area of both lateral ventricles was 
measured on the H&E coronal sections of brain at 0.3mm posterior to Bregma where the 
fornix and the anterior commissure were visible. Tissue sections were observed under 
bright field microscopy and images were captures using an Axiocam digital camera (Carl 
Zeiss, Germany), and the ventricular area was calculated using the appropriate software 
(Axiovision 4.8, Carl Zeiss). 
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2.9.4. Evan’s ratio on tissue sections and MRI scans 
The Evan’s ratio is used clinically to diagnose hydrocephalus and a ratio of greater 
than 0.3 is classed as hydrocephalic (Shprecher et al., 2008).The Evan’s ratio (ratio of 
the greatest width of both lateral ventricles to the greatest width of the brain) was 
measured in one tissue section or one coronal MRI scan from each experimental animal, 
at the level of the foramen of Monro (Fig. 2.6.C).  
 
2.9.5. Ventricular volume measured on MRI scans 
Ventricular volume was estimated by measuring the total ventricular area of the 
lateral, third and fourth ventricles, using ImageJ, in 15 sequential coronal MRI scans 
from each experimental animal (Fig. 2.6.D) and multiplying this value by 0.75 (distance 
in mm between each scan). 
 
2.10. Statistical Analysis 
The ‘resources equation’ was used to confirm that the appropriate number of 
animals were included in this study (NC3Rs, 2012). Statistical analyses were carried out 
using SPSS PASW statistics 18 (IBM, NY, USA) to determine if there was any significant 
difference between treatment groups at the various time points.  
The data were tested using the Shapiro-Wilk test to evaluate the normal distribution 
of the residual values for the data. This test indicated that the oedema, TGF-β1 and 
pSmad2/3 data were normally distributed and therefore it was analysed using the one 
way ANOVA and post hoc Tukey tests. Similarly, after transformation (Log10), ventricular 
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volume, Evan’s ratio and GFAP data were shown to be normally distributed and so were 
analysed using the one way ANOVA. Data were reported as group means ± standard 
error of the mean (SEM). 
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Chapter 3 
 
Developing an experimental rat model of 
communicating hydrocephalus 
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3.1. Rationale 
Post-haemorrhagic communicating hydrocephalus is thought to develop due to 
fibrosis in the subarachnoid space obstructing CSF drainage. Transforming growth 
factor-β1 (TGF-β1) plays a significant role in the development of fibrosis through 
promoting inflammation and extracellular matrix (ECM) deposition in multiple tissues, 
and has also been implicated in the aetiology of post-haemorrhagic hydrocephalus. 
Therefore a TGF-β antagonist may be useful as a therapeutic agent to prevent post-
haemorrhagic hydrocephalus. Post-haemorrhagic hydrocephalus is difficult to induce in 
a rat therefore other experimental models of hydrocephalus such as an injection of 
kaolin may be more useful. The injection of kaolin into the cisterna magna produces 
non-communicating hydrocephalus but this is not appropriate for studying the 
development of post-haemorrhagic communicating hydrocephalus. Therefore the first 
aim of this study was to generate a reliable in vivo rat model of communicating 
hydrocephalus and assess endogenous levels of TGF-β1. The second aim was to 
generate an in vitro model of rat meningeal fibroblasts to determine the bioactive range 
of TGF-β1 required to promote maximum fibrosis, and to assess the effects of a TGF-β 
antagonist (Decorin) on TGF-β1 induced meningeal fibrogenesis. 
 
3.2. Experimental design 
3.2.1. Model of communicating hydrocephalus 
Kaolin was either injected into the prechiasmatic cistern or the basal cisterns to 
induce communicating hydrocephalus as described in sections 2.3.2 and 2.3.3 
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respectively. The rats were killed 2, 7, 14 and 28 days later in the prechiasmatic cistern 
model and 14 days later in the basal cisterns model (Table 3.1). Ventricular enlargement 
and TGF-β immunohistochemistry were determined on coronal sections as outlined in 
sections 2.9.3, 2.9.4 and 2.4.4.  
 
Hydrocephalus model Group Day 2 Day 7 Day 14 Day 28 
Prechiasmatic cistern model 
Saline 3 4 3 3 
Kaolin  2 2 3 2 
Basal cistern model 
Saline - - 4 - 
Kaolin - - 7 - 
Table 3.1. Hydrocephalus models. The number of rats in each group for the 
prechiasmatic cistern model and the basal cistern model of hydrocephalus 
 
3.2.2. Primary rat meningeal cell cultures 
Adult rat meninges were removed and cultured to produce a rat meningeal cell 
culture as described in sections 2.1.1 and 2.1.2. To determine the type of cells present 
in the culture the cells were passaged 3 or 4 times before being cultured on poly-D-
lysine coated chamber slides for 48 hours, fixed and stained with antibodies for specific 
cell markers as described in section 2.4.2. To examine the effects of TGF-β1 and 
Decorin on the production of extracellular matrix (ECM) molecules, the meningeal cell 
cultures were treated with TGF-β1 (0, 10, 25 and 50ng/ml) and/or 20μg/ml Decorin as 
described in section 2.1.3. The cells were then lysed and the levels of NG2 determined 
by western blot as described in section 2.2. 
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3.3. Results 
3.3.1. Prechiasmatic cistern model of hydrocephalus 
3.3.1.1. Kaolin injection into the prechiasmatic cistern did not reliably induce 
hydrocephalus 
At 7 and 28 days the ventricular area (mm2) was similar between the Saline group 
(1.63mm2 and 1.11mm2, respectively) and the Kaolin group (1.50±0.28mm2 and 
1.24±0.13mm2, respectively). However at 14 days the Kaolin group (2.85±0.30mm2) had 
larger ventricles compared to the Saline group (1.84±0.10mm2) although the difference 
was not statistically significant (Fig. 3.1). This data suggests that kaolin injected into the 
prechiasmatic is not a reliable or reproducible model of hydrocephalus.  
 
3.3.1.2. Raised TGF-β1 levels after prechiasmatic cistern injection 
TGF-β1 positive staining was localised to the meninges in both the Kaolin and 
Saline groups at all time points (data not shown). At 2 days after the prechiasmatic 
cistern injection, intense TGF-β1 staining was localised to the cytoplasm of cells in the 
ependyma, choroid plexus, cortex and corpus callosum in both the Saline and the Kaolin 
groups (Fig. 3.2). TGF-β1 positive staining was associated with neurones in the cortex 
and glial cells such as oligodendrocytes in the corpus callosum based on their 
morphology and distribution in these areas (Fig. 3.2). At 7, 14 and 28 days the staining 
in the cortex and corpus callosum was lost.  
TGF-β1 positive staining in ependymal cells demonstrated a biphasic response, 
with more intense TGF-β1 staining at 2 and 14 days compared to the low levels of TGF-
100 | P a g e  
 
β1 observed at 7 and 28 days in both the Kaolin and Saline groups (Fig. 3.3). This data 
suggests that changes in endogenous TGF-β1 levels were not related to the kaolin 
injection or enlargement of ventricles. 
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Figure 3.1. Lateral ventricle area in the prechiasmatic cistern model. The scatter 
plot summarises the mean of the ventricular area in the Saline and Kaolin groups at 7, 
14 and 28 days. Ventricular enlargement was only observed in the Kaolin group 14 days 
after the injection of kaolin into the prechiasmatic cistern.  
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Figure 3.2. TGF-β1 staining in the ependyma, choroid plexus, cortex and corpus callosum at 2 days. 
Representative images of TGF-β1 staining in the Saline (A-C) and Kaolin (D-E) groups. There was intense 
cytoplasmic TGF-β1 staining in the ependyma and choroid plexus in both treatment groups (A+D). TGF-β1 staining 
in the cortex appeared to be mainly associated with neurones (black arrows; B+E) and in the white matter associated 
with glial cells (black arrow heads) based on their morphology and typical arrangement in these areas of the brain 
(C+F). Scale bar - 50µm; CP – choroid plexus, E – ependyma, LV – lateral ventricle. 
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Figure legend on following page... 
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Figure 3.3. TGF-β1 staining in the ependyma at time points 2, 7, 14 and 28 days. 
Representative images of TGF-β1 positive staining in the Saline (A,C,E,G) and Kaolin 
(B,D,F,H) groups. There was intense cytoplasmic TGF-β1 staining in the ependyma of 
both the Saline and Kaolin groups at 2 (A-B) and 14 days (E-F). The intensity of TGF-β1 
staining was relatively reduced at 7 (C-D) and 28 days (G-H) in the ependyma of the 
Saline and Kaolin groups. Scale bar - 50µm; CP – choroid plexus, E – ependyma, LV – 
lateral ventricle. 
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3.3.2. Basal cistern model of hydrocephalus 
3.3.2.1. Kaolin injection into the basal cistern induced hydrocephalus 
The second model used in this study has already been used previously to induce 
communicating hydrocephalus (Li et al., 2008). After basal cistern injection of kaolin, the 
lateral ventricle area was larger in the Kaolin group (2.69±0.66mm2) compared to the 
Saline group (1.52±0.57mm2; Fig. 3.4.A). In addition, the Evans ratio was greater in the 
Kaolin group (0.32±0.01) compared to the Saline group (0.26±0.01; Fig. 3.4.B). This 
data suggests that the basal cistern injection is a reliable and reproducible experimental 
model of communicating hydrocephalus. 
 
3.3.2.2. Hydrocephalus was associated with raised endogenous TGF-β1 levels  
In the Saline group, there was weak cytoplasmic TGF-β1 staining of the 
ependymal and choroid plexus epithelium cells (Fig. 3.4.C), and strong staining of 
meninges (not shown). There was more intense TGF-β1 staining in the ependymal and 
sub-ependymal cells of the Kaolin group (Fig. 3.4.D). In addition in the Kaolin group, 
animals with the largest increase in ventricular size had more intense TGF-β1 staining. 
This suggests that the basal cistern injection induced hydrocephalus was associated 
with an increase in TGF-β1 levels in the ependyma. 
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Figure 3.4. Lateral ventricle area, Evan’s ratio and TGF-β1 levels in the basal 
cistern model. The scatter plots summarise the mean of the ventricular volumes (A) 
and Evan’s Ratio (B) in the Saline and Kaolin groups. Ventricular enlargement was 
observed in the Kaolin group after the injection of kaolin into the basal cisterns. 
Representative images of ependymal TGF-β1 staining in the brains of Saline (C) and 
Kaolin (D) groups. TGF-β1 staining was more intense in the ependyma of the Kaolin 
group compared to the Saline group. Scale bar - 100µm; CP – choroid plexus, E – 
ependyma, LV – lateral ventricle. 
A B 
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3.3.3. Characterisation of rat meningeal fibroblasts 
There were no specific markers of meningeal fibroblasts available, therefore the 
cells that were isolated and cultured from meningeal tissue were characterised for the 
presence of  cell types known to be present within the meninges and brain parenchyma 
(Manwaring et al., 2001). The cells were stained for endothelial cells (RECA-1), 
astrocytes (GFAP), macrophages (ED-1), monocytes and microglia (OX-42) and 
neurones (βIII-tubulin). Cells that were positive for vimentin, an intermediate filament 
which is highly expressed in fibroblasts, and negative for the other cells types were 
assumed to be meningeal fibroblasts.   
As expected, in the cell culture the majority of cells stained positive for vimentin 
and vimentin positive fibres were observed in the cytoplasm (Fig. 3.5.A). In addition the 
cells had elongated cytoplasm, a hallmark of fibroblastic-like morphology. βIII-tubulin 
staining was confined to small round neurones in the cultures (Fig. 3.5. B), and around 
2% of the total cell population were positive for ED-1, GFAP and OX-42 (Fig. 3.5.C-E). 
No cells were RECA-1 positive (data not shown). The cultures were therefore assumed 
to be >95% enriched for meningeal fibroblasts. Numerous cells of the meningeal 
cultures were also associated with ECM molecules including collagen, fibronectin and 
NG2 (Fig. 3.5.F-H). 
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Figure 3.5. Characterisation of rat brain meningeal cell cultures. Cells were cultured for 48 hours then fixed and 
stained for cell markers. (A) The majority of cell stained positive for vimentin (red). Occasional cells stained positive 
(red) for βIII-tubulin (B), OX-42 (C), ED-1 (D), and GFAP (E). Numerous cells in the cultures also stained postive 
(green) for the extracellular matrix molecules collagen (F), NG2 (G) and fibronectin (H). DAPI (blue) was used as a 
generic nuclear marker; scale bars A+E-H - 50µm, B-D - 10µm.  
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3.3.4. TGF-β1 increases NG2 protein levels in primary rat meningeal cell cultures 
To determine whether the primary rat meningeal cell culture responds to TGF-β1, 
the levels of NG2, an extracellular matrix (ECM) molecule, were determined by Western 
blot of the cell lysate. Untreated meningeal cells showed negligible levels of NG2. TGF-
β1 induced an increase in NG2 protein levels which was concentration dependent, with 
25ng/ml inducing the greatest response. Rat central nervous system tissue lysate was 
used as a positive control (Fig 3.6). This data suggests that at specific concentration 
TGF-β1 induces the production of ECM molecules. 
 
3.3.5. Decorin attenuates TGF-β1 induced NG2 protein levels 
To test the efficacy of the human recombinant Decorin we examined the effects of 
Decorin on TGF-β1 induced NG2 protein levels. Decorin treatment alone showed similar 
negligible NG2 levels to the untreated meningeal cell cultures. Decorin attenuated TGF-
β1 induced NG2 levels and was dependent on the concentration of TGF-β1. Decorin 
had a greater effect on NG2 protein expression induced by 10ng/ml TGF-β1 compared 
with 25ng/ml TGF-β1 (Fig. 3.6). These results suggest that Decorin inhibits the TGF-β1 
induced ECM deposition in meningeal cultures. 
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Figure 3.6. Western blot analysis of meningeal culture lysate after treatment with 
TGF-β1 and Decorin. (A) Primary rat meningeal cell cultures were treated with TGF-β1 
(0, 10, 25 and 50 ng/ml) and/or Decorin (20μg/ml). NG2 protein levels were increased 
dependent on the concentration of TGF-β1, with 25ng/ml TGF-β1 inducing the greatest 
response (lane 3). Decorin reduced the TGF-β1 induced expression of NG2 and this 
effect was dependent on the dose of TGF-β1 (lanes 6 and 7). A rat central nervous 
system tissue lysate was used as a positive control for NG2 (lane 8). (B) The scatter plot 
summarises the mean of the intensity of the NG2 band to the β-actin band (n=3). TGF-
β1 increased the levels of NG2 produced by meningeal cell cultures while Decorin 
attenuated this response. 
B 
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3.4. Discussion 
3.4.1. Prechiasmatic cistern model of hydrocephalus 
The prechiasmatic cistern model of SAH uses a simple technique of blood 
injection that is well tolerated, reliable and reproducible, and distributes blood throughout 
the basal subarachnoid space (Prunell et al., 2002). Here, the prechiasmatic cistern 
model was adapted by injecting 50µl of kaolin instead of blood. It was hypothesised that 
this would also induce fibrosis in the subarachnoid space and subsequently the 
development of communicating hydrocephalus. The rats were killed at 7, 14 and 28 
days after the injection of kaolin to establish the time course of hydrocephalus 
development. Unfortunately, ventricular enlargement was only observed at the 14 day 
time point. It is unlikely that the hydrocephalus developed transiently in all kaolin-
injected rats and reduce to normal levels by 28 days and has not been described in any 
other studies. Therefore it can be assumed that hydrocephalus did not develop in the 28 
day rats. During the injection the needle is advanced until resistance is felt, however the 
needle may have gone too far and injected kaolin between the dura mater and the bone. 
This could account for the variation in the induction of hydrocephalus as kaolin injected 
between the dura mater and bone would have no effect on subarachnoid fibrosis.  
In addition, levels of TGF-β in the ependyma were similar between the saline and 
kaolin injected rats. Although care was taken to minimise brain damage, the needle 
could still cause an injury and induce bleeding around the olfactory bulbs. As this 
bleeding is not controlled it could also occur in the saline injected rats and confound the 
assessment of TGF-β as it is released by activated platelets (Assoian et al.,1983). 
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Moreover, around the lesion site activated astrocytes, microglia and macrophages would 
produce TGF-β (Logan et al., 1992). These sources of TGF-β production could have 
contributed to the similar levels of ependymal TGF-β observed between the kaolin and 
saline injected rats. Altogether, this suggests the prechiasmatic cistern injection of kaolin 
is not a reliable or reproducible model of hydrocephalus. 
 
3.4.2. Basal cisterns model of hydrocephalus 
 Most studies investigating hydrocephalus inject kaolin into the cisterna magna 
which produces obstructive non-communicating hydrocephalus. The basal cisterns 
model of hydrocephalus was adapted to model communicating hydrocephalus by 
injecting kaolin into the subarachnoid space at the base of the brain. It is a complicated 
technique as the basal cisterns are accessed through the atlanto-occipital membrane 
localised in the ventral region of the neck. In addition, the injections are performed blind 
as the surgeon is unable to see the end of the needle and therefore the risk of lesioning 
the brainstem is high (Li et al., 2008). However it results in an 80% hydrocephalus 
induction rate and the saline injection is a reliable control. In this study the basal cistern 
injection of kaolin reliably induced hydrocephalus. Although the basal cisterns injection 
technique is more complex compared to the prechiasmatic cistern route, it is more 
reliable and reproducible and therefore was used in further studies. 
 Moreover, the experiments were performed in 3-week old rats as neonates 
tolerate the induction of hydrocephalus better and produce a greater severity of 
hydrocephalus (Del Bigio and Enno, 2008). While most neonatal studies are conducted 
in 7 day old rats, they are quite small for the implantation of the osmotic mini pumps and 
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the brain cannulae required in these studies. Also there could be problems with the 
mother rejecting the pups or attempting to remove the brain cannulae. Rats are weaned 
at 3 weeks, therefore 3-week old rats were chosen for subsequent studies. 
 
3.4.3. TGF-βs in hydrocephalus 
TGF-β1 was only present at low levels in the meninges and the choroid plexus of 
the normal rat brain (Unsicker et al., 1991). After injury, TGF-β1 gene and protein 
expression were increased around the wound in macrophages, microglia and astrocytes 
for up to 14 days post lesion, with the levels highest in the first 2-3 days. Also the levels 
of TGF-β1 in the meninges and choroid plexus were increased (Logan et al., 1992). In a 
model of neonatal IVH, there was a correlation between ventricular enlargement and 
TGF-β1 levels in the brain. The hydrocephalus was also associated with increased 
levels of the ECM molecules laminin and fibronectin. In rats injected with either blood or 
artificial CSF without ventricular enlargement, patchy ependymal TGF-β1 
immunostaining was observed at 14 days (Cherian et al., 2004). 
In the study reported here, there was intense ependymal TGF-β1 staining 
detected in the rats with a saline injection into the prechiasmatic cistern. This suggests 
that the injury caused by the needle induced an increase in TGF-β1 staining in the 
ependyma. In the hydrocephalic rats from the both prechiasmatic and basal cisterns 
models, TGF-β1 immunostaining was observed in the ependyma periventricular white 
matter and al low levels in the cortex at 14 days. This is in agreement with the study by 
Cherian et al. (2004) who observed raised levels of TGF-β1 in the periventricular white 
matter, blood vessels and cortex after blood injection. In addition, Hatta et al (2006) 
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demonstrated that hydrocephalus was associated with TGF-β1 increases in 
macrophages in the subarachnoid space, meninges and choroid plexus. In the basal 
cisterns model of hydrocephalus it was apparent that TGF-β1 levels were higher in the 
Kaolin group compared to the Saline group. Together these results further support a role 
for TGF-β1 in the development of hydrocephalus. 
 
3.4.4. In vitro rat meningeal cell cultures respond to TGF-β1 and Decorin 
Adult rat brain meninges were removed and cultured to generate an enriched 
primary meningeal cell culture so that the fibrotic responsiveness of the cells to TGF-β1 
and Decorin inhibition could be determined. The results demonstrated that in these 
primary cell cultures there was less than 5% contamination from non-fibroblast cells after 
3-4 passages of the cell culture. Manwaring et al. (2001) also used this approach with 
cultured rat brain meningeal tissue from postnatal day 1 rats, and found that by 24 hours 
there was less than 15% cell contamination which was further reduced to 4% when the 
cells reached confluency.  
The cultured meningeal fibroblasts responded to TGF-β1 by producing ECM 
molecules such as NG2 and this fibrogenic response was attenuated by human 
recombinant Decorin. These results confirm previous studies from our laboratory 
(Mahay, unpublished data) in which adult rat spinal cord meningeal cells in culture 
produced increased levels of NG2 protein in response to TGF-β2 and this response was 
attenuated with the addition of human recombinant Decorin. A similar modulation of the 
response to fibrogenic agents in cultured meningeal fibroblasts has been reported Minor 
et al. (2010). They demonstrated that decorin suppressed the meningeal fibroblast 
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levels of Semaphorin 3A, a molecule thought to be an inhibitor of axonal regeneration by 
promoting growth cone collapse. The results presented here demonstrated that this 
bioassay is very useful for assessing the efficacy of anti-fibrotic agents.  
 
3.4.5. Conclusion 
Although an injection of kaolin into the basal cisterns is more complex compared 
to the prechiasmatic cistern approach, it demonstrates better reliability and 
reproducibility compared to the prechiasmatic cistern model. Therefore, the basal 
cisterns model was used as a model of communicating hydrocephalus in the further 
studies. This preliminary study also demonstrated that primary rat meningeal cell 
cultures respond to TGF-β1 by producing ECM and that human recombinant Decorin 
was able to suppress the fibrogenic effects of TGF-β1. This suggests that human 
recombinant Decorin has the potential to reduce TGF-β1-induced fibrogenesis after an 
in vivo basal cistern injection of kaolin, thereby preventing the development of of 
communicating hydrocephalus. 
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4.1. Rationale 
Post-haemorrhagic hydrocephalus develops because fibrosis in the subarachnoid 
space obstructs CSF drainage. Transforming growth factor-β1 (TGF-β1) plays a 
significant role in the development of fibrosis through promoting inflammation and 
extracellular matrix (ECM) deposition, and has also been implicated in the aetiology of 
post-haemorrhagic hydrocephalus. Therefore it was hypothesised that a TGF-β 
antagonist would be useful as a therapeutic agent to prevent the development of post-
haemorrhagic hydrocephalus. The aim of this study was to test this hypothesis by 
investigating the effects of continuous intraventricular Decorin treatment on the 
development of kaolin-induced communicating hydrocephalus. 
 
4.2. Experimental design 
Kaolin was injected into the basal cistern to induce communicating hydrocephalus 
as described in section 2.3.3. In this model the kaolin does not obstruct the ventricular 
system (like in cisterna magna injections) but causes a cellular response that obstructs 
flow in the subarachnoid space, hence it relates more closely to the communicating 
hydrocephalus that develops after a haemorrhage. As TGF-β1 is continually produced 
by different cell types throughout the development of post-haemorrhagic fibrosis a bolus 
injection of Decorin may not be sufficient to inhibit TGF-β1. Therefore, immediately after 
kaolin injection, osmotic pumps were implanted subcutaneously and connected through 
a catheter to a cannula placed in the right lateral ventricle for continuous intraventricular 
infusion of either Decorin or phosphate buffered saline (PBS) vehicle for 14 days (Fig 
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4.1) as described in section 2.3.4. In vivo magnetic resonance imaging (MRI) was 
conducted after 14 days of treatment to assess the extent of hydrocephalus prior to 
sacrifice as described in section 2.9.1, followed by tissue collection and 
immunohistochemical analyses of the brain as described in sections 2.3.6. and 2.4. 
Three week old rats were randomly assigned to 4 groups: (1), intact age-matched 
controls (Intact group, n=4), with no kaolin injection and no intraventricular infusion to 
obtain baseline data; (2), basal cistern kaolin injections only (Kaolin group, n=8) to 
evaluate the effects of subarachnoid kaolin without intraventricular cannulation and 
agent delivery; (3), kaolin injection with intraventricular infusion of PBS (Kaolin+PBS 
group; n=8), to determine the effect of vehicle delivery and ventricular cannulation on 
kaolin-induced subarachnoid fibrosis and ventriculomegaly; and (4), kaolin injection with 
intraventricular infusion of Decorin (Kaolin+Decorin group; n=8), to measure the effects 
of Decorin on kaolin-induced TGF-β levels, subarachnoid fibrosis, ventricular 
enlargement and brain damage caused by hydrocephalus.  
Eight rats were excluded from the final analyses because they either did not 
develop hydrocephalus or because they died before the end of the study (Table 4.1.). 
Equal numbers of rats died in Decorin and non-Decorin treated groups, suggesting that 
the deaths were not Decorin related. Residual numbers in each group that were 
included in the analyses were as follows: Intact n=4, Kaolin n=5, Kaolin+PBS n=6, and 
Kaolin+Decorin n=5. 
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Figure 4.1. Experimental protocol. Kaolin was injected into the basal cisterns on day 0 
followed immediately by implantation of the osmotic pump delivering either Decorin or 
PBS (control). Decorin or PBS was continually infused into the lateral ventricle for 14 
days at which point MRI was conducted followed by sacrifice and tissue collection.  
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Animal  Group Reason  
1 Kaolin Non responder (no hydrocephalus) 
2 Kaolin Non responder (no hydrocephalus) 
3 Kaolin Found dead (day 2) 
4 Kaolin+PBS Euthanised (day 6) 
5 Kaolin+PBS Euthanised (day 11) 
6 Kaolin+Decorin Euthanised (day 3) 
7 Kaolin+Decorin Found dead (day 6) 
8 Kaolin+Decorin Found dead (day 14 before MRI) 
 
 
Table 4.1. Table of Animal exclusions and consort diagram. Eight animals were 
excluded from the study. Two animals from the Kaolin group did not develop 
hydrocephalus (had normal ventricular volumes) and were excluded from the analysis. 
Animals were euthanised if they showed severe adverse effects of treatment, including 
rapid weight loss, distress, lethargy and seizures. 
121 | P a g e  
 
4.3. Results 
4.3.1. Decorin prevented the development of communicating hydrocephalus 
The model used in this study was developed in adult rats but had not previously 
been optimised in neonatal or juvenile rats. In the present study hydrocephalus 
developed in 87% of juvenile rats in the Kaolin and Kaolin + PBS groups, which is 
comparable to the induction rate reported in adult rats by Li et al (2008). MRI 
demonstrated that, in the Kaolin and Kaolin+PBS groups, the lateral ventricles enlarged 
bilaterally through all anterior-posterior levels (Fig. 4.2) and had Evan’s ratios of greater 
than 0.3. Ventricular volumes in the Kaolin and Kaolin+PBS groups were similar (Fig. 
4.3), indicating that cannulation of the ventricles did not affect the development of 
ventriculomegaly. Oedema was often observed posteriorly in the corpus callosum and 
periventricular white matter of hydrocephalic brains (Fig. 4.2.). In all groups the 
aqueduct of Sylvius and foramina of Luschka were patent, confirming the induction of 
communicating hydrocephalus and large kaolin deposits could be seen in the basal 
subarachnoid space in the Kaolin and Kaolin+PBS groups (not shown).  
Hydrocephalus development was initially determined in all the animals in each 
group (baseline numbers; Table 4.1). Hydrocephalus was determined as either an 
Evan’s ratio of greater than 0.3 or a ventricular volume of greater than 50mm3 (in 2 
cases hydrocephalus could not be determined and therefore they was classed as 
unknown). Significantly more rats (Kruskal Wallis test, P=0.003) developed 
hydrocephalus in the Kaolin and Kaolin+PBS groups compared to the Kaolin+Decorin 
group (Table 4.2). The majority of studies into hydrocephalus do not include data on 
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animals that do not develop hydrocephalus after kaolin injection. Two rats in the Kaolin 
group demonstrated normal ventricular volumes which was most likely due to an 
unsuccessful kaolin injection into the basal cisterns and therefore were not included in 
the final analysis. In addition the main comparison will be between the Kaolin+PBS 
group and the Kaolin+Decorin group. Data from the animals that died or were 
euthanised were incomplete (lack of MRI scans and viable tissue) therefore further 
analysis was only conducted on the final numbers presented in Table 4.1. 
 
 
 
 
 
 
 
Group Hydrocephalic Non-hydrocephalic Unknown 
Kaolin 5 2 1 
Kaolin+PBS 8 0 0 
Kaolin+Decorin 1 6 1 
Table 4.2. Analysis of hydrocephalus development in all animals (including 
exclusions). Hydrocephalus was determined as either an Evan’s ratio of greater than 
0.3 or a ventricular volume of greater than 50mm3. Significantly more rats (Kruskal 
Wallis test, P=0.003) were hydrocephalic in the Kaolin and Kaolin+PBS groups 
compared to the Kaolin+Decorin group. 
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After basal cistern injection of kaolin, ventricular volumes were significantly 
enlarged (P<0.001) in the Kaolin (155.7±31.9mm3) and Kaolin+PBS (198.3±92.9mm3) 
groups, compared to normal ventricular volumes measured in the Intact group 
(10.9±1.0mm3). Also the Evan’s ratio was significantly greater (P<0.05) in the Kaolin 
(0.39±0.02) and Kaolin+PBS (0.38±0.04) groups compared to the Intact group 
(0.27±0.02). Decorin treatment prevented ventricular enlargement, so that the ventricular 
volume and the Evan’s ratio in the Kaolin+Decorin group (21.1±5.4mm3 and 0.27±0.01 
respectively) were indistinguishable from the normal values of the Intact group (Fig. 4.2 
and Fig 4.3). Thus, continuous Decorin infusion prevented the development of 
hydrocephalus after basal cistern injection of kaolin. 
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Figure 4.2. Representative coronal T-2 weighted MRI anterior and posterior images from Intact, Kaolin, 
Kaolin+PBS and Kaolin+Decorin groups. Ventriculomegaly developed in the Kaolin and Kaolin+PBS groups, 
however the ventricles in the Kaolin+Decorin group appeared similar to the Intact group. The intraventricular cannula 
(bold arrow), delivering either Decorin or PBS, is seen within the right lateral ventricle.  White matter oedema was 
often observed in the hydrocephalic animals (arrowheads).  LV – lateral ventricle; 3V – third ventricle. 
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Figure 4.3. Ventricular volume measurements and Evan’s ratios. The scatter plots 
summarise the mean of the ventricular volumes (A) and Evan’s Ratio (B) in the 4 
groups. Ventriculomegaly that characterised the Kaolin and Kaolin+PBS groups did not 
develop in the Kaolin+Decorin group in which intact volumes/ratios were recorded. 
*P<0.05, ***P<0.001. 
A 
B 
*** 
*** ** 
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4.3.2. Decorin was delivered throughout the entire ventricular system and basal 
subarachnoid space 
MRI located the cannula in the frontal horn of the right lateral ventricle (Fig. 4.2). 
There was no positive human Decorin staining in the brains of Intact, Kaolin and 
Kaolin+PBS groups, as illustrated in the Intact group (Fig. 4.4.A). By contrast, in the 
Kaolin+Decorin group, Decorin staining was observed throughout the ventricular system 
on the apical surface of the choroid plexus epithelium and lateral ventricle ependymal 
cells (Fig. 4.4.B, C). Decorin staining was also abundant in the basal cisterns through 
the entire rostral-caudal axis of the brain, especially in the basement membranes of 
subarachnoid vessels and in the meninges over the cortex (Fig. 4.4.D). The wide 
distribution of Decorin throughout the subarachnoid space confirmed successful 
delivery. 
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Figure 4.4. Distribution of human Decorin in the brain and subarachnoid space in 
the Kaolin+Decorin group. No human Decorin was detected in the lateral ventricles of 
Intact rats (A). In the Kaolin+Decorin group, Decorin staining (red) was observed on the 
apical surface of the choroid plexus epithelial and ependymal cells in the ipsilateral (B) 
and contralateral ventricles (C). Decorin staining was also detected in the basal 
subarachnoid space (D), with intense staining in the basement membranes of the 
arachnoid vasculature (arrow). DAPI (blue) was used as a generic nuclear marker; scale 
bar – 100µm; CP – choroid plexus; E – ependyma; BV – blood vessel. 
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4.3.3. Decorin reduced TGF-β1 staining intensity in the ependyma  
Decorin is a TGF-β antagonist therefore it is important to first characterise TGF-
β1 in the hydrocephalic brain and then determine whether Decorin influences TGF-β1 
levels. In the Intact group, there was weak cytoplasmic TGF-β1 staining of the 
ependymal and choroid plexus epithelium cells in the lateral ventricles (Fig. 4.5.A), and 
strong staining of meningeal cells and cells of the ependyma in the third ventricle (not 
shown). In the Kaolin and Kaolin+PBS groups, there was more intense TGF-β1 staining 
in ependymal and sub-ependymal cells (Fig. 4.5.B,C), macrophages and fibroblasts 
within sites of subarachnoid fibrosis and in occasional astrocytes and oligodendrocytes 
in the corpus callosum (data not shown). The intensity of ependymal TGF-β1 staining 
(arbitrary units of pixel intensity) in the Kaolin (40.5±4.2) and Kaolin+PBS (44.0±5.6) 
groups was statistically greater (p<0.05) compared to the Intact group (21.6±2.3). The 
intensity of TGF-β1 staining in the ependyma of the Kaolin+Decorin (23.3±1.2) group 
was indistinguishable from that in the Intact group, and significantly lower than in the 
Kaolin and Kaolin+PBS groups indicating widespread antagonism of the kaolin-induced 
cytokine elevation by Decorin (Fig. 4.5.D, E). There was also a high frequency of TGF-
β1 positive macrophages in areas of subarachnoid fibrosis in the Kaolin and Kaolin+PBS 
groups, but numbers were much lower in the Kaolin+Decorin group (Fig. 4.6).  Thus, 
Decorin prevented both the increase in ependymal TGF-β1 and the ingress of TGF-β1 
positive macrophages into the subarachnoid space after Kaolin injection into the basal 
cistern. 
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Figure 4.5. TGF-β1 staining in the ependyma.  Representative images of ependymal TGF-β1 staining in Intact (A), 
Kaolin (B), Kaolin+PBS (C) and Kaolin+Decorin (D) groups. (E) Scatter plot of mean TGF-β1 pixel intensities in the 4 
groups. The normal constitutive levels of TGF-β1 that were observed in the Intact group were significantly increased 
in the ependyma of the Kaolin and Kaolin+PBS groups, however TGF-β1 staining in the Kaolin+Decorin group 
remained at the constitutive levels seen in Intact group. Scale bar – 100µm; *P<0.05; **P<0.01; CP – choroid plexus; 
E – ependyma; LV – lateral ventricle. 
E ** 
* 
** 
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Figure 4.6. TGF-β1 staining in macrophages in the subarachnoid space. In areas of subarachnoid fibrosis, there 
was a high frequency of ED-1 positive macrophages (red) that also stained positive for TGF-β1 (green) in the Kaolin 
and Kaolin+PBS (top panels) groups compared to markedly lower numbers in the Kaolin+Decorin group (bottom 
panels). DAPI (blue) was used as a generic nuclear marker; scale bars – 200µm; SAS – subarachnoid space. 
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4.3.4. Decorin reduced Smad2/3 phosphorylation in the ependyma 
The widespread bioactivity of intraventricular Decorin against TGF-β1 was also 
reflected by differences in elements of the TGF-β intracellular signalling cascades. 
Accordingly, patterns of phosphorylated Smad 2/3 (pSmad2/3) staining of meningeal, 
choroid plexus epithelial and ependymal cells were similar to those of TGF-β1 staining. 
Thus, ependymal cell pSmad2/3 staining was weak and cytoplasmic in the Intact group 
and more intense, especially at apical surfaces of ependymal cells in the lateral 
ventricles of the Kaolin and Kaolin+PBS groups (Fig. 4.7.A-D). The intensity of 
ependymal pSmad2/3 staining (arbitrary units of pixel intensity) in the Kaolin (37.7±2.7) 
and Kaolin+PBS (36.8±0.8) groups was statistically greater (p<0.001) compared to the 
Intact group (15.2±3.5). The intensity of pSmad2/3 staining in the ependyma of the 
Kaolin+Decorin (19.0±3.0) group was indistinguishable from the Intact group (Fig. 
4.7.E). This finding suggests that Decorin suppressed TGF-β receptor activation and the 
induction of downstream Smad2/3 signalling. 
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Figure 4.7. Phosphorylated Smad 2/3 staining in the ependyma. Representative images of ependymal pSmad2/3 
staining in Intact (A), Kaolin (B), Kaolin+PBS (C) and Kaolin+Decorin (D) groups. (E) Scatter plot of mean pSmad2/3 
pixel intensity in the 4 groups. After induction of hydrocephalus, there was an increase in pSmad2/3 levels in the 
Kaolin and Kaolin+PBS groups, however pSmad2/3 staining in the Kaolin+Decorin group remained at the constitutive 
levels seen in the intact group. Scale bar – 100µm; ***P<0.001; CP – choroid plexus; E – ependyma; LV – lateral 
ventricle, pSmad2/3 – phosphorylated Smad2/3. 
E 
*** 
*** *** 
*** 
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4.3.5. Decorin reduced astrogliosis and fibrosis in the subarachnoid space 
Astrogliosis and fibrosis in the subarachnoid space have not previously been 
examined in this model of hydrocephalus, therefore glial fibrillary acidic protein (GFAP) 
levels and the deposition of ECM such as molecules laminin and fibronectin in the 
subarachnoid space was investigated. In the Intact group, laminin immunostaining was 
present in thin strands of ECM in the subarachnoid space and vascular basement 
membranes. Laminin and GFAP co-immunostained the glial limitans externa (Fig. 4.8). 
In both the Kaolin and Kaolin+PBS groups at 14 days post-kaolin injection, the 
deposition of laminin extended throughout the basal subarachnoid space into which 
GFAP positive astrocytic processes infiltrated (Fig. 4.8) where the glial limitans externa 
was disrupted. The laminin staining in the subarachnoid space of the Kaolin+Decorin 
group was similar to that seen in the Intact group, largely confined to the glial limitans 
and vascular basement membranes. Laminin deposits were also present on the apical 
surface of ependymal cells in the Kaolin and Kaolin+PBS groups (data not shown), but 
not in the Intact or Kaolin+Decorin groups. By 14 days a dense disorganised network of 
fibronectin was deposited in the fibrosed subarachnoid space of Kaolin and Kaolin+PBS 
groups but was absent from the Intact and Kaolin+Decorin groups (Fig. 4.9). Thus, 
Decorin prevented astrogliosis, ECM deposition and fibrosis in the subarachnoid space 
of Kaolin-treated rats. 
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Figure 4.8. Laminin deposition in the subarachnoid space. Images of coronal sections of brain illustrating areas 
of fibrosis in the basal subarachnoid space. In the figure, panels in the upper row show sections taken at the level of 
Bregma and in the lower row at a level 5mm posterior to Bregma (see inserts); boxed areas in the inserts indicate the 
areas of basal subarachnoid space selected for analysis and illustrated in each row. Representative images show 
more laminin (red) staining in areas of fibrosis in the basal subarachnoid space in the Kaolin and Kaolin+PBS groups 
compared to the Intact and Kaolin+Decorin groups. In the Kaolin and Kaolin+PBS groups, GFAP positive (green) 
astrocytic processes (arrows) penetrated fibrotic areas.  DAPI (blue) was used as a generic nuclear marker; scale 
bars – 100µm; BV – blood vessels; SAS – subarachnoid space; ON – optic nerve. 
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Figure 4.9. Fibronectin deposition in the subarachnoid space. Images of coronal sections illustrating areas of 
fibrosis in the subarachnoid space. In the figure, panels in the upper row show sections taken at the level of Bregma 
and in the lower row at a level 5mm posterior to Bregma (see inserts); boxed areas in the inserts indicate the areas 
of basal subarachnoid space selected for analysis and illustrated in each row. Fibronectin (green) staining was 
increased in the fibrosed subarachnoid space of Kaolin and Kaolin+PBS groups compared to the Intact and 
Kaolin+Decorin groups.  ED1 positive macrophages (red) amassed in the fibrotic areas of the Kaolin and Kaolin+PBS 
groups but few invaded the subarachnoid space of the Kaolin+Decorin group. DAPI (blue) was used as a generic 
nuclear marker; scale bars – 100µm; BV – blood vessels; SAS – subarachnoid space; ON – optic nerve. 
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4.3.6. Decorin protected against hydrocephalus-induced brain damage 
There are various pathological consequences of hydrocephalus, including 
astrogliosis and reactive microglia within compromised neural tissue. Therefore, it was 
important to determine whether Decorin treatment had any effect on hydrocephalic brain 
damage. GFAP is a marker of astrocytes and is upregulated during reactive astrogliosis. 
After induction of hydrocephalus, the levels of GFAP immunostaining (percentage of 
immunofluorescent pixels per area) in both the corpus callosum and periventricular white 
matter were higher in the Kaolin (7.0±2.4% and 10.7±1.9%, respectively) and 
Kaolin+PBS (11.6±4.7% and 12.8±4.40%, respectively) groups compared to the Intact 
group (1.7±0.7% and 1.9±0.4%, respectively). The levels of GFAP immunostaining in 
the Kaolin+Decorin group (1.0±0.3% and 1.4±0.4%, respectively) were similar to the 
normal levels observed in the Intact group (Fig. 4.10.A,B). In the corpus callosum, 
perivascular basement membrane laminin staining was increased in the Kaolin and 
Kaolin+PBS groups compared to the Kaolin + Decorin group (Fig. 4.11). Also, in the 
Kaolin and Kaolin+PBS groups, OX-42 positive microglia accumulated in areas adjacent 
to ependymal rupture in the walls of the expanded lateral ventricles (Fig. 4.12) 
demonstrating a distinctive amoeboid morphology with shortened, thicker processes 
characteristic of activated microglia. Numerous ED-1 positive haematogenous 
macrophages accumulated in areas of fibrosis in the subarachnoid space in the Kaolin 
and Kaolin+PBS groups but very few macrophages immigrated into the subarachnoid 
space of the Kaolin+Decorin group (Fig. 4.9). These findings are consistent with the 
hypothesis that Decorin protects against ventriculomegaly and the development of 
hydrocephalus associated pathology. 
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Figure 4.10. Astrogliosis in hydrocephalic brains (A) Representative images of 
GFAP positive staining (green) in the corpus callosum of the 4 treatment groups.  (B)  
Scatter plot of the mean percentage GFAP positive staining in the corpus callosum and 
periventricular white matter in the 4 groups. Above normal levels of GFAP were 
observed in the Kaolin and Kaolin+PBS groups, whilst normal constitutive levels were 
maintained in the Kaolin+Decorin group. DAPI (blue) was used as a generic nuclear 
marker; scale bar – 100µm; *P<0.05, **P<0.01, ***P<0.001. 
* 
* 
*** ** *** 
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Figure 4.11. Laminin staining associated with blood vessels in the corpus 
callosum. (A) In the corpus callosum of the Kaolin and Kaolin+PBS groups there was 
intense perivascular laminin staining (red) around RECA-1 positive (green) vessels 
(white arrows) compared to the weak laminin staining seen in the vasculature of the 
Kaolin+Decorin group. DAPI (blue) was used as a generic nuclear marker; scale bar – 
100µm. 
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Figure 4.12. Reactive microglia in hydrocephalic brains. Increased OX-42 (red) 
staining reflecting microglia activation was observed in the periventricular white matter of 
the Kaolin and Kaolin+PBS groups, especially in areas where the ependyma was lost in 
the expanding lateral ventricles, was not apparent in the brains of the Kaolin+Decorin 
group. DAPI (blue) was used as a generic nuclear marker; scale bar – 50µm. 
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4.4. Discussion 
This study demonstrated that continuous intraventricular delivery of human 
recombinant Decorin prevented the development of ventriculomegaly in a kaolin model 
of juvenile communicating hydrocephalus. Moreover, Decorin treatment was associated 
with reduced laminin and fibronectin deposition, inflammation and astrogliosis, showing 
that Decorin prevents the development of fibrosis and protects against hydrocephalic 
brain damage. Furthermore, in the hydrocephalic animals, the kaolin-induced increase in 
subarachnoid fibrosis was associated with raised levels of TGF-β/Smad2/3 signalling, 
whereas Decorin treatment suppressed a key stimulus for the development of 
subarachnoid fibrosis, maintaining normal levels of TGF-β/Smad2/3 signalling. These 
findings support the hypothesis that the arrested development of subarachnoid fibrosis, 
hydrocephalus and associated brain pathology are to some extent causally linked with 
Decorin-mediated blockade of TGF-β signalling, despite the range of Decorin influences 
described in the introduction (Chapter 1). 
 
4.4.1. Induction of hydrocephalus in juvenile rats 
MRI analysis confirmed that a basal cistern injection of kaolin induced 
hydrocephalus in 3-week old rats, whilst immunohistochemistry demonstrated that this 
was accompanied by inflammation plus fibronectin and laminin ECM accumulation in the 
subarachnoid space. Comparison of the Kaolin and Kaolin+PBS group data confirmed 
that the implanted intraventricular cannula did not ameliorate ventricular enlargement by 
shunting CSF subcutaneously. The combined incidence of induction of hydrocephalus in 
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the Kaolin and Kaolin+PBS groups was 87%, giving a projected incidence of induction of 
hydrocephalus in the Kaolin+Decorin group (n=5) of 4.3 rats. Thus, the normal 
ventricular volume in the Kaolin+Decorin group was attributed to the Decorin-induced 
suppression of hydrocephalus by blockade of subarachnoid fibrosis and not to either 
shunting effects or failure of the kaolin injection technique.  
The relevance of the kaolin model of communicating hydrocephalus to clinical 
post-haemorrhagic communicating hydrocephalus has been demonstrated by 
observations that intraventricular or subarachnoid injection of blood generates a pattern 
of ventriculomegaly similar to that induced by kaolin (Suzuki et al., 1977; Cherian et al., 
2004). The present study also corroborates the findings of Slobodian et al. (2007), 
demonstrating that kaolin injection causes acute inflammatory cell infiltration into the 
subarachnoid space, with subsequent phagocytosis of the kaolin granules by 
macrophages and deposition of ECM.  
 
4.4.2. TGF-β’s involvement in hydrocephalus 
Low TGF-β levels occur in the CSF and brain parenchyma of healthy humans 
(Mogi et al., 1995; Krupinski et al., 1996; Flood et al., 2001) and rats (Unsicker et al., 
1991; Logan et al., 1992).  TGF-β1 levels are increased in the meninges, subarachnoid 
macrophages and choroid plexus after kaolin injection into the cisterna magna (Hatta et 
al., 2006), in the CSF and choroid plexus of post-haemorrhagic communicating 
hydrocephalus patients, (Kitazawa et al., 1994; Whitelaw et al., 1999; Flood et al., 2001; 
Heep et al., 2004; Douglas et al., 2009) and in experimental intraventricular 
haemorrhage (IVH; Cherian et al., 2004). In this study the kaolin and Kaolin+PBS 
142 | P a g e  
 
groups showed upregulation of the TGF-β/Smad signalling throughout the ventricular 
system including the choroid plexus, suggesting that raised CSF levels of TGF-β 
mediate the progression from meningeal inflammation through to subarachnoid fibrosis. 
Although the Smad intracellular signalling pathway is central to the actions of the TGF-β 
family, TGF-β also signals through the mitogen-activated protein kinase (MAPK), Rho-
like GTPase and phosphatidylinositol-3-kinase (PI3K)/AKT signalling pathways, which 
mediate a wide range of other cellular functions including epithelial-mesenchymal 
transition, activating fibroblasts and promoting ECM production (Zhang, 2009; 
Nakerakanti and Trojanowska, 2012). For example, in an experimental model of IVH, it 
was demonstrated that phosphorylated MAPK levels are increased in the ependymal 
and sub-ependymal glia (Cherian et al., 2004), providing a possible alternative 
supplementary fibrogenic signalling pathway in hydrocephalus. In the studies described 
here, Decorin suppression of subarachnoid deposition of fibronectin and laminin after 
kaolin injection was linked to the maintenance of constitutive levels of TGF-β1 and 
down-stream Smad signalling. Since Decorin sequestration of TGF-β into ECM blocks 
all forms of TGF-β signalling, suppression of activation of non-Smad pathways also 
probably occurred in these studies. 
 
4.4.3. Decorin and hydrocephalus 
Aquilina et al. (2008) and Hoque et al. (2011) have reported no protection against 
ventriculomegaly in a neonatal rat model of IVH after administration of the TGF-β 
antagonists Perfenidone, Losartan, and Colchicine (administered by gavage) and 
Decorin (injected into the lateral ventricle 1 and 6 days after the induction of 
143 | P a g e  
 
hydrocephalus). One explanation for these findings could be that, since the former three 
reagents target TGF-β transcription, they were ineffective in neutralising translated TGF-
β stored in platelet granules and released on haemorrhage. Platelet release accounts for 
the initial phase of the biphasic TGF-β surge in the CSF (Flood et al., 2001; Douglas et 
al., 2009) which initiates TGF-β-mediated subarachnoid fibrosis. Macrophages and 
monocytes subsequently immigrate into the CSF and release a second wave of TGF-β 
which is supplemented by a sustained supply from ependymal, choroid plexus epithelial 
and meningeal cell sources (Wahl et al., 1989; Flood et al., 2001).  The two-bolus 
injection regime of Decorin, used by Hoque et al. (2011), was unlikely to have blocked 
sustained high levels of TGF-β production, since the findings from this study indicate 
that continuous delivery of Decorin was required for effective neutralisation of TGF-β 
signalling in the kaolin model of communicating hydrocephalus. The results presented 
here clearly suggest that initiation of continuous Decorin delivery immediately after basal 
cistern kaolin injection suppressed the development of hydrocephalus by blocking TGF-
β signalling from the outset as a prophylactic treatment and thus maintained normal 
ventricular volumes. 
 
4.4.4. Decorin prevents hydrocephalic induced brain pathology 
 Hydrocephalic brain damage developing from multiple insults, including 
compression, stretch, ischaemia and hypoxia, ultimately leads to periventricular 
oedema, demyelination, axonal degeneration, metabolic impairments, accumulation of 
metabolic waste products, gliosis and inflammation (Silva, 2004; McAllister, 2012). In the 
thinned corpus callosum and periventricular white matter of the hydrocephalic rats, MRI 
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detected oedema and immunohistochemistry demonstrated increased perivascular 
laminin and astrocytic GFAP staining. Similar increases in perivascular laminin staining 
have been seen in hydrocephalic transgenic mice over-expressing TGF-β1 (Wyss-Coray 
et al., 1995) and in blood vessels local to brain lesions (Szabo and Kalman, 2004), 
suggesting similar mechanisms may affect the integrity of the blood brain barrier and 
contribute to the development of oedema in both these conditions. 
Meningeal inflammation and progressive reactive astrogliosis and microgliosis in 
the periventricular matter are prevalent features of hydrocephalus (Fukumizu et al., 
1996; Khan et al., 2006; Del Bigio, 2010b; McAllister, 2012). Reactive astrogliosis in the 
brain is reflected by an upregulation of GFAP and hypertrophy of the astrocytic 
processes. After CNS injury, activated astrocytes may be beneficial in the acute stages 
but detrimental in the latter stages (Pekny and Nilsson, 2005). In hydrocephalus, 
ongoing reactive astrogliosis makes the brain less compliant, affecting shunt success, 
and could prevent axon regeneration and remyelination (McAllister, 2012). In the current 
study, GFAP positive staining increased in the corpus callosum and periventricular white 
matter after induction of hydrocephalus and this astrogliosis correlated with the 
magnitude of ventricular enlargement irrespective of treatment. These results extend 
previous research findings showing a positive correlation between the severity of 
ventriculomegaly and the mRNA and protein levels of GFAP (Yamada et al., 1992; 
Deren et al., 2010; Eskandari et al., 2011; Xu et al., 2012). Unlike sustained 
intraventricular infusion of Decorin that normalises gliosis and prevents oedema, 
shunting reduces but does not restore GFAP to normal levels (Miller and McAllister, 
2007; Eskandari et al., 2011). Ependymal disruption of the enlarged ventricles of the 
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hydrocephalic rats was similar to that described by Del Bigio et al. (2010b) in post-
haemorrhagic communicating hydrocephalus and associated with the underlying 
accumulation of reactive microglia. 
 
4.4.5. Conclusion 
In summary, continuous intraventricular Decorin infusion prevented the 
development of Kaolin-induced hydrocephalus by blockade of TGF-β-mediated 
subarachnoid fibrosis, protecting against the development of hydrocephalic brain 
damage. As post-haemorrhagic communicating hydrocephalus develops after a readily 
diagnosed haemorrhagic insult, it is likely that initiating Decorin delivery immediately 
after the bleed would block the effects of TGF-β signalling from the outset as a 
prophylactic rather than a curative treatment. Therefore, these findings demonstrate that 
sustained intraventricular Decorin is a potential therapeutic treatment that prevents the 
development of acute juvenile post-haemorrhagic communicating hydrocephalus and its 
associated morbidity. Further studies are required to investigate whether Decorin is also 
able to treat established hydrocephalus. 
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5.1. Rationale 
Kaolin injected into the basal cisterns induces a robust inflammatory response in 
the subarachnoid space which leads to the development of fibrosis, astrogliosis and 
hydrocephalus. In the previous chapter it was demonstrated that Decorin prevented the 
development of kaolin-induced hydrocephalus in juvenile rats, probably by inhibiting 
TGF-β1 induced fibrosis. The aim of this study was to determine whether Decorin 
influenced the early inflammatory response after kaolin injection.  
 
5.2. Experimental Design 
Kaolin was injected into the basal cistern to induce communicating hydrocephalus 
in 3-week old rats as described in section 2.3.3. Immediately after kaolin injection, 
osmotic pumps were implanted subcutaneously and connected through a catheter to a 
cannula placed in the right lateral ventricle for continuous intraventricular infusion of 
either human recombinant Decorin or phosphate buffered saline (PBS) for 3 days as 
described in section 2.3.4. The rats were killed 3 days after kaolin injection, the brains 
removed and processed for histology and immunohistochemistry to assess the early 
cellular response to kaolin injection (Fig. 5.1) as outlined in sections 2.3.6. and 2.4. Rats 
were randomly assigned to 4 groups: Intact group n=4, Kaolin group n=5, Kaolin+PBS 
group n=3 and Kaolin+Decorin group n=5. 
 
 
 
148 | P a g e  
 
 
Figure 5.1. Experimental protocol. Kaolin was injected into the basal cisterns on day 0 
followed immediately by implantation of an osmotic pump containing either human 
recombinant Decorin or PBS (control). Decorin or PBS was continuously infused into the 
lateral ventricle for 3 days, at which point the rats were sacrificed. 
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5.3. Results 
5.3.1. Human Decorin was detected in the CSF  
Human recombinant Decorin was infused into the lateral ventricles at a rate of 
2.5µg/0.5µl/hour in the Kaolin+Decorin group. A human Decorin ELISA kit was used to 
measure the levels of human Decorin in the CSF removed from the rat cistern magna on 
day 3 as described in sections 2.3.5 and 2.5.2. The levels of human Decorin in the 
intact, Kaolin and Kaolin+PBS groups were negligible. Levels in the Kaolin+Decorin 
group ranged from 1.7ng/ml to 16.3ng/ml (mean of 8.6±3.0ng/ml; Fig. 5.2). These 
results demonstrate the levels of Decorin achieved in the CSF through continuous 
infusion into the lateral ventricles. 
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Figure 5.2. Human Decorin levels in the CSF. Scatter plot of the mean concentration 
of human Decorin in the rat CSF measured by ELISA. Human Decorin was only 
detected in the CSF after infusion of 2.5µg/0.5µl/hour into the lateral ventricles in the 
Kaolin+Decorin group. 
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5.3.2. Decorin reduced the kaolin-induced inflammatory response in the basal 
subarachnoid space 
At 3 days, the basal subarachnoid space in the Kaolin and Kaolin+PBS groups 
contained thick kaolin deposits associated with a considerable accumulation of 
inflammatory cells including neutrophils, macrophages and eosinophils (Fig. 5.3.A,C-E). 
Eosinophils were identified by their bright pink granules in the cytoplasm, Neutrophils by 
their multi-lobed nuclei and pale pink cytoplasm and macrophages had an acentric large 
round or kidney shaped nucleus surrounded by light bluish cytoplasm (Fig. 5.4.A). The 
distribution of these cells within the basal subarachnoid space was not homogeneous. 
Eosinophils tended to form large accumulations in close proximity to meningeal blood 
vessels while numerous macrophages and neutrophils amassed on the edges of the 
kaolin deposits. Within kaolin deposits the cell density was considerably lower and while 
it was difficult to identify the cell types based on their morphology, the majority of them 
stained positive for ED-1 suggesting they were macrophages (Fig. 5.5). Under the 
microscope kaolin appeared as reflective granules and could be observed within the 
cytoplasm of macrophages suggesting that phagocytosis of kaolin had begun within the 
first 3 days (Fig. 5.4.B). In the Kaolin+Decorin group, the subarachnoid space appeared 
smaller, containing fewer inflammatory cells and only small kaolin deposits (Fig. 5.3.B 
and 5.3.F-H) compared to the Kaolin and Kaolin+PBS groups. 
The relative percentages of eosinophils, neutrophils and macrophages in the 
subarachnoid space were similar between the Kaolin (1.7±0.6%, 22.2±1.9% and 
13.7±0.9%, respectively), Kaolin+PBS (3.2±1.3%, 23.5±2.1% and 20.1±2.6%, 
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respectively) and Kaolin+Decorin groups (5.4±1.7%, 17.0±4.3% and 14.8±1.1%, 
respectively; Fig. 5.4.C). In contrast, the extent of ED-1 positive staining (expressed as 
the percentage of immunofluorescent pixels in the subarachnoid space) showed a trend 
towards being lower in the Kaolin+Decorin group (10.6±1.0%) compared to the Kaolin 
(19.3±3.7%) and Kaolin+PBS groups (18.6±3.5%; Fig. 5.5). These findings suggest that 
Decorin treatment suppressed the kaolin-induced inflammatory response from as early 
as day 3. 
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Figure 5.3. The basal subarachnoid space 3 days after kaolin injection. Representative composite images of the 
basal subarachnoid space from posterior coronal sections of the brain stained with H&E in the Kaolin+PBS (A) and 
Kaolin+Decorin (B) groups. The 6 lower panels show higher magnification images of the subarachnoid space from 
Kaolin+PBS (C-E) and Kaolin+Decorin (F-H) groups. In general, there were large accumulations of cells around 
blood vessels (C+F), fewer cells embedded within kaolin deposits (D+G) and more cells amassing on the edges of 
the kaolin deposits (E+H) in both groups. However, the subarachnoid space in the Kaolin and Kaolin+PBS groups 
contained thicker kaolin deposits and greater accumulations of inflammatory cells compared to the Kaolin+Decorin 
group. Scale bars A-B – 500µm, C-H – 100µm; BCP – basal cerebral peduncle; BV – blood vessels; SAS – 
subarachnoid space; 3N – oculomotor nerve. 
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Figure 5.4. Inflammatory cells types in the basal subarachnoid space. (A) A high 
magnification image identifying the various inflammatory cell types in the subarachnoid 
space including eosinophils (white arrow) with bright pink cytoplasm, neutrophils (white 
arrowhead) with a multi-lobed nuclei and macrophages (black arrow) with an acentric 
round nucleus. (B) Kaolin granules (black arrows) could be seen in the subarachnoid 
space and within the cytoplasm of macrophages. (C) Scatter plot of the mean 
percentage of eosinophils, neutrophils and macrophages in the subarachnoid space of 
Kaolin, Kaolin+PBS and Kaolin+Decorin groups showing that the distribution of each cell 
type was similar between the 3 groups. Scale bars A – 20µm, B – 10µm. 
C 
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Figure 5.5. ED-1 positive macrophages in the basal subarachnoid space. 
Representative composite images of ED-1 staining (red) in the basal subarachnoid 
space of the Kaolin+PBS (A) and Kaolin+Decorin (B) groups. (C) Scatter plot of the 
mean percentage of ED-1 positive pixels in the subarachnoid space in the 3 groups. ED-
1 staining was increased in the Kaolin and Kaolin+PBS groups compared to the 
Kaolin+Decorin group. Scale bar – 500µm; BCP – basal cerebral peduncle; BV – blood 
vessels; SAS – subarachnoid space; 3N – oculomotor nerve. 
C 
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5.3.3. Decorin reduced the inflammatory response in the lateral ventricles 
In addition to the meningeal blood vessels, inflammatory cells are able to enter 
the CNS through the choroid plexus (Chodobski et al., 2011). In the choroid plexus of 
intact rat brains, occasional OX-42 positive cells were detected on the apical side of the 
epithelium, and based on their morphology and location these cells were identified as 
macrophages (Fig. 5.6.A). In the Kaolin and Kaolin+PBS groups these OX-42 positive 
macrophages were more numerous and formed clusters (Fig. 5.6.B+C) while in the 
Kaolin+Decorin group their numbers were clearly lower (Fig. 5.6.D). These results 
suggest that Decorin treatment may decrease the influx of macrophages through the 
choroid plexus. 
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Figure 5.6. OX-42 positive macrophages associated with the choroid plexus. 
Representative images of OX-42 positive cells (red) in the lateral ventricles in Intact (A), 
Kaolin (B), Kaolin+PBS (C) and Kaolin+Decorin (D) groups. There were more OX-42 
positive macrophages associated with the choroid plexus in the Kaolin and Kaolin+PBS 
compared to the Kaolin+Decorin group. DAPI (blue) was used as a generic nuclear 
marker; scale bar – 100µm. 
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5.3.4. Decorin did not affect the proliferation or apoptosis of macrophages in the 
basal subarachnoid space 
TGF-β1 can influence chemotaxis, proliferation and apoptosis of inflammatory 
cells (Wahl et al., 1989; Xaus et al., 2001; Comalada et al., 2003) and therefore, 
Decorin’s effects on reducing the inflammatory response could be due to a combination 
of these factors. In all groups injected with kaolin there were cells positive for Ki67 
(marker of proliferation) and cleaved caspase-3 (marker of apoptosis) present in the 
basal subarachnoid space. The majority of these cells were not ED-1 positive (Fig. 5.7). 
This suggests that the macrophages in the subarachnoid space were not proliferating or 
dying 3 days after kaolin injection. 
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Figure 5.7. Proliferation and apoptosis in the basal subarachnoid space. Images 
showing Ki67 (left panels) and cleaved caspase-3 positive cells (right panels) in the 
basal subarachnoid space of rats injected with kaolin. The majority of cells (white 
arrows) that were positive for Ki67 (green) or cleaved caspase-3 (green) were not ED-1 
positive (red). DAPI (blue) was used as a generic nuclear marker; scale bar – 50µm. 
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5.3.5. Decorin reduced astrogliosis and reactive microglia at 3 days after kaolin 
injection 
Three days after the injection of kaolin, the levels of GFAP immunostaining 
(measured as the percentage of immunofluorescent pixels per unit area) at the base of 
the brain (olfactory tubercle) located close to kaolin deposits, and in the corpus callosum 
demonstrated a trend to being higher in the Kaolin (19.6±4.3% and 15.6±1.9%, 
respectively) and Kaolin+PBS (20.2±3.1% and 12.8±1.3%, respectively) groups 
compared to the Intact group (3.7±0.3% and 5.4±0.8%, respectively). The levels of 
GFAP immunostaining in brain tissue adjacent to kaolin deposits and in the corpus 
callosum of  the Kaolin+Decorin group (12.8±3.4% and 9.5±2.5%, respectively) were 
higher compared to the Intact group but did not reach the levels seen in the Kaolin and 
Kaolin+PBS groups (Fig. 5.8 and 5.9).  
The OX-42 immunostaining (microglia) was more intense in the corpus callosum 
and periventricular white matter in the Kaolin and Kaolin+PBS groups compared to the 
Intact group at 3 days after the injection of kaolin (Fig. 5.10). The OX-42 positive 
microglia had thicker processes and took on an amoeboid morphology which is 
characteristic of activated microglia. This was especially evident in close proximity to the 
injury site left by the cannula (in the Kaolin+PBS group) and along the ventricle wall. In 
the Kaolin+Decorin group, OX-42 immunostaining was more intense at the injury site 
where cannulation occurred, while in distal portions of the corpus callosum and 
periventricular white matter the staining was similar to that in the Intact group (Fig. 5.10). 
In both the Kaolin+PBS and Kaolin+Decorin groups, the OX-42 positive microglia 
appeared to be migrating along the white matter towards the injury site produced by the 
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cannula. These results suggest that Decorin may affect the early microglial and 
astrocytic responses to the injection of kaolin.  
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Figure 5.8. Astrogliosis at the base of the brain. Representative images of GFAP 
positive staining (green) in the neural parenchyma at the base of the brain in the Intact 
(A), Kaolin (B), Kaolin+PBS (C) and Kaolin+Decorin (D) groups. Increased GFAP 
staining was observed in the Kaolin and Kaolin+PBS groups at the base of the brain in 
close proximity to kaolin deposits when compared to the Intact group. The levels of 
GFAP staining in the Kaolin+Decorin group was lower when compared to the Kaolin and 
Kaolin+PBS groups. DAPI (blue) was used as a generic nuclear marker; scale bar – 
200µm; BV – blood vessel, SAS – subarachnoid space, Tu - olfactory tubercle. 
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Figure 5.9. Astrogliosis 3 days after the injection of kaolin. Scatter plots of the mean 
percentage of GFAP positive staining at the base of the brain (olfactory tubercle; A) and 
in the corpus callosum (B). Increased levels of GFAP were observed in the Kaolin and 
Kaolin+PBS groups compared to the Intact group. In the Kaolin+Decorin group the 
levels were reduced compared to the Kaolin and Kaolin+PBS groups but did not reach 
the constitutive levels seen in the Intact group. 
A 
B 
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Figure 5.10. Reactive microglia in the periventricular white matter. Representative 
images showing OX-42 positive microglia (red) in the periventricular white matter in the 
Intact (A), Kaolin (B), Kaolin+PBS (C) and Kaolin+Decorin (D) groups. Microglia with 
more intense OX-42 staining were observed in the Kaolin and Kaolin+PBS groups 
compared to the Intact group, whilst normal constitutive levels of OX-42 stained cells 
were maintained in the Kaolin+Decorin group. DAPI (blue) was used as a generic 
nuclear marker; scale bar – 50µm. 
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5.3.6. Injection of kaolin increased nestin positive staining in the subventricular 
zone and subarachnoid space 
One of the main sources of neural progenitor cells is the subventricular zone of 
the lateral ventricle. Nestin, an intermediate filament protein, is expressed by neural 
progenitor cells and is down regulated upon differentiation (Hendrickson et al., 2011). 
The ependyma and underlying subventricular zone are the first areas to be affected by 
expansion of the ventricles therefore sections were stained using antibodies against 
nestin to determine any changes in the neural progenitor population. In the Intact group 
there were nestin positive cytoplasmic processes associated with the meninges in the 
subarachnoid space, and in particular surrounding blood vessels. Compared to intact 
brains, in the Kaolin and Kaolin+PBS groups there was an increase in the extent of 
nestin staining with more nestin positive cytoplasmic processes observed throughout the 
subarachnoid space, particularly within and around kaolin granules. There was also an 
increase in nestin positive processes in the Kaolin+Decorin group although not to the 
same extent as that seen in the Kaolin and Kaolin+PBS groups (Fig. 5.11). In addition, 
the extent of nestin staining appeared to be relative to the inflammatory response and 
kaolin deposits present in the subarachnoid space (Fig. 5.3.A+B).  
Furthermore in the subventricular zone and ependymal cell layer there were more 
nestin positive cells and processes in the Kaolin and Kaolin+PBS groups compared to 
the Intact group. Nestin positive cells were also increased in the Kaolin+Decorin group 
although to a lesser extent in the subventricular zone (Fig. 5.12.A-D). However, in all the 
kaolin injected groups there were ‘pockets’ of nestin positive cells present just beneath 
the ependyma and in certain instances, these cells extended into the lateral ventricle 
167 | P a g e  
 
(Fig. 5.12.E+F). Therefore, the results from these studies suggest that Decorin 
treatment reduces the Kaolin induced nestin staining in the subventricular zone and 
subarachnoid space. 
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Figure 5.11. Nestin positive processes in the basal subarachnoid space at 3 days 
after kaolin injection. Representative images of nestin positive staining (red) in the 
subarachnoid space in the Intact (A), Kaolin (B), Kaolin+PBS (C) and Kaolin+Decorin 
(D) groups. Nestin positive cytoplasmic processes were observed in the Intact group 
associated with the meninges and blood vessels in the subarachnoid space. Increased 
nestin positive processes were observed in the Kaolin and Kaolin+PBS groups 
compared to the Intact group. The extent of nestin positive processes in the 
Kaolin+Decorin group was lower compared to the Kaolin and Kaolin+PBS groups. DAPI 
(blue) was used as a generic nuclear marker; scale bar – 100µm; BV – blood vessel, 
SAS – subarachnoid space. 
169 | P a g e  
 
 
Figure 5.12. Nestin staining in the subventricular zone at 3 days after kaolin injection. Representative images 
of nestin positive staining (red) in the subventricular zone in the Intact (A), Kaolin (B), Kaolin+PBS (C) and 
Kaolin+Decorin (D) groups. There was an increase in nestin positive cells and processes seen in the Kaolin and 
Kaolin+PBS groups compared to the Intact group. The extent of nestin staining in the Kaolin+Decorin group was 
lower when compared to the Kaolin and Kaolin+PBS groups. Distinct ’pockets’ of nestin positive cells were observed 
beneath the ependyma in the Kaolin+PBS (E) and Kaolin+Decorin (F) groups. DAPI (blue) was used as a generic 
nuclear marker; scale bar – 100µm; E – ependyma, LV – lateral ventricle. 
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5.3.7. α-smooth muscle actin positive cells in the third ventricle ependyma at 3 
days after kaolin injection 
In order to determine whether the fibrogenic response had begun at the 3 day 
time point, sections were stained for α-smooth muscle actin (α-SMA) which is 
expressed by smooth muscle cells of blood vessels and myofibroblasts. 
Myofibroblasts are activated fibroblasts that are involved in producing extracellular 
matrix and contracting the wound (Gabbiani et al., 2003). In the Intact group, as 
expected, α-SMA positive staining was observed in blood vessels in the brain 
parenchyma and subarachnoid space. While in the kaolin-injected rat brains there 
were no changes in the staining pattern for α-SMA in the subarachnoid space (data 
not shown), α-SMA positive cells were detected in close proximity to the ependymal 
lining of the third ventricle (Fig. 5.13). The α-SMA positive staining in the 
Kaolin+Decorin group was clearly lowered compared to the Kaolin and Kaolin+PBS 
groups. These results suggest that by 3 days after kaolin injection there was an 
increase in fibroblastic-like cells in the third ventricle and that Decorin reduced this 
response.  
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Figure 5.13. α-SMA in the third ventricle at 3 days after kaolin injection. 
Representative images of α-SMA positive staining (red) in the third ventricle 
ependyma of the Intact (A), Kaolin (B), Kaolin+PBS (C) and Kaolin+Decorin (D) 
groups. In the Intact group there were no α-SMA positive cells observed along the 
surface of the ependyma. There was an increase in α-SMA positive cells in the 
Kaolin and Kaolin+PBS groups and, to a lesser extent, also in the Kaolin+Decorin 
group. DAPI (blue) was used as a generic nuclear marker; scale bar – 50µm; BV – 
blood vessel, E – ependyma, 3V – third ventricle. 
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5.4. Discussion 
In the previous chapter (Chapter 4) it was demonstrated that continuous 
intraventricular delivery of human recombinant Decorin prevented the development of 
ventriculomegaly in a kaolin model of juvenile communicating hydrocephalus by 
reducing neuroinflammation and fibrosis in the subarachnoid space. This acute 
phase study further supports the previous observations by demonstrating that the 
suppressive effect of Decorin on the inflammatory response was seen as early as 3 
days after kaolin injection, with reduced numbers of inflammatory cells populating the 
subarachnoid space. In addition, Decorin suppressed the response of other 
populations of cells to the kaolin injection in periventricular regions and the 
subarachnoid space. 
 
5.4.1. Decorin’s effects on the early inflammatory response 
After a haemorrhage or blood injection, the cisternal subarachnoid space is 
filled with erythrocytes embedded within a fibrin matrix containing TGF-β-rich 
platelets that evoke an inflammatory response characterised by the recruitment of 
leukocytes (Dumont et al., 2003), the invasion of cytokine expressing macrophages 
supplemented by the transformation of pial cells into macrophages that phagocytose 
erythrocytes and debris (Jackowski et al., 1990), and the production of ECM by 
meningeal fibroblasts (Sajanti et al., 1999a, 1999b). This study corroborates the 
findings of Slobodian et al. (2007), demonstrating that kaolin injection causes acute 
inflammatory cell infiltration into the subarachnoid space, with subsequent 
phagocytosis of kaolin granules by macrophages and deposition of ECM. Hence, at 3 
days there were eosinophils, neutrophils and macrophages present in the 
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subarachnoid space. The ratio of each cell type was similar between all the groups 
injected with kaolin, however the numbers of ED-1 positive macrophages were 
reduced with Decorin treatment. During inflammation, leukocytes are able to gain 
entry to the CNS through blood vessels in the meninges, parenchyma and choroid 
plexus (Muldoon et al., 2013). In the present study, the bulk of the inflammatory cells 
in the subarachnoid space were located in close proximity to meningeal blood 
vessels and clusters of inflammatory cells were also present near to the choroid 
plexus suggesting a large influx of these cells from the bloodstream. 
TGF-β1 is chemotactic for monocytes, macrophages (Wahl et al., 1987) 
neutrophils (Lagraoui and Gagnon, 1997) and eosinophils (Luttmann et al., 1998), 
and the influx of these cells to sites of injury can be attenuated by TGF-β antibodies 
(Bottoms et al., 2010). This suggests that through inhibition of TGF-β1, Decorin could 
influence chemotaxis of inflammatory cells into the subarachnoid space. However, 
there is conflicting evidence regarding Decorin’s effects on inflammatory cell 
infiltration and the majority of this research has been conducted in Decorin deficient 
mice. In a model of diabetic nephropathy, a lack of Decorin appeared to lead to an 
increase in the accumulation of inflammatory cells in perivascular regions of the 
kidney (Merline et al., 2009), implying a role for Decorin in the reduction of 
inflammatory cell recruitment. In contrast, in a model of contact allergy, there was a 
reduction in leukocyte influx to the site of insult, due to increased adhesion of 
inflammatory cells to endothelial cells and a reduction in their migration across the 
endothelium (Seidler et al., 2011). Further research conducted by Logan et al 
(1999a) have shown that after a cerebral lesion, continuous Decorin treatment 
reduced the number of ED-1-positive macrophages in and around the wound site. In 
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addition, Xaus et al. (2001) and Comalada et al. (2003) reported that Decorin 
inhibited macrophage proliferation through p27Kip1, protects macrophages from 
apoptosis through p21Waf1 and prevented TGF-β1-induced inhibition of macrophage 
activation. In the present study, there were very few, if any, ED-1 positive 
macrophages that were positive for either Ki67 or cleaved caspase-3, suggesting that 
Decorin did not influence the proliferation or apoptosis of macrophages within the first 
3 days of treatment. Altogether, these results suggest that the anti-inflammatory 
actions of Decorin are achieved by both reducing the number of ED-1 positive 
macrophages recruited from the blood stream and increasing their efficiency to clear 
debris from the subarachnoid space. 
 
5.4.2. The acute effects of Decorin on astrogliosis and reactive microglia 
The results presented in this chapter suggest that the induction of reactive 
gliosis in hydrocephalus is due to astrocytes responding to the mechanical stresses 
placed upon them by increasing intracranial pressure (ICP), which causes distortion 
of the brain parenchyma. Astrocytes respond to those mechanical stresses by 
increasing intracellular calcium through mechanosensitive ion channels such as the 
stretch activated channel, and propagating the signal to surrounding astrocytes 
(Ostrow and Sachs, 2005). Consequently during the genesis of hydrocephalus, 
molecular mediators of astrogliosis may not be responsible for the initial glial 
response but involved in progressing its severity. Therefore, the initial astrogliosis 
induced by the early increase in ICP (caused by kaolin) may not be preventable. This 
could explain why Decorin reduces, but not completely abolishes, the early reactive 
astrogliosis and microgliosis. Nevertheless, this may not be a disadvantage as mild 
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reactive astrogliosis can be beneficial to compromised neural tissue (Pekny and 
Nilsson, 2005). Complete prevention of reactive astrogliosis can lead to a lack of 
astrocytic hypertrophy, failed glial scar formation, increased inflammation and lesion 
size, a lack of blood brain barrier repair and degeneration of neurones (Bush et al., 
1999; Herrmann et al, 2008). In addition, reactive microglia surround the injury site, 
protecting neurones from damage and removing cellular debris (Nimmerjahn et al., 
2005; Raivich et al., 1999) which, if abolished, could cause further damage to 
neurones. 
 
5.4.3. Neuroprogenitor response to kaolin injection 
Krueger et al., (2006) demonstrated that there were nestin positive neural 
progenitor cells present in the CSF of post haemorrhagic hydrocephalic infants and 
hypothesised that these cells entered the CSF through the disrupted ependyma. 
However, it is also known that cells of the subventricular zone will proliferate and 
migrate to areas of brain damage (Fallon et al., 2000) probably in response 
chemotactic molecules. In the present study, pockets of nestin positive cells were 
identified beneath the ependyma and appeared to be proliferating towards the 
ventricle. Together this data suggests that the injection of kaolin induces the 
proliferation and possibly the migration of neural progenitor cells in the subventricular 
zone towards the lateral ventricles, most likely in response to cytokines released into 
the CSF. The progressive loss of these neural progenitor cells into the CSF could 
result in a reduction of neural progenitor cells present in the subventricular zone to 
repopulate the hydrocephalic brain (Rodriguez et al., 2012). Moreover, the results 
from the present study demonstrate an increase in nestin positive cell processes in 
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the subarachnoid space of hydrocephalic animals. Recently it has been 
demonstrated that the meninges contain nestin positive cells resembling neural 
progenitor cells (Bifari et al., 2009; Nakagomi et al., 2011), which are able to migrate 
into damaged brain parenchyma (Nakagomi et al., (2012). This, together with our 
data suggests that these cells may represent an important pool of cells in the repair 
of the brain after hydrocephalus. 
Studies from Owen-Lynch et al (2003) have shown that CSF from 
hydrocephalic animals has anti-neurogenic properties and prevents the proliferation 
of neural progenitor cells. It is tempting to speculate that TGF-β1 could play a role in 
the proliferation of these neural progenitor cells since the levels of  TGF-β1 are 
increased in the CSF of post-haemorrhagic hydrocephalus patients (Douglas et al., 
2009), and inhibition of TGF-β1 results in reduced apoptosis and increased 
proliferation of neural progenitor cells (Pineda et al., 2013). The lower levels of nestin 
staining observed in the subventricular zone of Decorin treated animals may not 
necessarily indicate a role for Decorin in reducing the neural progenitor cell 
response, but could be related to Decorin attenuating the hydrocephalic cues.  
 
5.4.4. α-smooth muscle actin positive cells; myobibroblasts or macrophages? 
Fibroblasts and activated myofibroblasts (α-SMA positive) respond to pro-
fibrotic molecules such as TGF-β1 by increasing their production of ECM molecules 
(Kisseleva and Brenner, 2008). In the present study there was no increase in 
immunoreactive α-SMA in cells of the subarachnoid space at 3 days after kaolin 
injection. These findings are corroborated by Darby et al (1990) who demonstrated 
that in a wound healing model, α-SMA is not expressed within the lesion site until 6 
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days after injury. In these studies α-SMA positive cells were associated with the 
ependymal lining of the third ventricle 3 days after kaolin injection. These cells could 
be inflammatory cells as a small subset of monocytes and macrophages have been 
shown to express α-SMA (Ludin et al., 2012), but as these cells are very rare, it is 
unlikely that the α-SMA positive cells observed in the third ventricle were all 
macrophages. Unfortunately, co-immunostaining of α-SMA with ED-1 or OX-42 
antibodies could not be performed (all mouse antibodies) to confirm this, and it would 
have been difficult to identify macrophages based on morphology in this area using 
H&E.  
Alternatively, these α-SMA positive cells could represent ependymal cells 
undergoing epithelial-mesenchymal transition (EMT). Whether ependymal cells can 
undergo EMT or if this mechanism is involved in the aetiology of hydrocephalus has 
not been investigated, however there is evidence that supports this hypothesis. For 
example, it is well known that ependymal cells are damaged in hydrocephalus due to 
stretching during the ventricular enlargement, a feature that leads to ependymal 
denudation (Sarnat, 1995). Epithelial cell damage often precedes EMT and increased 
α-SMA expression is one of the critical steps in EMT (Kisseleva and Brenner, 2008). 
Furthermore, TGF-β1 levels are increased in post-haemorrhagic hydrocephalus and 
TGF-β1 is a potent inducer of EMT and directly induces α-SMA expression (Sarrazy 
et al., 2011). Therefore, this data suggests that the ependyma could potentially be a 
source of fibroblastic cells that contribute to the deposition of ECM in the 
subarachnoid space. The lower numbers of these cells observed in the Decorin 
treated group could indicate that Decorin has attenuated TGF-β1 induced EMT. 
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5.4.5. Variation in the early development of hydrocephalus 
In this acute phase study the differences observed between the groups did not 
reach statistical significance and therefore only demonstrated trends. This was due to 
the high variation of the responses observed within each treatment group, particularly 
in the immunostaining parameters evaluated in periventricular tissue. It is recognised 
that the development of kaolin-induced hydrocephalus is not always uniform. 
Analysis of the MRI scan images in the previous chapter indicated that there was a 
correlation between the rapid enlargement of the ventricles and the appearance of 
oedema in the periventricular area. Therefore, there may have been a lot of variation 
in the timing of responses in the periventricular tissue at this early 3 day time point. 
Also within the Decorin group, the amount of human Decorin present in the CSF was 
very variable and ranged between 1.7-16.3ng/ml. It is possible that the high variability 
in the levels of Decorin observed in the CSF of the animals in these studies could be 
due technical problems with the pumps used for continuous delivery of Decorin. In 
this acute study there were air bubbles observed in the tubing of some of the pumps 
before they were implanted, which could have affected the early phase efficiency of 
Decorin delivery.  
However, this study does demonstrate that infusion of Decorin into the lateral 
ventricles leads to the continuous delivery of low levels of Decorin to the CSF, 
compared to a 25µg/5µl bolus injection that results in around 5µg/ml Decorin in the 
CSF after 30 minutes (Lisa Hill, unpublished work). Continuous delivery of Decorin 
should inhibit the sustained release of TGF-β1 that occurs during the development of 
hydrocephalus while reducing the side effects associated with overdosing. 
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5.4.6. Conclusion 
In summary, the results from these studies show that continuous Decorin 
infusion suppresses the acute phase inflammatory and cellular responses in the 
subarachnoid space and periventricular regions resulting from the kaolin injection. 
This work further demonstrates the potential use of Decorin as a therapeutic agent in 
reducing inflammation in the early stages of post-haemorrhagic hydrocephalus,  
 
 
 
 
 
 
 
 
 
 
 
 
180 | P a g e  
 
 
 
 
 
 
 
Chapter 6 
 
Decorin’s effects on degrading subarachnoid 
fibrosis in established hydrocephalus 
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6.1. Rationale 
Post-haemorrhagic hydrocephalus is thought to develop due to fibrosis in the 
subarachnoid space obstructing CSF drainage. Transforming growth factor β1 (TGF-
β1) plays a significant role in the development of fibrosis through promoting 
inflammation and extracellular matrix (ECM) deposition, as well as in reducing 
degradation of ECM in established fibrosis. As such it has been implicated in post-
haemorrhagic hydrocephalus. Therefore it was hypothesised that a TGF-β antagonist 
may be useful as a therapeutic agent to prevent the development and degradation of 
subarachnoid fibrosis to protect against post-haemorrhagic hydrocephalus. 
Previously in Chapter 4 it was demonstrated that Decorin was able to prevent the 
development of kaolin-induced communicating hydrocephalus. Therefore the aim of 
this study was to investigate the effects of continuous Decorin treatment on 
degrading subarachnoid fibrosis and resolving established hydrocephalus. 
 
6.2. Experimental design 
Kaolin was injected into the basal cistern to induce communicating 
hydrocephalus in 3 week old rats as described in section 2.3.3. In vivo magnetic 
resonance imaging (MRI) was conducted 6 days after the injection of kaolin to 
determine the development of hydrocephalus as described in section 2.9.2. Rats that 
had not developed hydrocephalus at this point were excluded from the study (n=5). 
Twenty-two rats were paired up based on their ventricular volumes and randomly 
assigned to either receive an osmotic pump containing phosphate buffered saline 
(PBS) or Decorin and became the Kaolin+PBS group (n=11) and the Kaolin+Decorin 
group (n=11) respectively. The surgeon was blinded to the treatment each rat 
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received. The remaining rats received no further surgery and became the Kaolin 
group (n=6). On day 7 the osmotic pumps were implanted subcutaneously and 
connected through a catheter to a cannula placed in the right lateral ventricle for 
continuous intraventricular infusion of either Decorin or PBS for 14 days as described 
in section 2.3.4. In vivo MRI was conducted on day 20 to assess the extent of 
hydrocephalus and the rats were sacrificed on day 21, followed by 
immunohistochemical analyses of the brain as described in section 2.4 (Fig. 6.1). 
Age matched intact rats were sacrificed immediately after receiving an MRI scan and 
became the Intact group (n=5). 
Three rats from the Kaolin+Decorin group pulled the tubing off the pump which 
allowed CSF to leak out, so that it acted similar to a shunt. These rats were sacrificed 
as soon as the disconnection of the pump was discovered. Immunohistochemical 
analyses were still conduced on these rat brains and they were put into a separate 
group named the Kaolin+Decorin-Pump group (n=3). Severe hydrocephalus 
developed in 4 rats (2 from the Kaolin+PBS group and 2 from the Kaolin+Decorin 
group) and they were euthanised before the end of the study (days 17-19) as they 
had reached a pre-defined humane endpoint. Fortunately MRI scans were conducted 
before sacrifice and therefore these rats were included in this study. Therefore the 
residual numbers in each group that were included in the analyses were as follows: 
Intact n=5, Kaolin n=6, Kaolin+PBS n=11 (includes 2 severely hydrocephalic rats), 
Kaolin+Decorin n=8 (includes 2 severely hydrocephalic rats) and Kaolin+Decorin-
Pump n=3. 
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Figure 6.1. Experimental protocol. Kaolin was injected into the basal cisterns on day 0 followed by the first MRI scan on day 
6. Osmotic pumps containing either Decorin or PBS (control) were implanted on day 7 in hydrocephalic animals. Decorin or 
PBS was continually infused into the lateral ventricles for 14 days. A second MRI scan was conducted on day 20 followed by 
sacrifice on day 21. 
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6.3. Results 
6.3.1. Early development of hydrocephalus and oedema 
In this study hydrocephalus developed in 85% of juvenile rats injected with 
kaolin and was comparable to the induction rate in Chapter 4. The first MRI scan 
conducted on day 6 determined that hydrocephalus had already developed within 6 
days of the kaolin injection with the ventricles expanding significantly (P<0.001) to 
203.8±14.3mm3 compared to 10.7±0.8mm3 in intact rats (Fig. 6.2). In the T2-weighted 
MRI scans, fluid appeared lighter compared to the brain parenchyma therefore 
oedema was identified as lighter areas present within the brain parenchyma that 
were not part of the ventricular system. Further analysis of the 6 day MRI scan 
indicated the presence of oedema in the white matter (periventricular white matter 
and corpus callosum) and cortex in 17 out of 28 rats (61%) injected with kaolin (Fig. 
6.3). Oedema was not present on the MRI scans from the Intact group. Rats with 
oedema had significantly (P<0.01) larger ventricles (236.3±8.3mm3) compared to 
those rats without oedema (153.5±28.7mm3, Fig. 6.4). This data suggests that 
ventricles that enlarge quickly are associated with oedema in the periventricular white 
matter and cortex. 
 
6.3.2. Hydrocephalic characteristics 
The rats injected with kaolin demonstrated classic hydrocephalus associated 
behaviour. The day after the injection of kaolin, the rats had porphyrin secretions 
around the eyes and nose, piloerection of the fur and weight loss compared to intact 
rats. During the following days the rats improved and most were walking round the 
cage normally, although some rats demonstrated weakness and lethargy. The 4 rats 
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with severe hydrocephalus were killed early due to severe weight loss, lethargy, 
agitation and gait problems. 
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Figure 6.2. Induction of hydrocephalus. The scatter plot summarises the mean of 
the ventricular volumes of intact rats (n=5) and kaolin injected rats (n=28). 
Hydrocephalus was induced within 6 days of the kaolin injection. ***P<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 *** 
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Figure 6.3. Representative coronal T-2 weighted MRI images from kaolin injected rats at 6 days. Ventriculomegaly 
developed by 6 days after kaolin injection. (A) Images (Left to right – anterior to posterior) from a kaolin injected rat whose 
ventricles enlarged to 135.6mm3 and showed no oedema. (B) Images from a kaolin injected rat whose ventricles enlarged to 
275.5mm3 and demonstrated oedema in the white matter (white arrow heads, periventricular white matter and corpus 
callosum) and cortex (black arrow heads and black arrow). CA – cerebral aquaduct, LV – lateral ventricle, 3V – third ventricle. 
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Figure 6.4. Comparison of ventricular volumes with oedema on day 6 MRI 
scans. The scatter plot summarise the mean of the ventricular volumes of rats 
presenting with and without oedema. At 6 days after the kaolin injection, larger 
ventricular volumes were associated with the presence of oedema in the white matter 
and cortex. **P<0.01. 
 
 
 
 
 
 
 
 
 
 
 ** 
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6.3.3. Delayed Decorin treatment did not affect ventriculomegaly 
On the 6 day MRI (before pump implantation) there was no difference between 
the ventricular volumes of the Kaolin (237.9±12.2mm3), Kaolin+PBS 
(197.7±26.3mm3) and Kaolin+Decorin (207.9±24.2mm3) groups. Overall on the 20 
day MRI scan there was an increase in ventricular volume in the Kaolin 
(288.7±46.8mm3), Kaolin+PBS (299.7±85.2mm3) and Kaolin+Decorin 
(346.7±108.8mm3) groups compared to the 6 day measurements. At 20 days there 
was no significant difference between the three groups (Fig. 6.5). The scatter plot 
(Fig. 6.6) shows the ventricular volume changes for each rat. The results 
demonstrated that there were 3 types of hydrocephalus that developed; 
a) Progressive – increase in ventricular volume between the two MRI scans 
b) Stable – similar ventricular volumes on both MRI scans (±10mm3) 
c) Declining – decrease in ventricular volume between the two MRI scans.  
In progressive hydrocephalus the lateral ventricles continued to expand 
throughout all anterior-posterior sections. In stable hydrocephalus the lateral 
ventricles remained a similar size with slight changes in shape. In declining 
hydrocephalus the majority of changes occurred posterior with the lateral ventricle 
horns, cerebral aqueduct and fourth ventricle reducing in size (Fig. 6.7). These 3 
types of hydrocephalus were present in all the groups (Table 6.1). There were 4 rats, 
2 from the Kaolin+PBS group and 2 from the Kaolin+Decorin group, that developed 
severe hydrocephalus and were killed early (Fig. 6.8)  with the ventricles enlarging 
more than 250% between MRI scan 1 and the MRI scan conducted on the day they 
were killed (day 17-19). 
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Figure 6.5. Ventricular volumes from day 6 and day 20 MRI scans. The scatter 
plot summarises the mean of the ventricular volumes from the MRI scans on day 6 
and day 20 in the Kaolin, Kaolin+PBS and Kaolin+Decorin groups. In all three groups 
the mean ventricular enlargement increased between the MRI scans. There was no 
significant difference between the 3 groups. 
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Figure 6.6. Individual rat ventricular volumes from day 6 and 20 MRI scans. The scatter plot summarises the data from 
the MRI scans on day 6 and day 20 in the Kaolin, Kaolin+PBS and Kaolin+Decorin groups. The ventricular volumes between 
the day 6 and day 20 MRI scan demonstrated 3 types of hydrocephalus; progressive, stable and declining. There were 4 rats 
(2 from the Kaolin+PBS group and 2 from the Kaolin+Decorin group) with severe hydrocephalus that demonstrated ventricular 
volumes of over 700mm3 on the day 20 MRI scan. 
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Group Progressive Stable (±10mm3) Declining 
Kaolin (n=6) 3 1 2 
Kaolin + PBS (n=11) 5 1 5 
Kaolin +Decorin (n=8) 4 1 3 
 
Table 6.1. Types of hydrocephalus. The number of rats in the Kaolin, Kaolin+PBS 
and Kaolin+Decorin groups that showed progressive, stable and declining 
hydrocephalus between the MRI scans on day 6 and day 20. 
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Figure legend on following page… 
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Figure 6.7. Representative coronal T-2 weighted MRI images of the three types 
of hydrocephalus. Images (Left to right – anterior to posterior) from MRI scans 
conducted on day 6 and day 20 illustrating the 3 types of hydrocephalus. (A) A rat 
from the Kaolin+PBS group demonstrating progressive hydrocephalus with 
enlargement of the lateral ventricles throughout the brain. (B) A rat from the Kaolin 
group demonstrating stable hydrocephalus with little or no change in size of the 
lateral ventricles and sometimes a smaller fourth ventricle. (C) A rat from the 
Kaolin+Decorin group with declining hydrocephalus which mainly affected the 
posterior of the brain leading to reductions in the size of the lateral ventricles, 
cerebral aqueduct and the fourth ventricle. CA – cerebral aquaduct, LV – lateral 
ventricle, 3V – third ventricle, 4V – fourth ventricle. 
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Figure 6.8. Representative coronal T-2 weighted MRI images of the development severe hydrocephalus. MRI was 
conducted on day 6 (MRI scan 1) before the implantation of the pump and just before sacrifice (day 17-19; MRI scan 2). 
Images (left to right – anterior to posterior) of rats with severe hydrocephalus from the Kaolin+PBS group (A) and the 
Kaolin+Decorin group (B). 
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6.3.4. Early oedema leads to greater enlargement of the ventricles 
There was a reduction in the number of rats with oedema in the 20 day MRI 
scan (11/25 rats, 44%) compared to the 6 day MRI scan. In addition, if rats exhibited 
oedema on the day 6 MRI scan they had significantly larger ventricles on the day 20 
MRI scan (398.2±69.5mm3) compared to those rats without oedema 
(159.0±27.0mm3, Fig. 6.9.A). In comparison, rats with oedema only present on the 
day 20 MRI scan had similar ventricular volumes on the day 20 MRI scan 
(309.0±54.8mm3) to rats without oedema (314.5±81.6mm3; Fig. 6.9.B). The 4 rats 
with severe hydrocephalus demonstrated major oedema on the day 6 MRI scan, 
which was reduced to little or no oedema in the day 20 MRI scan most likely due to 
the progressive expansion of the ventricles (Fig. 6.8). 
In the Kaolin+PBS group there appeared to be an association between 
ventricular enlargement and oedema. 4/6 (67%) of rats without oedema in the day 6 
MRI scan demonstrated a reduction in ventricular volume between the two scans 
while 4/5 (80%) of rats with oedema showed an increase in ventricular volume. This 
comparison could not be done in the Kaolin group as there were no rats without 
oedema in the day 6 MRI scan and in the Kaolin+Decorin group there was no 
association. 
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Figure 6.9. Comparison of ventricular volumes and oedema. The scatter plots 
summarise the mean of the ventricular volumes of rats on day 20 MRI scans. (A) 
Rats with oedema on the day 6 MRI scan went on to develop larger ventricles on the 
day 20 MRI scan compared to rats without oedema on day 6. (B) The presence of 
oedema only on the day 20 MRI scan was not correlated to higher ventricular 
volume. **P<0.01. 
A 
B 
 ** 
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6.3.5. Human Decorin was undetectable in brains with severe hydrocephalus 
Human Decorin staining was performed in this study to determine the 
distribution of the infused human Decorin throughout the brain. The staining was also 
conducted in rats from the Kaolin+Decorin group described in Chapter 4 to determine 
whether there were any differences in distribution resulting from the delayed delivery 
of Decorin. In the acute Kaolin+Decorin group described in Chapter 4, intraventricular 
Decorin infusion began on the same day as the injection of kaolin into the basal 
cistern used to induce hydrocephalus. Human Decorin staining was observed in the 
subarachnoid space and on the apical surface of the choroid plexus and ependymal 
cells (Fig. 4.4 and Fig. 6.10.A-B). In the chronic Kaolin+Decorin group, Decorin 
infusion began 7 days after the injection of kaolin. In this chronic group there were 
varying intensities of human Decorin staining apparent in the subarachnoid space. In 
3 rats there was no detectable human Decorin staining and in the remaining 5 rats 
the levels varied from low to moderate intensities. Human Decorin staining was only 
observed in the lateral ventricles of 1 rat (Fig. 6.10.C-F). This data suggests that the 
distribution of Decorin is not as efficient when Decorin is infused after fibrotic 
blockade of CSF flow and hydrocephalus has developed.  
Further investigations revealed that all the rats with no detectable human 
Decorin staining in the subarachnoid space showed an increase in ventricular volume 
between the 2 MRI scans and this included the 2 rats with severe hydrocephalus. 
Out of the remaining rats with positive human Decorin staining in the subarachnoid 
space, 3 rats had declining hydrocephalus, 1 rat had stable hydrocephalus and 1 rat 
had progressive hydrocephalus, although the increase in ventricular volume was only 
13.5mm3 (76.0 to 89.5mm3).  
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Figure 6.10. Distribution of Decorin in the brain and subarachnoid space in the 
acute and chronic Kaolin+Decorin groups. When Decorin infusion began the 
same day as the kaolin injection (acute), human Decorin (red) staining was observed 
in the subarachnoid space (A) and on the apical surface of the choroid plexus in the 
lateral ventricles (B). When Decorin infusion began 7 days after the kaolin injection 
(chronic), the intensity of Decorin staining in the subarachnoid space varied from no 
detectable Decorin (C) to low (D) and medium (E) intensities. Human Decorin 
staining was not observed in the lateral ventricles (F). DAPI (blue) was used as a 
generic nuclear marker; scale bar – 100µm; BV – blood vessel, CP – choroid plexus, 
LV – lateral ventricle, SAS – subarachnoid space. 
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6.3.6. Decorin did not affect the levels of fibronectin in the subarachnoid space 
In the Intact group, thin strands of fibronectin were present in the 
subarachnoid space. In all kaolin injected groups there was an increase in fibronectin 
staining in the subarachnoid space, and there were no apparent differences between 
the groups (Fig 6.11). There did not appear to be any correlation between the 
amount of fibronectin staining and the treatment group or the size of the ventricles. 
This data suggests that delayed Decorin treatment did not reduce ECM deposition in 
the subarachnoid space. 
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Figure 6.11. Fibrosis in the subarachnoid space 21 days after kaolin injection. 
Representative images of fibronectin (green) staining in the Intact (A), Kaolin (B), 
Kaolin+PBS (C) and Kaolin+Decorin (D) groups. The amount of fibronectin positive 
staining increased in the Kaolin, Kaolin+PBS and Kaolin+Decorin groups compared 
to the Intact group. DAPI (blue) was used as a generic nuclear marker; scale bar – 
200µm; BV – blood vessel, SAS – subarachnoid space. 
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6.3.7. Delayed intraventricular Decorin did not affect TGF-β levels in the 
ependyma 
Previously (in Chapter 4) it was demonstrated that acutely delivered human 
Decorin prevented the kaolin-induced increase in TGF-β1 levels in the ependyma, 
therefore in this study the same approach was used to determine whether delayed 
Decorin treatment could influence ependymal TGF-β1 levels. Interestingly, the 
intensity of ependymal TGF-β1 staining (arbitrary units of pixel intensity) was similar 
between the Intact (36.8±3.3), Kaolin (40.7±9.7), Kaolin+PBS (45.7±6.7) and 
Kaolin+Decorin (47.4±3.7) groups. The intensity of TGF-β1 staining in the ependyma 
of the Kaolin+Decorin-Pump (29.8±9.3) group showed a trend to being lower 
compared to the other 4 groups (Fig 6.12.A-C). The TGF-β1 staining appeared 
patchy in places and this may be due to denuadation of the ependyma caused by 
hydrocephalus (Fig. 6.12.D). In addition, there were numerous cells beneath the 
ependyma that were positive for TGF-β1, especially in the periventricular white 
matter (Fig. 6.12.E). This data suggests that delayed Decorin treatment did not affect 
ependymal TGF-β1 levels possibly due to poor Decorin delivery and distribution. 
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Figure 6.12. TGF-β1 staining in the white matter and ependyma after 21 days.  (A) Scatter plot of mean TGF-β1 pixel 
intensities in the 5 groups. The levels of TGF-β1 staining in the ependyma was similar between the Intact, Kaolin, Kaolin+PBS, 
Kaolin+Decorin and Kaolin+Decorin-Pump group. Representative images of TGF-β1 positive staining in the ependyma from 
an Intact rat (B) and a hydrocephalic rat (C). (D) Denudation of the ependyma could be observed as patchy TGF-β1 staining in 
hydrocephalic rats. (E) Subependymal cells and cells in the periventricular white matter were also positive for TGF-β1. Scale 
bar–100µm; CP – choroid plexus; E – ependyma; LV – lateral ventricle, PWM – periventricular white matter. 
A 
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6.3.8. Decorin did not affect GFAP levels in the corpus callosum 
In Chapter 4 it was demonstrated that Decorin prevented the increase in 
kaolin-induced GFAP levels in the corpus callosum, most likely by preventing the 
enlargement of the ventricles and the underlying tissue damage. Therefore in this 
study it was important to determine whether Decorin had any impact on GFAP once 
hydrocephalus had developed. The levels of GFAP immunostaining (percentage of 
immunofluorescent pixels per area) in the corpus callosum showed a trend to being 
higher in the Kaolin (11.6±3.1%) and Kaolin+PBS (10.2±3.0%) groups compared to 
the Intact group (3.3±0.8%). The levels of GFAP immunostaining showed a trend to 
being lower in the Kaolin+Decorin (7.0±1.6%) and Kaolin+Decorin-Pump (5.0±3.7%) 
groups compared to the Kaolin and Kaolin+PBS groups (Fig. 6.13.A). Also in the 
Kaolin+Decorin group the highest levels of GFAP were observed in the 3 rats with no 
visible Decorin staining in the subarachnoid space. Therefore these results suggest 
that Decorin did not affect astrogliosis associated with hydrocephalus. The levels of 
GFAP in the corpus callosum were also compared in rats with and without oedema 
as the corpus callosum is one of the areas that is most affected by oedema. The rats 
that had oedema on the day 6 MRI scan had significantly (P<0.001) higher levels of 
GFAP (12.6±2.0%) compared to rats without oedema (4.1±1.5%; Fig. 6.13.B). This 
suggests that oedema may influence astrogliosis in the corpus callosum. 
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Figure 6.13. Astrogliosis in the corpus callosum at 21 days after kaolin 
injection. Scatter plots of the mean percentage GFAP positive staining in the corpus 
callosum. (A) The levels of GFAP were similar between all the groups however there 
was a trend towards the Kaolin and Kaolin+PBS groups being higher compared to 
the Intact, Kaolin+Decorin and Kaolin+Decorin-Pump groups. (B) Rats with oedema 
in the day 6 MRI scan had significantly higher levels of GFAP compared to those rats 
which did not have oedema. ***P<0.001. 
 *** 
A 
B 
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6.4. Discussion 
This study demonstrated that continuous intraventricular infusion of human 
recombinant Decorin delivered by osmotic min pump, 7 days after the injection of 
kaolin to induce hydrocephalus, did not affect ventriculomegaly. In addition, infused 
Decorin did not affect the kaolin-induced increase in subarachnoid fibrosis, 
ependymal TGF-β1 levels or astrogliosis in the corpus callosum.  These findings 
suggest that intraventricular delivery of human Decorin by osmotic mini pump is not a 
useful treatment strategy or regime for hydrocephalus after fibrosis has developed, 
probably because of problems with drug delivery. 
 
6.4.1. Decorin’s effects on degradation of extracellular matrix molecules 
Chapter 4 demonstrated that Decorin is able to prevent the deposition of ECM 
leading to the subsequent development of subarachnoid fibrosis and hydrocephalus. 
TGF-βs not only increase the deposition of ECM but also reduce the degradation of 
ECM through inhibition of matrix metalloproteinases (MMPs) and enhancing tissue 
inhibitors of metalloproteinases (TIMPs; Border and noble, 1994). Therefore, Decorin 
may have a role in ECM degradation (fibrolysis) through its inhibition of TGF-β and 
consequent action of proteases. ECM deposition occurs as early as 3 days after the 
injection of kaolin and therefore this study was set up to determine whether delayed 
intraventricular Decorin was also able to treat established hydrocephalus by 
degrading mature subarachnoid fibrosis. The results demonstrated that 
intraventricular human Decorin had no effect on the amount of fibrosis present in the 
subarachnoid space and therefore did not affect the degradation of ECM. In previous 
studies, exogenous human Decorin was able to increase the levels of MMP-2 and 
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cause a decrease in TIMP-2 in a model of chronic spinal cord injury, thereby aiding 
tissue remodelling in chronic fibrotic wounds (Z. Ahmed and D Mahay, unpublished 
data). In addition, Decorin deficient mice with hepatic fibrosis demonstrate reduced 
MMP-9 and -2 and increased TIMP-1 levels when compared to wild type mice (Baghy 
et al., 2011). On the other hand, Decorin has also been shown to reduce MMP-1 and 
-3 in gingival fibroblasts, possibly through its induction of interleukin 4 (Al Haj Zen et 
al., 2003). These inconsistencies indicate that Decorin’s actions may be cell specific 
and possibly TGF-β independent.  
The results presented here and in Chapter 4 suggest that intraventricular 
Decorin delivery via osmotic mini pump is better suited to preventing the formation of 
subarachnoid fibrosis rather than degrading established ECM when CSF circulation 
is compromised.  
 
6.4.2. Efficiency of Decorin delivery 
An alternative interpretation of the results is that Decorin was not delivered 
efficiently through intraventricular infusion to elicit a therapeutic response. The lack of 
detectable levels of Decorin in the subarachnoid space of 3/4 rats with progressive 
hydrocephalus could be evidence towards this theory. ICP increases significantly in 
hydrocephalus and accounts for some of the pathology associated with the disease, 
however it usually reduces to normal levels by 6 weeks (Kondzeilla et al., 2002). 
Therefore, it could be postulated that the osmotic mini pumps were unable to infuse 
efficiently into a high pressure environment. These pumps were used in studies to 
deliver agents that induce hydrocephalus (Krishnamurthy et al., 2009) however there 
is limited information about their use in treating established hydrocephalus. Tada et 
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al, (2006) induced hydrocephalus and then implanted an osmotic mini pump 
containing hepatocyte growth factor (HGF), an anti-fibrotic agent that counteracts 
TGF-β activity, 6 weeks after the induction of hydrocephalus. It was demonstrated 
that continual infusion of HGF for 14 days caused a reduction in ventricular size 
(measured on one MRI scan). Implanting the pumps after 6 weeks, when ICP has 
reduced to normal levels, may have allowed the pump to work efficiently. Hence, 
studies need to be conducted to determine the efficiency of the pumps in high 
pressure situations. It may be pointed out that when implanting the pump, CSF was 
able to leak out before the cannula was permanently attached to the skull thereby 
reducing ICP. However this would have only been for a short period of time as it only 
takes 2 hours for CSF to be completely replaced in a rat (Preston, 2001) and 
therefore ICP would have increased again relatively rapidly. The results presented 
here also demonstrate the need to measure ICP changes in the model. It may be that 
the treatment needs to be delayed until ICP has returned to normal levels. 
 
6.4.3. Decorin and TGF-β1  
In Chapter 4 it was shown that infused human Decorin was detected in the 
lateral ventricles on the apical surface of the choroid plexus and ependyma. In 
addition Decorin infusion prevented the kaolin-induced increase in ependymal TGF-
β1 levels. In this study there was a lack of detectable human Decorin in the lateral 
ventricles and furthermore ependymal TGF-β1 levels were similar between the rats 
receiving PBS and human Decorin. This data suggests that human Decorin was not 
present in the lateral ventricles at bioactive levels to inhibit TGF-β1. In hydrocephalus 
the flow of CSF will be affected, causing stagnation of CSF in the ventricles. 
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Consequently it was presumed that there would be higher levels of Decorin in the 
lateral ventricles compared to the subarachnoid space, however this was not the 
case. Furthermore there was denudation of the ependyma which could have affected 
the levels of TGF-β1 observed lining the ventricle. Immunohistochemistry is 
extremely useful for establishing the localisation of molecules within the tissue 
however it only indicates differences in the levels of molecules and therefore is at 
best semi-quantitative. Additional studies where the ependyma is removed and 
processed are required to get definitive quantitative results on TGF-β1 protein and 
gene expression. 
 
6.4.4. Oedema, ventricular enlargement and astrogliosis 
This study demonstrated the importance of early oedema in the development 
of hydrocephalus. The presence of oedema in the early day 6 MRI scan was 
associated with a greater increase in ventricular size by the day 20 MRI scan. In 
addition, there was a link between the levels of GFAP in the white matter and the 
early presence of oedema. Oedema is closely associated with raised ICP as oedema 
often reduces once ICP levels have normalised (Braun et al., 1997, 1998). Also in 
hydrocephalic rats, GFAP levels dramatically increase at the same time as ICP 
begins to rise, and shunting, which effectively reduces ICP causes a reduction in 
GFAP levels (Miller and McAllister, 2007). Together this data suggests that raised 
ICP and oedema are causally linked, which is also associated with a worse outcome. 
More studies need to be conducted to measure the direct effect of ICP on oedema, 
ventricular enlargement and the associated neural pathologies. 
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6.4.5. Diversity in hydrocephalus development 
The kaolin-induced model of communicating hydrocephalus used here is 
relatively new and had not previously been used in 3 week-old rats, therefore the 
aetiology and progression of hydrocephalus is unknown. The results from this study 
corroborate the work conducted in the kaolin model of non-communicating 
hydrocephalus where 3 types of hydrocephalus development were proposed; 
progressive, stable and declining (Braun et al.,1998). In this study all types of 
hydrocephalus were observed in the Kaolin group, which suggests that the pump 
implantation, which could potentially release a small amount of CSF thereby lowering 
ICP, had no bearing on the progression of hydrocephalus.  
This experiment has brought to light the diversity of hydrocephalus 
development in this model which most likely reflects the development of 
hydrocephalus in humans. It also highlights the fact that other factors need to be 
taken into account when assessing outcomes including oedema and ICP. In this 
study the appearance of oedema in the early scan appeared to be predictive in the 
progression of hydrocephalus. ICP was not measured in this study, however it would 
be beneficial to further aid in the understanding of the changes in ventricular volume 
with time. 
 
6.4.6. The Kaolin+Decorin-Pump group 
During this chronic experiment, 3 rats in the Kaolin+Decorin group removed 
the pump from the catheter tubing, which would stop the delivery of Decorin but more 
importantly would mean that the cannulae acted similar to a shunt draining CSF. 
These rats were therefore put into a separate group called the Kaolin+Decorin-Pump 
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group. While the data from this group cannot give any definitive results, it indicates 
what changes may occur with shunting. There was a non-significant trend towards a 
reduction in TGF-β1 in the ependyma and GFAP in the corpus callosum in this group. 
Previously shunting in HTx rats had also shown a reduction in GFAP levels in the 
cortex although not to control levels (Miller and McAllister, 2007). Therefore, shunting 
is able to reduce the effects of hydrocephalus, although generally not to normal 
levels. 
 
6.4.7. Conclusion 
There is diversity in the development of hydrocephalus in response to blocking 
CSF drainage and therefore it is important that treatments are given at the right time 
to have a beneficial effect. In the chronic study reported here intraventricular Decorin 
delivered by osmotic mini pump began 7 days after the injection of kaolin, and the 
results showed that this treatment regime had no significant effects on resolving 
established subarachnoid fibrosis and hydrocephalus. Future studies need to be 
conducted to investigate the effects of ICP in the model of communicating 
hydrocephalus and on the delivery of Decorin into the lateral ventricles.  
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Chapter 7 
 
Discussion 
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7.1. General conclusions 
The studies described in this thesis aimed to investigate the effects of the 
transforming growth factor-β (TGF-β) antagonist Decorin on the development of 
juvenile communicating hydrocephalus. An advantage of this study was that the 
human recombinant Decorin was manufactured at a GMP grade that would be 
suitable for use in humans, and therefore highlights the potential for Decorin 
treatment to be translated from experimental research to clinical trials. 
Initial studies were conducted to establish a suitable in vivo model of 
communicating hydrocephalus and to explore the efficacy of human recombinant 
Decorin on fibrogenesis in rat brain meningeal cell cultures. Two models of kaolin 
induced hydrocephalus were assessed; the prechiasmatic cistern model and the 
basal cisterns model. After the initial studies, it was established that the basal 
cisterns model was more appropriate for future studies as it reliably induced 
ventricular enlargement and changes in endogenous TGF-β1 levels. These studies 
support a role for TGF-β in the development of hydrocephalus. In addition, the in vitro 
studies showed that recombinant human Decorin reproducibly blocked TGF-β1-
induced extracellular matrix (ECM) production by meningeal fibroblasts.  
Post-haemorrhagic hydrocephalus develops after a bleed due to the formation 
of fibrotic lesions in the subarachnoid space that obstruct the flow and drainage of 
cerebrospinal fluid (CSF; Motohashi et al., 1995a; Massicotte and Del Bigio, 1999). 
Therefore initiating Decorin delivery immediately after the bleed should block the 
effects of TGF-β signalling from the outset as a prophylactic therapy. This hypothesis 
formed the basis for the acute experiment (Chapter 4), which was set up to 
determine if Decorin could prevent the formation of fibrosis in the subarachnoid 
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space. To achieve this, Decorin delivery began immediately after the injection of 
kaolin and continued for 14 days. It was established that continuous intraventricular 
infusion of Decorin prevented the development of kaolin-induced hydrocephalus. 
Decorin reduced inflammation and ECM deposition in the subarachnoid space, 
maintained normal levels of TGF-β1/Smad signalling in the ependyma and prevented 
the kaolin-induced increase in astrogliosis in white matter. These findings suggest 
that Decorin prevents the formation of subarachnoid fibrosis by inhibiting the TGF-β 
signalling pathway, thus protecting against the development of hydrocephalus and 
associated brain pathology. 
Chapter 5 further supported this work by investigating the early effects of 
Decorin treatment on kaolin-induced inflammation. In these studies, the early cellular 
response after the onset of hydrocephalus was assessed. The results from these 
studies clearly indicate that Decorin reduces the inflammatory response in the 
subarachnoid space, potentially by reducing inflammatory cell infiltration. In addition, 
Decorin reduces the response of resident cells in the subarachnoid space and 
periventricular regions, and also reduces astrogliosis and microgliosis in the white 
matter. These findings further signify the importance of early application of human 
recombinant Decorin, as it suppresses the early inflammatory response which will 
subsequently influence subarachnoid fibrosis.  
Finally the chronic experiment (Chapter 6) was set up to investigate whether 
Decorin is able to degrade subarachnoid fibrosis in an in vivo model of established 
hydrocephalus. In this chronic study intraventricular human recombinant Decorin 
infusion via osmotic mini pump began 7 days after the injection of kaolin to induce 
fibrosis and hydrocephalus. Under these experimental conditions Decorin has no 
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effect on ventriculomegaly, subarachnoid fibrosis or ependymal TGF-β1 levels. 
Together, all these findings suggest continuous intraventricular Decorin infusion can 
attenuate inflammation, subarachnoid fibrosis and hydrocephalus. In contrast, it is 
likely that alternative methods of Decorin delivery need to be developed to assess 
whether it can degrade subarachnoid fibrosis and resolve established hydrocephalus. 
 
7.2. Recent advances in haemorrhagic hydrocephalus 
There are four recent studies that have contributed to our knowledge of post-
haemorrhagic hydrocephalus. Okubo et al. (2013) have induced subarachnoid 
haemorrhage (SAH) in rats using the endovascular perforation model and measured 
ventricular volume on MRI scans 24 hours later. They demonstrated that ventricular 
enlargement was apparent in 44% (12/27) of rats at 24 hours, which was associated 
with ventricular wall damage and activation of microglia. Although the hydrocephalus 
induced was most likely non-communicating and caused by blood clots blocking the 
ventricular system, it often leads to communicating hydrocephalus. Lackner et al. 
(2013) advanced this work and allowed the rats to survive for 21 days and measured 
intracranial pressure (ICP) at 7, 14 and 21 days. They demonstrated 40% (4/10) of 
the SAH rats had raised ICP and that these rats had enlarged ventricles compared 
the SAH without raised ICP. Together these studies demonstrated that the 
endovascular perforation model was able to induce post-haemorrhagic 
hydrocephalus in rats. On the other hand these studies also highlight the drawback of 
this model; that the perforation technique releases inconsistent amount of blood 
leading to high variability and low induction rates of hydrocephalus. If there was a 
way to regulate the amount of blood released, the endovascular perforation model 
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would be more viable for testing therapeutic agents. In addition, these studies 
showed that increased ICP was related to ventricular enlargement. This suggests 
that ICP could be used as surrogate marker for determining the development of 
hydrocephalus.  
An interesting study by Li et al. (2013) demonstrated that thrombin injected into 
the lateral ventricles induced proliferative changes in the meninges. In addition, the 
effects of thrombin were reversed by a TGF-β inhibitor. This work corroborated 
previous in vitro studies where thrombin and other growth factors including TGF-β, 
have been shown to induce proliferation of leptomeningeal cells (Motohashi et al., 
1995). Therefore, this study further supports the significant role of TGF-β in the 
development of hydrocephalus. 
Finally Ahn et al. (2013) investigated the effect of human umbilical cord blood 
derived mesenchymal stem cells on post-haemorrhagic hydrocephalus. The 
experiment was based on the model developed by Cherian et al. (2004). Cherian et 
al (2004) injected 80µl of citrated adult rat blood into each ventricle on consecutive 
days in postnatal day 7 rat pups. Artificial CSF was injected in control rats. In the rats 
injected bilaterally with blood, there was a 20% mortality rate and 65% of surviving 
rats developed ventricular enlargement. Rats injected with artificial CSF had a 27% 
mortality rate and 50% developed ventricular enlargement. They did not use more 
than 80µl blood as it resulted in leakage of blood around the needle tract, and 
suggested that the increased ventricular enlargement in the rats injected with CSF 
was due to distension of the ventricles and increased ICP induced by the injection. In 
the study by Ahn et al. (2013) IVH was generated in postnatal day 4 rats by injecting 
100µl of maternal whole blood into each lateral ventricle on the same day. A sham 
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operation without blood injection was performed in control rats. In the rats injected 
with blood, there was a 16% mortality rate and 85% developed ventricular 
enlargement. On postnatal day 7, rats either received an injection of mesenchymal 
stem cells, fibroblasts or saline. Only the injection of mesenchymal stem cells 
reduced the ventricular volume and was associated with a reduction in the 
inflammatory cytokines. These results are promising as they corroborate the findings 
presented in this thesis and suggest that reducing the blood induced-inflammatory 
response is important in preventing the development of post-haemorrhagic 
hydrocephalus.  
 
7.3. Future Experiments 
7.3.1. Cyclooxygenase-2 inhibition and Decorin 
In the chronic study (Chapter 6), it was concluded that intraventricular Decorin was 
unable to degrade subarachnoid fibrosis or resolve hydrocephalus and therefore 
differences between the acute (Chapter 4) and the chronic (Chapter 6) experiments 
were examined. At this point it was discovered that different types of analgesics had 
been used. Due to restrictions at the University of Utah in 2012, Buprenophine was 
not permitted as an analgesic in the acute experiment, therefore the rats received 
Carprofen tablets the night before the kaolin injection and for the subsequent 2 days 
after the injection. In 2013 these restrictions were lifted and in the chronic experiment 
the rats received subcutaneous injections of Buprenophine before the surgery, and 
twice daily for the following 3 days. Carprofen is a non-steroidal anti-inflammatory 
drug mainly used for managing pain in animals. It specifically inhibits 
cyclooxygenase-2 (COX-2) and affects the synthesis of prostaglandins with pro-
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inflammatory activity (Mitchell and Warner, 2006). In a model of traumatic brain 
injury, Carprofen was neuroprotective and reduced oedema, reactive microglia and 
pro-inflammatory cytokines (Thau-Zuchman et al., 2012). Moreover, levels of COX-2 
have been shown to be increased after IVH (Lekic et al., 2012) and another COX-2 
inhibitor, Celecoxib, reduced prostaglandin E2, neurophil infiltration, reactive 
astrogliosis and microgliosis in a rabbit model of IVH (Vinukonda et al., 2010). In 
wound healing, Prostaglandin E2 was involved in promoting inflammation however it 
was also anti-fibrotic as it reduced fibroblast proliferation and inhibited collagen 
production (Su et al., 2010). Therefore these studies suggest that Carprofen could 
have influenced the kaolin-induced subarachnoid fibrosis. 
Carprofen was only given acutely for 2 days in the acute experiment therefore 
it would potentially reduce early inflammation while still allowing the anti-fibrotic 
properties of prostaglandins in the later stages. When observing the ventricular 
volumes for the two Kaolin groups from the acute and chronic experiments, the 
Kaolin group with Carprofen had lower ventricular volumes at 14 days 
(155.7±31.9mm3, n=5) compared to the Kaolin group without Carprofen at 6 and 20 
days (237.9±12.2mm3 and 288.7±46.8mm3, respectively, n=6, significance at 20 day 
P<0.05). This demonstrates that Carprofen potentially reduced ventricular volume 
after the induction of hydrocephalus, however on its own it is not able to completely 
prevent it. This data suggests that Carprofen may have been acting synergistically 
with Decorin as the combination of the two did prevent hydrocephalus, but further 
studies are required to assess this association. Continuous Decorin infusion for 14 
days would need to be given with and without Carprofen tablets for the first 2 days. In 
addition to determining ventricular volume, changes in the levels of inflammatory 
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cytokines and prostaglandin E2, a product of COX-2, could be measured in the brain 
and subarachnoid space to determine the effect on the inflammatory response. 
 
7.3.2. Decorin treatment in a haemorrhagic model 
The results presented in this thesis are very promising and demonstrate 
Decorin’s therapeutic potential for preventing the development of post-haemorrhagic 
hydrocephalus. Accordingly, to progress the work described in this thesis, the 
Decorin treatment regime needs to be tested in a haemorrhagic model to determine 
whether Decorin is able to prevent haemorrhage-induced subarachnoid fibrosis and 
hydrocephalus. Haemorrhagic models would be more clinically relevant and more 
closely resemble the events that occur in humans. The basal cisterns injection of 
kaolin was used to induce communicating hydrocephalus in this thesis because at 
the time haemorrhagic models rarely demonstrated ventricular enlargement or had 
low induction rates. More recent studies have demonstrated that previous 
haemorrhagic models can be modified to produce a greater induction rate. Adapting 
both the Cherian et al. (2004) and the Ahn et al. (2013) models could produce a 
reliable model of post-IVH hydrocephalus. Injecting lower amounts (around 80ul) of 
citrated blood into both lateral ventricles would limit leakage of blood up the needle 
tract and would increase the haematocrit to levels required for inducing ventricular 
enlargement (Cherian et al., 2004), however injecting on the same day would better 
model a single IVH event (Ahn et al., 2013). Once established, this model would be 
more clinically relevant to test the therapeutic potential of human recombinant 
Decorin.  
220 | P a g e  
 
Throughout these studies immunohistochemistry has been performed so that the 
location of specific proteins could be elucidated and different cell types could be 
identified. Although changes in protein levels can be assessed semi-quantitatively by 
immunohistochemistry, it is not as accurate as other techniques such as western 
blotting or enzyme-linked immunosorbent assay (ELISA). Ideally the number of 
animals in each group would have been increased so that half of the animals could 
have been used for gene and protein analysis. In addition, it is important to take into 
account that Decorin interacts with a diverse number of molecules other than TGF-β 
including ECM molecules, growth factors and growth factor receptors. Hence, it 
would be critical to establish whether Decorin influences other pathways that may 
contribute to the prevention of hydrocephalus. 
 
7.3.3. Finding the therapeutic window for successful Decorin treatment 
In the acute experiment, it was established that when continuous Decorin 
infusion was started immediately after the injection of kaolin, it prevented 
subarachnoid fibrosis and hydrocephalus. Unfortunately, starting Decorin treatment 
immediately after an IVH in premature infants would not be possible, as IVH can 
clinically present without symptoms and is often only picked up on routine cranial 
ultrasound (Martin, 2011). Therefore further experiments where Decorin is delivered 
in the days after the induction of hydrocephalus are required to establish the window 
of therapeutic opportunity and increase its clinical relevance. Border et al. (1992) 
suggested that there was a window of therapeutic opportunity for successful Decorin 
treatment of fibrosis. Administration of Decorin within the first two days has no effect 
on preventing ECM deposition, however Decorin treatment from day 3 onwards 
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suppressed the production of ECM. It was hypothesised that Decorin was only 
effective after 2 days as this was the time point when the cells surrounding the injury 
started producing detectable levels of TGF-β. Therefore subsequent studies need to 
be conducted to determine the optimum timing for Decorin treatment, ideally in a 
clinically relevant window but before substantial ECM has been deposited in the 
subarachnoid space. 
In addition, altering the duration and dose of Decorin may improve efficacy. The 
dose used in these studies was based on experiments conducted in spinal cord 
(Minor et al., 2010) where Decorin was infused locally into the lesion site. In the 
studies presented here, intraventricularly delivered Decorin was distributed 
throughout the ventricular system and therefore susceptible to dilution so that higher 
doses may be required. Also it would be beneficial to determine the long term effects 
of Decorin infusion on hydrocephalus after treatment has stopped. 
 
7.3.4. Improving the efficiency of Decorin delivery 
The chronic study highlighted the importance of efficient Decorin delivery. It is 
not known whether the osmotic mini pumps were able to infuse efficiently into the 
high pressure hydrocephalic environment. Therefore the results from the chronic 
study are inconclusive as it cannot be established that Decorin was delivered at a 
suitable concentration to the required sites of action to elicit a biological response. 
Ideally it would have been useful to have measured the levels of Decorin in the CSF 
in all the studies, however this was complicated by the lack of necessary equipment 
in the Utah laboratories. Therefore studies need to be conducted to establish whether 
osmotic mini pumps are able to work efficiently to deliver Decorin throughout the 
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ventricular system and subarachnoid space in a high pressure environment. This 
may be through filling the pumps with dyes and testing them in ex vivo or in vivo high 
pressure situations. On the other hand after establishing hydrocephalus 
development, intraventricular Decorin infusion could be combined with a shunt which 
would reduce ventricular volume and ICP. After the 14 days of continuous Decorin 
treatment the shunt could be removed and the progression of hydrocephalus from 
this point assessed. This experiment would examination whether Decorin is able to 
degrade subarachnoid fibrosis, providing the shunt did not affect Decorin delivery to 
the subarachnoid space. 
Further work using ICP measuring devices would also be extremely valuable. 
ICP rises during the injection of blood into the ventricles and returns to normal levels 
soon after the injection (Cherian et al., 2004). Rats that go on to develop post-
haemorrhagic hydrocephalus have increased ICP at 14 and 21 days (Lackner et al., 
2013), then in kaolin-induced hydrocephalus ICP usually normalises at around 6 
weeks (Konziella et al., 2002). In subsequent experiments it would be extremely 
interesting to monitor ICP with an indwelling device daily and be able to correlate this 
with oedema and ventricular enlargement on MRI scans to further characterise the 
progression of hydrocephalus. Not only would this increase our understanding of the 
model but it may give us markers that could influence when Decorin treatment is 
started. For example, treatment could begin as soon as ICP has reduced back to 
normal levels. 
Alternatively, other techniques for continually delivering Decorin into the high 
pressure ventricular system and subarachnoid space could be considered. A 
ventricular access device or reservoir is often implanted in premature infants with 
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post-haemorrhagic hydrocephalus to facilitate repeat ventricular tapping (Brouwer et 
al., 2011). This device could be used to deliver Decorin by giving daily injections into 
the device that would replicate a delivery technique usable in premature infants. 
Nasal delivery could also be another potential route for Decorin administration as it is 
a non-invasive way of getting drugs into the CNS. However, a significant amount of 
work would need to be invested into getting the formulation right so that there is 
efficient uptake of Decorin without it being distributed systemically (Dhuria et al., 
2010). In this laboratory a hydrogel is being developed that is in liquid form at room 
temperature but solidifies at 37⁰C. Hence there is the potential for incorporating 
Decorin into the gel and injecting it into the subarachnoid space so it slowly releases 
Decorin, however its effects on obstructing CSF flow would need to be established. 
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